USRE46511E1 - Fused pyrimidine derivatives for inhibition of tyrosine kinase activity - Google Patents
Fused pyrimidine derivatives for inhibition of tyrosine kinase activity Download PDFInfo
- Publication number
- USRE46511E1 USRE46511E1 US15/099,171 US201115099171A USRE46511E US RE46511 E1 USRE46511 E1 US RE46511E1 US 201115099171 A US201115099171 A US 201115099171A US RE46511 E USRE46511 E US RE46511E
- Authority
- US
- United States
- Prior art keywords
- phenyl
- pyrimidin
- thieno
- acrylamide
- yloxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active, expires
Links
- 0 */C(B)=C/C(=O)CC1=CC(CC2=C3[W]C=CC3=NC(NC)=N2)=CC=C1.C[Y] Chemical compound */C(B)=C/C(=O)CC1=CC(CC2=C3[W]C=CC3=NC(NC)=N2)=CC=C1.C[Y] 0.000 description 3
- RGQYGYUDZDXAIJ-VYFOIEQHSA-N *.CC(C)C1=CC=C(N2CCC(N3C=CN=C3)C2)C=C1.CC(C)C1=CC=C(N2CCCCC2)C=C1.CC(C)C1=CC=C(N2CCOCC2)C=C1.CC(C)C1=CC=C(N2CC[C@@H](N3C=CN=C3)C2)C=C1.CC(C)C1=CC=C(N2CC[C@H](N(C)C)C2)C=C1.S Chemical compound *.CC(C)C1=CC=C(N2CCC(N3C=CN=C3)C2)C=C1.CC(C)C1=CC=C(N2CCCCC2)C=C1.CC(C)C1=CC=C(N2CCOCC2)C=C1.CC(C)C1=CC=C(N2CC[C@@H](N3C=CN=C3)C2)C=C1.CC(C)C1=CC=C(N2CC[C@H](N(C)C)C2)C=C1.S RGQYGYUDZDXAIJ-VYFOIEQHSA-N 0.000 description 2
- LRIZOHPXUFFVHH-UHFFFAOYSA-N C=CC(=O)NC1=CC(NC2=NC(Cl)=NC3=C2SC=C3)=C(F)C=C1 Chemical compound C=CC(=O)NC1=CC(NC2=NC(Cl)=NC3=C2SC=C3)=C(F)C=C1 LRIZOHPXUFFVHH-UHFFFAOYSA-N 0.000 description 2
- LUNNHPIHWNYMDF-UHFFFAOYSA-N C=CC(=O)NC1=CC(NC2=NC(NC3=CC=C(N4CCN(C)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(NC2=NC(NC3=CC=C(N4CCN(C)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 LUNNHPIHWNYMDF-UHFFFAOYSA-N 0.000 description 2
- UXIVABWVJBVFRX-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=C3SC=CC3=NC(NC3=CC(F)=C(OCCN(C)C)C=C3)=N2)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=C3SC=CC3=NC(NC3=CC(F)=C(OCCN(C)C)C=C3)=N2)=CC=C1 UXIVABWVJBVFRX-UHFFFAOYSA-N 0.000 description 2
- JPRFJRBHZMVEEH-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=C3SC=CC3=NC(NC3=CC=C(CN(C)C)C=C3)=N2)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=C3SC=CC3=NC(NC3=CC=C(CN(C)C)C=C3)=N2)=CC=C1 JPRFJRBHZMVEEH-UHFFFAOYSA-N 0.000 description 2
- WJLPNIAIXXQTOM-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=C3SC=CC3=NC(NC3=CC=C(CN4CCN(C)CC4)C=C3)=N2)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=C3SC=CC3=NC(NC3=CC=C(CN4CCN(C)CC4)C=C3)=N2)=CC=C1 WJLPNIAIXXQTOM-UHFFFAOYSA-N 0.000 description 2
- WZGQRRGEZWDOIA-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=C3SC=CC3=NC(NC3=CC=C(N4CCN(C)CC4)C=C3)=N2)=C(F)C=C1 Chemical compound C=CC(=O)NC1=CC(OC2=C3SC=CC3=NC(NC3=CC=C(N4CCN(C)CC4)C=C3)=N2)=C(F)C=C1 WZGQRRGEZWDOIA-UHFFFAOYSA-N 0.000 description 2
- MSYBFOLEIIVPRU-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=C3SC=CC3=NC(NC3=CC=C(OC4CCN(CC)CC4)C=C3)=N2)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=C3SC=CC3=NC(NC3=CC=C(OC4CCN(CC)CC4)C=C3)=N2)=CC=C1 MSYBFOLEIIVPRU-UHFFFAOYSA-N 0.000 description 2
- UNORZHQKORNVTK-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=NC(NC3=C(OC)C=C(N4CCN(CC)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=NC(NC3=C(OC)C=C(N4CCN(CC)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 UNORZHQKORNVTK-UHFFFAOYSA-N 0.000 description 2
- WGSIBYJLEIFZGF-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=NC(NC3=CC(C)=C(N4CCN(C)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=NC(NC3=CC(C)=C(N4CCN(C)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 WGSIBYJLEIFZGF-UHFFFAOYSA-N 0.000 description 2
- RUHLLPKWQXJFOV-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=NC(NC3=CC(Cl)=C(CN4CCN(C5CCN(C)CC5)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=NC(NC3=CC(Cl)=C(CN4CCN(C5CCN(C)CC5)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 RUHLLPKWQXJFOV-UHFFFAOYSA-N 0.000 description 2
- SJSXEGCTAXXODU-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=NC(NC3=CC(F)=C(CC4CCN(C)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=NC(NC3=CC(F)=C(CC4CCN(C)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 SJSXEGCTAXXODU-UHFFFAOYSA-N 0.000 description 2
- UUJVGNSVUMBYGJ-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(C4CCN(C)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(C4CCN(C)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 UUJVGNSVUMBYGJ-UHFFFAOYSA-N 0.000 description 2
- HZCIPBLNCBLOBF-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(N4CCC(N5C=CN=C5)C4)C=C3)=NC3=C2SC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(N4CCC(N5C=CN=C5)C4)C=C3)=NC3=C2SC=C3)=CC=C1 HZCIPBLNCBLOBF-UHFFFAOYSA-N 0.000 description 2
- FDMQDKQUTRLUBU-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(N4CCN(C)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(N4CCN(C)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 FDMQDKQUTRLUBU-UHFFFAOYSA-N 0.000 description 2
- XRBKUNFRIBDEGL-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(N4CCN(CC)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(N4CCN(CC)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 XRBKUNFRIBDEGL-UHFFFAOYSA-N 0.000 description 2
- CMIZAVXINNMCQB-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=NC(NC3=CN=CC=C3)=NC3=C2SC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=NC(NC3=CN=CC=C3)=NC3=C2SC=C3)=CC=C1 CMIZAVXINNMCQB-UHFFFAOYSA-N 0.000 description 2
- SSDCUAKPCOOKHM-UHFFFAOYSA-N C=CC(=O)NC1=CC=CC(OC2=NC(NC3=CC=C(N4CCN(C)CC4)C(OC)=C3)=NC3=C2OC=C3)=C1 Chemical compound C=CC(=O)NC1=CC=CC(OC2=NC(NC3=CC=C(N4CCN(C)CC4)C(OC)=C3)=NC3=C2OC=C3)=C1 SSDCUAKPCOOKHM-UHFFFAOYSA-N 0.000 description 2
- UAUHXGLEZFIXBO-UHFFFAOYSA-N CC(=O)C1=CC=C(C(C)C)C=C1.CC(C)C1=CC=C(C2=NCCCN2)C=C1.CC(C)C1=CC=C(C2C(=O)N(C)CCN2C)C=C1.CC(C)C1=CC=C(C2CCCN(C)C2)C=C1.CC(C)C1=CC=C(CS(C)=O)C=C1.CCN1CCN(CC(=O)C2=CC=C(C(C)C)C=C2)CC1 Chemical compound CC(=O)C1=CC=C(C(C)C)C=C1.CC(C)C1=CC=C(C2=NCCCN2)C=C1.CC(C)C1=CC=C(C2C(=O)N(C)CCN2C)C=C1.CC(C)C1=CC=C(C2CCCN(C)C2)C=C1.CC(C)C1=CC=C(CS(C)=O)C=C1.CCN1CCN(CC(=O)C2=CC=C(C(C)C)C=C2)CC1 UAUHXGLEZFIXBO-UHFFFAOYSA-N 0.000 description 2
- JXCRTZUBHGHSMC-UHFFFAOYSA-N CC(=O)N1CCN(C2=CC=C(C(C)C)C=C2)CC1.CC(C)C1=CC=C(N2CCN(C(=O)CO)CC2)C=C1.CC(C)C1=CC=C(N2CCN(C3CCCCC3)CC2)C=C1.CC(C)C1=CC=C(N2CCN(C3CCN(C)CC3)CC2)C=C1 Chemical compound CC(=O)N1CCN(C2=CC=C(C(C)C)C=C2)CC1.CC(C)C1=CC=C(N2CCN(C(=O)CO)CC2)C=C1.CC(C)C1=CC=C(N2CCN(C3CCCCC3)CC2)C=C1.CC(C)C1=CC=C(N2CCN(C3CCN(C)CC3)CC2)C=C1 JXCRTZUBHGHSMC-UHFFFAOYSA-N 0.000 description 2
- MIKZGRLSBAMMPU-UHFFFAOYSA-N CC(C)C1=C(F)C=C(N2CCN(C)CC2)C=C1.CC(C)C1=CC(Cl)=C(N2CCN(C)CC2)C=C1.CC(C)C1=CC(F)=C(N2CCN(C)CC2)C(F)=C1.COC1=C(C(C)C)C=CC(N2CCN(C)CC2)=C1.COC1=CC(C(C)C)=CC=C1N1CCN(C)CC1 Chemical compound CC(C)C1=C(F)C=C(N2CCN(C)CC2)C=C1.CC(C)C1=CC(Cl)=C(N2CCN(C)CC2)C=C1.CC(C)C1=CC(F)=C(N2CCN(C)CC2)C(F)=C1.COC1=C(C(C)C)C=CC(N2CCN(C)CC2)=C1.COC1=CC(C(C)C)=CC=C1N1CCN(C)CC1 MIKZGRLSBAMMPU-UHFFFAOYSA-N 0.000 description 2
- VZHAOAIBPJQMMH-UHFFFAOYSA-N CC(C)C1=CC(Cl)=C(C(=O)N(C)C)C=C1.CC(C)C1=CC(F)=C(OC2CCN(C)CC2)C=C1.CC(C)C1=CC(F)=C(OCCN2CCN(C)CC2)C=C1.CC(C)C1=CC=C(OCCN2CCOCC2)C(F)=C1.CC(C)C1=CN=C(S(C)=O)C=C1.COC1=CC(C(C)C)=CC=C1OCCN1CCOCC1 Chemical compound CC(C)C1=CC(Cl)=C(C(=O)N(C)C)C=C1.CC(C)C1=CC(F)=C(OC2CCN(C)CC2)C=C1.CC(C)C1=CC(F)=C(OCCN2CCN(C)CC2)C=C1.CC(C)C1=CC=C(OCCN2CCOCC2)C(F)=C1.CC(C)C1=CN=C(S(C)=O)C=C1.COC1=CC(C(C)C)=CC=C1OCCN1CCOCC1 VZHAOAIBPJQMMH-UHFFFAOYSA-N 0.000 description 2
- SRKBYPMIDNSNCQ-UHFFFAOYSA-N CC(C)C1=CC(Cl)=C(C(=O)NC2CCN(C)CC2)C=C1.CC(C)C1=CC=C(C(=O)N2CCNCC2)C(Cl)=C1.CCN1CCN(C(=O)C2=CC=C(C(C)C)C=C2Cl)CC1.CC[SH](=O)=O.COC1=C(C(=O)NC2CCN(C)CC2)C=CC(C(C)C)=C1.COC1=C(C(C)C)C=CC(C(=O)NCCN2CCCC2)=C1 Chemical compound CC(C)C1=CC(Cl)=C(C(=O)NC2CCN(C)CC2)C=C1.CC(C)C1=CC=C(C(=O)N2CCNCC2)C(Cl)=C1.CCN1CCN(C(=O)C2=CC=C(C(C)C)C=C2Cl)CC1.CC[SH](=O)=O.COC1=C(C(=O)NC2CCN(C)CC2)C=CC(C(C)C)=C1.COC1=C(C(C)C)C=CC(C(=O)NCCN2CCCC2)=C1 SRKBYPMIDNSNCQ-UHFFFAOYSA-N 0.000 description 2
- RMUIAGUKXOIXKU-UHFFFAOYSA-N CC(C)C1=CC(Cl)=C(C2CCN(C)CC2)C=C1.CC(C)C1=CC(F)=C(C2CCN(C)CC2)C=C1.CC(C)C1=CC(F)=C(NC(=O)N2CCN(C)CC2)C=C1.CC1=C(C(=O)NC2CCN(C)CC2)C=CC(C(C)C)=C1.COC1=CC(C2CCN(C)CC2)=CC=C1C(C)C Chemical compound CC(C)C1=CC(Cl)=C(C2CCN(C)CC2)C=C1.CC(C)C1=CC(F)=C(C2CCN(C)CC2)C=C1.CC(C)C1=CC(F)=C(NC(=O)N2CCN(C)CC2)C=C1.CC1=C(C(=O)NC2CCN(C)CC2)C=CC(C(C)C)=C1.COC1=CC(C2CCN(C)CC2)=CC=C1C(C)C RMUIAGUKXOIXKU-UHFFFAOYSA-N 0.000 description 2
- PDLPVMYCJAWIIV-UHFFFAOYSA-N CC(C)C1=CC(Cl)=C(CN2CCN(C3CCN(C)CC3)CC2)C=C1.CC(C)C1=CC(F)=C(CN2CCC(N(C)C)C2)C=C1.CC(C)C1=CC(F)=C(CN2CCC(N(C)C)CC2)C=C1.CC(C)C1=CC(F)=C(CN2CCN(C)CC2)C=C1.CC(C)C1=CN=C(CN2CCN(C)CC2)C=C1 Chemical compound CC(C)C1=CC(Cl)=C(CN2CCN(C3CCN(C)CC3)CC2)C=C1.CC(C)C1=CC(F)=C(CN2CCC(N(C)C)C2)C=C1.CC(C)C1=CC(F)=C(CN2CCC(N(C)C)CC2)C=C1.CC(C)C1=CC(F)=C(CN2CCN(C)CC2)C=C1.CC(C)C1=CN=C(CN2CCN(C)CC2)C=C1 PDLPVMYCJAWIIV-UHFFFAOYSA-N 0.000 description 2
- RAKDJHQSODDJPX-UHFFFAOYSA-N CC(C)C1=CC(Cl)=C(N2CCC(N3CCOCC3)CC2)C=C1.CC(C)C1=CC(F)=C(N2CCC(N3CCCCC3)CC2)C=C1.CC(C)C1=CC(F)=C(NCCN(C)C)C(F)=C1.CC(C)C1=CC(F)=C(NCCN(C)C)C=C1.CC(C)C1=CN=C(N2CCC(N3CCCCC3)CC2)C=C1 Chemical compound CC(C)C1=CC(Cl)=C(N2CCC(N3CCOCC3)CC2)C=C1.CC(C)C1=CC(F)=C(N2CCC(N3CCCCC3)CC2)C=C1.CC(C)C1=CC(F)=C(NCCN(C)C)C(F)=C1.CC(C)C1=CC(F)=C(NCCN(C)C)C=C1.CC(C)C1=CN=C(N2CCC(N3CCCCC3)CC2)C=C1 RAKDJHQSODDJPX-UHFFFAOYSA-N 0.000 description 2
- YWDBWPYLKQTIRN-UHFFFAOYSA-N CC(C)C1=CC(Cl)=C(N2CCNCC2)C=C1.CC(C)C1=CC(F)=C(N2CCN(C)CC2)C=C1.CC(C)C1=CC2=C(C=C1)OCCO2.CC(C)C1=CC=C(F)C(Cl)=C1.CC(C)C1=CC=C2C(=C1)CCCC(=O)N2C.CC(C)C1=CC=C2OCCCNC2=C1 Chemical compound CC(C)C1=CC(Cl)=C(N2CCNCC2)C=C1.CC(C)C1=CC(F)=C(N2CCN(C)CC2)C=C1.CC(C)C1=CC2=C(C=C1)OCCO2.CC(C)C1=CC=C(F)C(Cl)=C1.CC(C)C1=CC=C2C(=C1)CCCC(=O)N2C.CC(C)C1=CC=C2OCCCNC2=C1 YWDBWPYLKQTIRN-UHFFFAOYSA-N 0.000 description 2
- AMWREIPIQSYNBZ-UHFFFAOYSA-N CC(C)C1=CC(Cl)=C(NC2CCN(C)CC2)C=C1.CC(C)C1=CC(Cl)=C(NCCN(C)C)C=C1.CC(C)C1=CC(F)=C(NC2CCN(C)CC2)C(F)=C1.CC(C)C1=CC(F)=C(NC2CCN(C)CC2)C=C1.CC(C)C1=CN=C(NCCN2CCCCC2)C=C1 Chemical compound CC(C)C1=CC(Cl)=C(NC2CCN(C)CC2)C=C1.CC(C)C1=CC(Cl)=C(NCCN(C)C)C=C1.CC(C)C1=CC(F)=C(NC2CCN(C)CC2)C(F)=C1.CC(C)C1=CC(F)=C(NC2CCN(C)CC2)C=C1.CC(C)C1=CN=C(NCCN2CCCCC2)C=C1 AMWREIPIQSYNBZ-UHFFFAOYSA-N 0.000 description 2
- CFJPNOHJDZUFLG-UHFFFAOYSA-N CC(C)C1=CC(F)=C(C2CCCN(C)C2)C=C1.CC(C)C1=CC(F)=C(CN(C)C)C=C1.CC1=C(C(C)C)C=CC(CN(C)C)=C1.CCN(CC)CC1=CC(OC)=C(C(C)C)C=C1.COC1=CC(C2CCCN(C)C2)=CC=C1C(C)C.COC1=CC(CN2CCCCC2)=CC=C1C(C)C Chemical compound CC(C)C1=CC(F)=C(C2CCCN(C)C2)C=C1.CC(C)C1=CC(F)=C(CN(C)C)C=C1.CC1=C(C(C)C)C=CC(CN(C)C)=C1.CCN(CC)CC1=CC(OC)=C(C(C)C)C=C1.COC1=CC(C2CCCN(C)C2)=CC=C1C(C)C.COC1=CC(CN2CCCCC2)=CC=C1C(C)C CFJPNOHJDZUFLG-UHFFFAOYSA-N 0.000 description 2
- VBDDNXSRRCUPGK-UHFFFAOYSA-N CC(C)C1=CC(F)=C(CNC2CCN(C)CC2)C=C1 Chemical compound CC(C)C1=CC(F)=C(CNC2CCN(C)CC2)C=C1 VBDDNXSRRCUPGK-UHFFFAOYSA-N 0.000 description 2
- RRMUEZDIMKHLTG-UHFFFAOYSA-N CC(C)C1=CC(F)=C(N2CCC(N3CCOCC3)CC2)C=C1.CC(C)C1=CC=C(N2CCC(N3CCCC3)CC2)C(Cl)=C1.CC(C)C1=CC=C(N2CCC(N3CCCC3)CC2)C(F)=C1.CC(C)C1=CN=C(N2CCC(N3CCCC3)CC2)C=C1 Chemical compound CC(C)C1=CC(F)=C(N2CCC(N3CCOCC3)CC2)C=C1.CC(C)C1=CC=C(N2CCC(N3CCCC3)CC2)C(Cl)=C1.CC(C)C1=CC=C(N2CCC(N3CCCC3)CC2)C(F)=C1.CC(C)C1=CN=C(N2CCC(N3CCCC3)CC2)C=C1 RRMUEZDIMKHLTG-UHFFFAOYSA-N 0.000 description 2
- DCUABZMQXAMRPK-UHFFFAOYSA-N CC(C)C1=CC(F)=C(N2CCN(C(=O)CN(C)C)CC2)C=C1.CC(C)C1=CC(F)=C(N2CCN(S(C)(=O)=O)CC2)C=C1.CC(C)C1=CN=C(N2CCN(C3CCN(C)CC3)CC2)C=C1.CCS(=O)(=O)N1CCN(C2=C(F)C=C(C(C)C)C=C2)CC1 Chemical compound CC(C)C1=CC(F)=C(N2CCN(C(=O)CN(C)C)CC2)C=C1.CC(C)C1=CC(F)=C(N2CCN(S(C)(=O)=O)CC2)C=C1.CC(C)C1=CN=C(N2CCN(C3CCN(C)CC3)CC2)C=C1.CCS(=O)(=O)N1CCN(C2=C(F)C=C(C(C)C)C=C2)CC1 DCUABZMQXAMRPK-UHFFFAOYSA-N 0.000 description 2
- RYBWUSFISRVGRQ-UHFFFAOYSA-N CC(C)C1=CC(F)=C(N2CCOCC2)C=C1.CC(C)C1=CC=C(N2CCC(N(C)C)CC2)N=C1.CC(C)C1=CN=C(N2CCOCC2)C=C1.CC1CN(C2=C(F)C=C(C(C)C)C=C2)CC(C)O1.COC1=C(C(C)C)C=CC(N2CCOCC2)=C1 Chemical compound CC(C)C1=CC(F)=C(N2CCOCC2)C=C1.CC(C)C1=CC=C(N2CCC(N(C)C)CC2)N=C1.CC(C)C1=CN=C(N2CCOCC2)C=C1.CC1CN(C2=C(F)C=C(C(C)C)C=C2)CC(C)O1.COC1=C(C(C)C)C=CC(N2CCOCC2)=C1 RYBWUSFISRVGRQ-UHFFFAOYSA-N 0.000 description 2
- HGTDIEQDLBBQIN-UHFFFAOYSA-N CC(C)C1=CC(F)=C(NC2CCN(C(C)C)CC2)C=C1.CC(C)C1=CC(F)=C(OCCN(C)C)C=C1.CC(C)C1=CN=C(NC2CCN(C(C)C)CC2)C=C1.CCN(CC)CCOC1=C(F)C=C(C(C)C)C=C1.COCCOC1=C(F)C=C(C(C)C)C=C1 Chemical compound CC(C)C1=CC(F)=C(NC2CCN(C(C)C)CC2)C=C1.CC(C)C1=CC(F)=C(OCCN(C)C)C=C1.CC(C)C1=CN=C(NC2CCN(C(C)C)CC2)C=C1.CCN(CC)CCOC1=C(F)C=C(C(C)C)C=C1.COCCOC1=C(F)C=C(C(C)C)C=C1 HGTDIEQDLBBQIN-UHFFFAOYSA-N 0.000 description 2
- TYNBXABJYHXTQL-DCTLWRSRSA-N CC(C)C1=CC2=C(C=C1)N(C(=O)CN(C)C)CC2.CC(C)C1=CC2=C(C=C1)N(C)/C=C\2.CC(C)C1=CC=C(/C=C/CN(C)C)C=C1.CC(C)C1=CC=C(/C=C/CN2CCCCC2)C=C1.CC(C)C1=CC=C(CC(=O)NC2CCN(C)CC2)C=C1.CC(C)C1=CN=CC=C1 Chemical compound CC(C)C1=CC2=C(C=C1)N(C(=O)CN(C)C)CC2.CC(C)C1=CC2=C(C=C1)N(C)/C=C\2.CC(C)C1=CC=C(/C=C/CN(C)C)C=C1.CC(C)C1=CC=C(/C=C/CN2CCCCC2)C=C1.CC(C)C1=CC=C(CC(=O)NC2CCN(C)CC2)C=C1.CC(C)C1=CN=CC=C1 TYNBXABJYHXTQL-DCTLWRSRSA-N 0.000 description 2
- GIHIYDSFXOOWDM-UHFFFAOYSA-N CC(C)C1=CC=C(C(=O)N(C)C)C=C1.CC(C)C1=CC=C(C(=O)N2CCN(C)CC2)C=C1.CC(C)C1=CC=C(C(=O)N2CCN(C3CCN(C)CC3)CC2)C=C1.CC(C)C1=CC=C(C(=O)NC2CCN(C(C)C)CC2)C=C1.CCN1CCN(C(=O)C2=CC=C(C(C)C)C=C2)CC1 Chemical compound CC(C)C1=CC=C(C(=O)N(C)C)C=C1.CC(C)C1=CC=C(C(=O)N2CCN(C)CC2)C=C1.CC(C)C1=CC=C(C(=O)N2CCN(C3CCN(C)CC3)CC2)C=C1.CC(C)C1=CC=C(C(=O)NC2CCN(C(C)C)CC2)C=C1.CCN1CCN(C(=O)C2=CC=C(C(C)C)C=C2)CC1 GIHIYDSFXOOWDM-UHFFFAOYSA-N 0.000 description 2
- BQSLLWKJRUWCCG-UHFFFAOYSA-N CC(C)C1=CC=C(C(=O)N2CCC(N(C)C)C2)C=C1.CC(C)C1=CC=C(C(=O)N2CCC(O)CC2)C=C1.CC(C)C1=CC=C(C(=O)N2CCOCC2)C=C1.CC(C)C1=CC=C(NC(=O)CCN2CCCC2)C=C1.CNC1CCN(C(=O)C2=CC=C(C(C)C)C=C2)C1 Chemical compound CC(C)C1=CC=C(C(=O)N2CCC(N(C)C)C2)C=C1.CC(C)C1=CC=C(C(=O)N2CCC(O)CC2)C=C1.CC(C)C1=CC=C(C(=O)N2CCOCC2)C=C1.CC(C)C1=CC=C(NC(=O)CCN2CCCC2)C=C1.CNC1CCN(C(=O)C2=CC=C(C(C)C)C=C2)C1 BQSLLWKJRUWCCG-UHFFFAOYSA-N 0.000 description 2
- IAWIRBPBUBMGGJ-UHFFFAOYSA-N CC(C)C1=CC=C(C(=O)NC2CCN(C)CC2)C=C1.CC(C)C1=CC=C(C(=O)NC2CCOCC2)C=C1.CC(C)C1=CC=C(C(=O)NCCN(C)C)C=C1.CC(C)C1=CC=C(C(=O)NCCN2CCCC2)C=C1 Chemical compound CC(C)C1=CC=C(C(=O)NC2CCN(C)CC2)C=C1.CC(C)C1=CC=C(C(=O)NC2CCOCC2)C=C1.CC(C)C1=CC=C(C(=O)NCCN(C)C)C=C1.CC(C)C1=CC=C(C(=O)NCCN2CCCC2)C=C1 IAWIRBPBUBMGGJ-UHFFFAOYSA-N 0.000 description 2
- CGJFBWYPLTUSCX-UHFFFAOYSA-N CC(C)C1=CC=C(C(=O)OCCCN(C)C)C=C1.CC(C)C1=CC=C(S(=O)(=O)N2CCOCC2)C=C1.CC(C)C1=CC=C(S(=O)(=O)NC2CCN(C(C)C)CC2)C=C1.CCN1CCN(S(=O)(=O)C2=CC=C(C(C)C)C=C2)CC1.CNC(=O)C1=CC=C(C(C)C)C=C1 Chemical compound CC(C)C1=CC=C(C(=O)OCCCN(C)C)C=C1.CC(C)C1=CC=C(S(=O)(=O)N2CCOCC2)C=C1.CC(C)C1=CC=C(S(=O)(=O)NC2CCN(C(C)C)CC2)C=C1.CCN1CCN(S(=O)(=O)C2=CC=C(C(C)C)C=C2)CC1.CNC(=O)C1=CC=C(C(C)C)C=C1 CGJFBWYPLTUSCX-UHFFFAOYSA-N 0.000 description 2
- VPAKLPGXAASVTF-UHFFFAOYSA-N CC(C)C1=CC=C(C2(N)CC2)C=C1.CC(C)C1=CC=C(CC(=O)O)C=C1.CC(C)C1=CC=C(CCO)C=C1.CC(C)C1=CC=C(CN(C)C)C=C1.CC(C)C1=CC=C(CS(C)(=O)=O)C=C1.COP(=O)(CC1=CC=C(C(C)C)C=C1)OC Chemical compound CC(C)C1=CC=C(C2(N)CC2)C=C1.CC(C)C1=CC=C(CC(=O)O)C=C1.CC(C)C1=CC=C(CCO)C=C1.CC(C)C1=CC=C(CN(C)C)C=C1.CC(C)C1=CC=C(CS(C)(=O)=O)C=C1.COP(=O)(CC1=CC=C(C(C)C)C=C1)OC VPAKLPGXAASVTF-UHFFFAOYSA-N 0.000 description 2
- DRCRAMFODJRXQG-UHFFFAOYSA-N CC(C)C1=CC=C(C2=CCN(C)CC2)C=C1.CC(C)C1=CC=C(C2CCN(C(C)C)CC2)C=C1.CC(C)C1=CC=C(C2CCN(C)CC2)C=C1.CC(C)C1=CC=C(NC(=O)N2CCN(C)CC2)C=C1.CCN1CCC(C2=CC=C(C(C)C)C=C2)CC1 Chemical compound CC(C)C1=CC=C(C2=CCN(C)CC2)C=C1.CC(C)C1=CC=C(C2CCN(C(C)C)CC2)C=C1.CC(C)C1=CC=C(C2CCN(C)CC2)C=C1.CC(C)C1=CC=C(NC(=O)N2CCN(C)CC2)C=C1.CCN1CCC(C2=CC=C(C(C)C)C=C2)CC1 DRCRAMFODJRXQG-UHFFFAOYSA-N 0.000 description 2
- WWIJZNVUERECEN-UHFFFAOYSA-N CC(C)C1=CC=C(CCN(C)C)C=C1.CC(C)C1=CC=C(CCS(C)(=O)=O)C=C1.CC(C)C1=CC=C(CCS(C)=O)C=C1.CC(C)C1=CC=C(CN2CCC(N(C)C)CC2)C=C1.CC(C)C1=CC=C(CN2CCC(N3CCOCC3)CC2)C=C1.CC(C)C1=CC=C(CN2CCC(O)CC2)C=C1 Chemical compound CC(C)C1=CC=C(CCN(C)C)C=C1.CC(C)C1=CC=C(CCS(C)(=O)=O)C=C1.CC(C)C1=CC=C(CCS(C)=O)C=C1.CC(C)C1=CC=C(CN2CCC(N(C)C)CC2)C=C1.CC(C)C1=CC=C(CN2CCC(N3CCOCC3)CC2)C=C1.CC(C)C1=CC=C(CN2CCC(O)CC2)C=C1 WWIJZNVUERECEN-UHFFFAOYSA-N 0.000 description 2
- RNQBCSCCEGYIRF-UHFFFAOYSA-N CC(C)C1=CC=C(CCN2CCCCC2)C=C1.CC(C)C1=CC=C(CCN2CCN(C)CC2)C=C1.CCN1CCN(CCC2=CC=C(C(C)C)C=C2)CC1.CCS(=O)(=O)N1CCN(CCC2=CC=C(C(C)C)C=C2)CC1 Chemical compound CC(C)C1=CC=C(CCN2CCCCC2)C=C1.CC(C)C1=CC=C(CCN2CCN(C)CC2)C=C1.CCN1CCN(CCC2=CC=C(C(C)C)C=C2)CC1.CCS(=O)(=O)N1CCN(CCC2=CC=C(C(C)C)C=C2)CC1 RNQBCSCCEGYIRF-UHFFFAOYSA-N 0.000 description 2
- MUXDFJRPHPEXCE-UHFFFAOYSA-N CC(C)C1=CC=C(CN2CCC(N(C)C)C2)C=C1.CC(C)C1=CC=C(CN2CCN(C3CCN(C)CC3)CC2)C=C1.CC(C)C1=CC=C(CN2CCN(CC3CC3)CC2)C=C1.CCN1CCN(C(C)C2=CC=C(C(C)C)C=C2)CC1.CCN1CCN(CC2=CC=C(C(C)C)C=C2)CC1 Chemical compound CC(C)C1=CC=C(CN2CCC(N(C)C)C2)C=C1.CC(C)C1=CC=C(CN2CCN(C3CCN(C)CC3)CC2)C=C1.CC(C)C1=CC=C(CN2CCN(CC3CC3)CC2)C=C1.CCN1CCN(C(C)C2=CC=C(C(C)C)C=C2)CC1.CCN1CCN(CC2=CC=C(C(C)C)C=C2)CC1 MUXDFJRPHPEXCE-UHFFFAOYSA-N 0.000 description 2
- DULYECXMZLESPJ-UHFFFAOYSA-N CC(C)C1=CC=C(CN2CCC2)C=C1.CC(C)C1=CC=C(CN2CCCC2)C=C1.CC(C)C1=CC=C(CN2CCCCC2)C=C1.CC(C)C1=CC=C(CN2CCN(C)CC2)C=C1.CC(C)C1=CC=C(CN2CCOCC2)C=C1.CCN(CC)CC1=CC=C(C(C)C)C=C1 Chemical compound CC(C)C1=CC=C(CN2CCC2)C=C1.CC(C)C1=CC=C(CN2CCCC2)C=C1.CC(C)C1=CC=C(CN2CCCCC2)C=C1.CC(C)C1=CC=C(CN2CCN(C)CC2)C=C1.CC(C)C1=CC=C(CN2CCOCC2)C=C1.CCN(CC)CC1=CC=C(C(C)C)C=C1 DULYECXMZLESPJ-UHFFFAOYSA-N 0.000 description 2
- KEYYMAIVVDJPOB-UHFFFAOYSA-N CC(C)C1=CC=C(N(C)C)C=C1.CC(C)C1=CC=C(N2C=CN=C2)C=C1.CC(C)C1=CC=C(N2CCC(CN(C)C)CC2)C=C1.CC(C)C1=CC=C(N2CCC(CN3CCCCC3)CC2)C=C1.CC(C)C1=CC=C(NCCN(C)C)C=C1 Chemical compound CC(C)C1=CC=C(N(C)C)C=C1.CC(C)C1=CC=C(N2C=CN=C2)C=C1.CC(C)C1=CC=C(N2CCC(CN(C)C)CC2)C=C1.CC(C)C1=CC=C(N2CCC(CN3CCCCC3)CC2)C=C1.CC(C)C1=CC=C(NCCN(C)C)C=C1 KEYYMAIVVDJPOB-UHFFFAOYSA-N 0.000 description 2
- LGRONJLFFSLPRN-UHFFFAOYSA-N CC(C)C1=CC=C(N2CCC(C(=O)O)CC2)C=C1.CC(C)C1=CC=C(N2CCC(O)CC2)C=C1.CC(C)C1=CC=C(N2CCS(=O)(=O)CC2)C=C1.CC(C)C1=CC=C(N2CCS(=O)CC2)C=C1.CC(C)C1=CC=C(N2CCSCC2)C=C1 Chemical compound CC(C)C1=CC=C(N2CCC(C(=O)O)CC2)C=C1.CC(C)C1=CC=C(N2CCC(O)CC2)C=C1.CC(C)C1=CC=C(N2CCS(=O)(=O)CC2)C=C1.CC(C)C1=CC=C(N2CCS(=O)CC2)C=C1.CC(C)C1=CC=C(N2CCSCC2)C=C1 LGRONJLFFSLPRN-UHFFFAOYSA-N 0.000 description 2
- OWJDPSNRDPELFW-UHFFFAOYSA-N CC(C)C1=CC=C(N2CCC(CCO)CC2)C=C1.CC(C)C1=CC=C(N2CCC(CO)CC2)C=C1.CC(C)C1=CC=C(N2CCC(N3CCOCC3)CC2)C=C1.CCN1CCN(C2CCN(C3=CC=C(C(C)C)C=C3)CC2)CC1 Chemical compound CC(C)C1=CC=C(N2CCC(CCO)CC2)C=C1.CC(C)C1=CC=C(N2CCC(CO)CC2)C=C1.CC(C)C1=CC=C(N2CCC(N3CCOCC3)CC2)C=C1.CCN1CCN(C2CCN(C3=CC=C(C(C)C)C=C3)CC2)CC1 OWJDPSNRDPELFW-UHFFFAOYSA-N 0.000 description 2
- XHQJPQXILYLLCT-UHFFFAOYSA-N CC(C)C1=CC=C(N2CCN(C(C)(C)C)CC2)C=C1.CC(C)C1=CC=C(N2CCN(C(C)C)CC2)C=C1.CC(C)C1=CC=C(N2CCN(C)CC2)C=C1.CC(C)C1=CC=C(N2CCNCC2)C=C1.CCN1CCN(C2=CC=C(C(C)C)C=C2)CC1 Chemical compound CC(C)C1=CC=C(N2CCN(C(C)(C)C)CC2)C=C1.CC(C)C1=CC=C(N2CCN(C(C)C)CC2)C=C1.CC(C)C1=CC=C(N2CCN(C)CC2)C=C1.CC(C)C1=CC=C(N2CCNCC2)C=C1.CCN1CCN(C2=CC=C(C(C)C)C=C2)CC1 XHQJPQXILYLLCT-UHFFFAOYSA-N 0.000 description 2
- PJXBNHCWXBDPKG-UHFFFAOYSA-N CC(C)C1=CC=C(N2CCN(C)CC2)C=C1.CC(C)C1=CC=C(N2CCN(CC(F)(F)F)CC2)C=C1.CC(C)C1=CC=C(N2CCN(S(=O)(=O)N(C)C)CC2)C=C1.CC(C)C1=CC=C(N2CCN(S(C)(=O)=O)CC2)C=C1.CCS(=O)(=O)N1CCN(C2=CC=C(C(C)C)C=C2)CC1 Chemical compound CC(C)C1=CC=C(N2CCN(C)CC2)C=C1.CC(C)C1=CC=C(N2CCN(CC(F)(F)F)CC2)C=C1.CC(C)C1=CC=C(N2CCN(S(=O)(=O)N(C)C)CC2)C=C1.CC(C)C1=CC=C(N2CCN(S(C)(=O)=O)CC2)C=C1.CCS(=O)(=O)N1CCN(C2=CC=C(C(C)C)C=C2)CC1 PJXBNHCWXBDPKG-UHFFFAOYSA-N 0.000 description 2
- MUQTUXFHVQYVHH-UHFFFAOYSA-N CC(C)C1=CC=C(N2CCN(CC(F)F)CC2)C=C1.CC(C)C1=CC=C(N2CCN(CCF)CC2)C=C1.CC(C)C1=CC=C(N2CCN(CCO)CC2)C=C1.COCCN1CCN(C2=CC=C(C(C)C)C=C2)CC1 Chemical compound CC(C)C1=CC=C(N2CCN(CC(F)F)CC2)C=C1.CC(C)C1=CC=C(N2CCN(CCF)CC2)C=C1.CC(C)C1=CC=C(N2CCN(CCO)CC2)C=C1.COCCN1CCN(C2=CC=C(C(C)C)C=C2)CC1 MUQTUXFHVQYVHH-UHFFFAOYSA-N 0.000 description 2
- WGCGVHVYQGURSX-UHFFFAOYSA-N CC(C)C1=CC=C(S(=O)(=O)NC2CC2)C=C1.CC(C)C1=CC=C(S(=O)(=O)NC2CCN(C)CC2)C=C1.CC(C)C1=CC=C(S(=O)(=O)NCCN(C)C)C=C1.CC(C)C1=CC=C(S(C)(=O)=O)C=C1.CC(C)C1=CC=C(S(C)=O)C=C1.CC(C)C1=CC=C(S(N)(=O)=O)C=C1 Chemical compound CC(C)C1=CC=C(S(=O)(=O)NC2CC2)C=C1.CC(C)C1=CC=C(S(=O)(=O)NC2CCN(C)CC2)C=C1.CC(C)C1=CC=C(S(=O)(=O)NCCN(C)C)C=C1.CC(C)C1=CC=C(S(C)(=O)=O)C=C1.CC(C)C1=CC=C(S(C)=O)C=C1.CC(C)C1=CC=C(S(N)(=O)=O)C=C1 WGCGVHVYQGURSX-UHFFFAOYSA-N 0.000 description 2
- CHAAUMCFPURPEA-UHFFFAOYSA-N CC(C)C1=CN=C(N2CCN(C(C)C)CC2)C=C1.CC(C)C1=CN=C(N2CCN(CCN(C)C)CC2)C=C1.CC(C)C1=NC=C(N2CCN(CCO)CC2)C=C1.CCN1CCN(C2=CN=C(C(C)C)C=C2)CC1 Chemical compound CC(C)C1=CN=C(N2CCN(C(C)C)CC2)C=C1.CC(C)C1=CN=C(N2CCN(CCN(C)C)CC2)C=C1.CC(C)C1=NC=C(N2CCN(CCO)CC2)C=C1.CCN1CCN(C2=CN=C(C(C)C)C=C2)CC1 CHAAUMCFPURPEA-UHFFFAOYSA-N 0.000 description 2
- HUJUFHNCTMAIRH-UHFFFAOYSA-N CC(C)C1=CN=C(N2CCN(C)CC2)C=C1.CC(C)C1=NC=C(N2CCN(C)CC2)C=C1.CC1=C(N2CCN(C)CC2)C=CC(C(C)C)=C1.CCN1CCN(C2=CC(OC)=C(C(C)C)C=C2)CC1.COC1=C(C(C)C)C=CC(N2CCN(C)CC2)=C1F Chemical compound CC(C)C1=CN=C(N2CCN(C)CC2)C=C1.CC(C)C1=NC=C(N2CCN(C)CC2)C=C1.CC1=C(N2CCN(C)CC2)C=CC(C(C)C)=C1.CCN1CCN(C2=CC(OC)=C(C(C)C)C=C2)CC1.COC1=C(C(C)C)C=CC(N2CCN(C)CC2)=C1F HUJUFHNCTMAIRH-UHFFFAOYSA-N 0.000 description 2
- MMHDCKVDIIMOTJ-UHFFFAOYSA-N C=CC(=O)NC1=CC(NC2=C3SC=CC3=NC(NC3=CC(F)=C(N4CCN(C)CC4)C=C3)=N2)=C(F)C=C1 Chemical compound C=CC(=O)NC1=CC(NC2=C3SC=CC3=NC(NC3=CC(F)=C(N4CCN(C)CC4)C=C3)=N2)=C(F)C=C1 MMHDCKVDIIMOTJ-UHFFFAOYSA-N 0.000 description 1
- ZTHVSMUBNJKEMY-UHFFFAOYSA-N C=CC(=O)NC1=CC(NC2=C3SC=CC3=NC(NC3=CC=C(C4CCN(C)CC4)C=C3)=N2)=CC=C1 Chemical compound C=CC(=O)NC1=CC(NC2=C3SC=CC3=NC(NC3=CC=C(C4CCN(C)CC4)C=C3)=N2)=CC=C1 ZTHVSMUBNJKEMY-UHFFFAOYSA-N 0.000 description 1
- CAZNOIGZOMUAFG-UHFFFAOYSA-N C=CC(=O)NC1=CC(NC2=C3SC=CC3=NC(NC3=CC=C(N4CCN(C)CC4)C=C3)=N2)=C(F)C=C1 Chemical compound C=CC(=O)NC1=CC(NC2=C3SC=CC3=NC(NC3=CC=C(N4CCN(C)CC4)C=C3)=N2)=C(F)C=C1 CAZNOIGZOMUAFG-UHFFFAOYSA-N 0.000 description 1
- WHYKPQZPZZTXML-UHFFFAOYSA-N C=CC(=O)NC1=CC(NC2=C3SC=CC3=NC(NC3=CC=C(OCCCN(C)C)C=C3)=N2)=CC=C1 Chemical compound C=CC(=O)NC1=CC(NC2=C3SC=CC3=NC(NC3=CC=C(OCCCN(C)C)C=C3)=N2)=CC=C1 WHYKPQZPZZTXML-UHFFFAOYSA-N 0.000 description 1
- ZPFHPQTXDIXLAM-UHFFFAOYSA-N C=CC(=O)NC1=CC(NC2=C3SC=CC3=NC(NC3=CC=C(OCCN(C)C)C=C3)=N2)=CC=C1 Chemical compound C=CC(=O)NC1=CC(NC2=C3SC=CC3=NC(NC3=CC=C(OCCN(C)C)C=C3)=N2)=CC=C1 ZPFHPQTXDIXLAM-UHFFFAOYSA-N 0.000 description 1
- URAVFLCMBFCZDR-UHFFFAOYSA-N C=CC(=O)NC1=CC(NC2=NC(NC3=CC(F)=C(CC4CCN(C)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(NC2=NC(NC3=CC(F)=C(CC4CCN(C)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 URAVFLCMBFCZDR-UHFFFAOYSA-N 0.000 description 1
- ODONGLPWSSYVJP-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=C3OC=CC3=NC(NC3=CC=C(CN(C)C)C=C3)=N2)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=C3OC=CC3=NC(NC3=CC=C(CN(C)C)C=C3)=N2)=CC=C1 ODONGLPWSSYVJP-UHFFFAOYSA-N 0.000 description 1
- WAFMNYLDHHRXKP-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=C3SC=CC3=NC(NC3=CC(Cl)=C(N4CCC(N5CCOCC5)CC4)C=C3)=N2)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=C3SC=CC3=NC(NC3=CC(Cl)=C(N4CCC(N5CCOCC5)CC4)C=C3)=N2)=CC=C1 WAFMNYLDHHRXKP-UHFFFAOYSA-N 0.000 description 1
- IDXHLBCOGCOKRV-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=C3SC=CC3=NC(NC3=CC(F)=C(CC4CCN(C)CC4)C(F)=C3)=N2)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=C3SC=CC3=NC(NC3=CC(F)=C(CC4CCN(C)CC4)C(F)=C3)=N2)=CC=C1 IDXHLBCOGCOKRV-UHFFFAOYSA-N 0.000 description 1
- TWLWSVXEDVOBJP-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=C3SC=CC3=NC(NC3=CC(F)=C(CCCN(C)C)C(F)=C3)=N2)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=C3SC=CC3=NC(NC3=CC(F)=C(CCCN(C)C)C(F)=C3)=N2)=CC=C1 TWLWSVXEDVOBJP-UHFFFAOYSA-N 0.000 description 1
- PFHNPVRTTXYMJY-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=C3SC=CC3=NC(NC3=CC(F)=C(N4CCC(N5CCCCC5)CC4)C=C3)=N2)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=C3SC=CC3=NC(NC3=CC(F)=C(N4CCC(N5CCCCC5)CC4)C=C3)=N2)=CC=C1 PFHNPVRTTXYMJY-UHFFFAOYSA-N 0.000 description 1
- RVGXVBZXLPUUMZ-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=C3SC=CC3=NC(NC3=CC(F)=C(N4CCC(N5CCOCC5)CC4)C=C3)=N2)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=C3SC=CC3=NC(NC3=CC(F)=C(N4CCC(N5CCOCC5)CC4)C=C3)=N2)=CC=C1 RVGXVBZXLPUUMZ-UHFFFAOYSA-N 0.000 description 1
- SMEKLDOFRCERSF-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=C3SC=CC3=NC(NC3=CC(F)=C(N4CCN(C)CC4)C(F)=C3)=N2)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=C3SC=CC3=NC(NC3=CC(F)=C(N4CCN(C)CC4)C(F)=C3)=N2)=CC=C1 SMEKLDOFRCERSF-UHFFFAOYSA-N 0.000 description 1
- SNZTUSJXDYFCOM-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=C3SC=CC3=NC(NC3=CC(F)=C(OC4CCN(C)CC4)C=C3)=N2)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=C3SC=CC3=NC(NC3=CC(F)=C(OC4CCN(C)CC4)C=C3)=N2)=CC=C1 SNZTUSJXDYFCOM-UHFFFAOYSA-N 0.000 description 1
- NLQKLPFYLIXUJS-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=C3SC=CC3=NC(NC3=CC(F)=C(OCCN(CC)CC)C=C3)=N2)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=C3SC=CC3=NC(NC3=CC(F)=C(OCCN(CC)CC)C=C3)=N2)=CC=C1 NLQKLPFYLIXUJS-UHFFFAOYSA-N 0.000 description 1
- DSKAUZVQWZJSKE-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=C3SC=CC3=NC(NC3=CC(F)=C(OCCN4CCN(C)CC4)C=C3)=N2)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=C3SC=CC3=NC(NC3=CC(F)=C(OCCN4CCN(C)CC4)C=C3)=N2)=CC=C1 DSKAUZVQWZJSKE-UHFFFAOYSA-N 0.000 description 1
- BZXKVZASJWKLPS-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=C3SC=CC3=NC(NC3=CC4=C(C=C3)OCCO4)=N2)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=C3SC=CC3=NC(NC3=CC4=C(C=C3)OCCO4)=N2)=CC=C1 BZXKVZASJWKLPS-UHFFFAOYSA-N 0.000 description 1
- IFZVYCZOSRCPHX-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=C3SC=CC3=NC(NC3=CC=C(C(=O)CN4CCN(CC)CC4)C=C3)=N2)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=C3SC=CC3=NC(NC3=CC=C(C(=O)CN4CCN(CC)CC4)C=C3)=N2)=CC=C1 IFZVYCZOSRCPHX-UHFFFAOYSA-N 0.000 description 1
- QPCYBTZVOPBDHW-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=C3SC=CC3=NC(NC3=CC=C(C(=O)N4CCN(CC)CC4)C(Cl)=C3)=N2)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=C3SC=CC3=NC(NC3=CC=C(C(=O)N4CCN(CC)CC4)C(Cl)=C3)=N2)=CC=C1 QPCYBTZVOPBDHW-UHFFFAOYSA-N 0.000 description 1
- ODJAXNBMOLBNFX-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=C3SC=CC3=NC(NC3=CC=C(C(=O)N4CCN(CC)CC4)C=C3)=N2)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=C3SC=CC3=NC(NC3=CC=C(C(=O)N4CCN(CC)CC4)C=C3)=N2)=CC=C1 ODJAXNBMOLBNFX-UHFFFAOYSA-N 0.000 description 1
- ZHPNGVZRPNOBTI-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=C3SC=CC3=NC(NC3=CC=C(C(C)N4CCN(CC)CC4)C=C3)=N2)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=C3SC=CC3=NC(NC3=CC=C(C(C)N4CCN(CC)CC4)C=C3)=N2)=CC=C1 ZHPNGVZRPNOBTI-UHFFFAOYSA-N 0.000 description 1
- MTRRWNYGGPJLGU-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=C3SC=CC3=NC(NC3=CC=C(C4CCCN(C)C4)C=C3OC)=N2)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=C3SC=CC3=NC(NC3=CC=C(C4CCCN(C)C4)C=C3OC)=N2)=CC=C1 MTRRWNYGGPJLGU-UHFFFAOYSA-N 0.000 description 1
- XYQLBHQBYWPFOM-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=C3SC=CC3=NC(NC3=CC=C(C4CCN(C)CC4)C=C3OC)=N2)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=C3SC=CC3=NC(NC3=CC=C(C4CCN(C)CC4)C=C3OC)=N2)=CC=C1 XYQLBHQBYWPFOM-UHFFFAOYSA-N 0.000 description 1
- JHSPFYRYBFXNIZ-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=C3SC=CC3=NC(NC3=CC=C(CC4CCN(C(C)C)CC4)N=C3)=N2)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=C3SC=CC3=NC(NC3=CC=C(CC4CCN(C(C)C)CC4)N=C3)=N2)=CC=C1 JHSPFYRYBFXNIZ-UHFFFAOYSA-N 0.000 description 1
- YFFCHLBPTHTBFC-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=C3SC=CC3=NC(NC3=CC=C(CCCN(C)C)C(Cl)=C3)=N2)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=C3SC=CC3=NC(NC3=CC=C(CCCN(C)C)C(Cl)=C3)=N2)=CC=C1 YFFCHLBPTHTBFC-UHFFFAOYSA-N 0.000 description 1
- BHIJUZAQCNASEF-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=C3SC=CC3=NC(NC3=CC=C(CCCN(C)C)C(F)=C3)=N2)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=C3SC=CC3=NC(NC3=CC=C(CCCN(C)C)C(F)=C3)=N2)=CC=C1 BHIJUZAQCNASEF-UHFFFAOYSA-N 0.000 description 1
- SYUCBABCGQUVLP-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=C3SC=CC3=NC(NC3=CC=C(CCCN(C)C)C=C3)=N2)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=C3SC=CC3=NC(NC3=CC=C(CCCN(C)C)C=C3)=N2)=CC=C1 SYUCBABCGQUVLP-UHFFFAOYSA-N 0.000 description 1
- NWWMOQSBEOZKTD-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=C3SC=CC3=NC(NC3=CC=C(CCCN4CCCCC4)N=C3)=N2)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=C3SC=CC3=NC(NC3=CC=C(CCCN4CCCCC4)N=C3)=N2)=CC=C1 NWWMOQSBEOZKTD-UHFFFAOYSA-N 0.000 description 1
- YMYZAMJQGGIGNW-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=C3SC=CC3=NC(NC3=CC=C(CCCN4CCN(C)CC4)C=C3)=N2)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=C3SC=CC3=NC(NC3=CC=C(CCCN4CCN(C)CC4)C=C3)=N2)=CC=C1 YMYZAMJQGGIGNW-UHFFFAOYSA-N 0.000 description 1
- MTTLWNDXDJSOSH-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=C3SC=CC3=NC(NC3=CC=C(CCN(C)C)C=C3)=N2)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=C3SC=CC3=NC(NC3=CC=C(CCN(C)C)C=C3)=N2)=CC=C1 MTTLWNDXDJSOSH-UHFFFAOYSA-N 0.000 description 1
- QJOFRWWBOBOBJZ-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=C3SC=CC3=NC(NC3=CC=C(CCN4CCN(CC)CC4)C=C3)=N2)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=C3SC=CC3=NC(NC3=CC=C(CCN4CCN(CC)CC4)C=C3)=N2)=CC=C1 QJOFRWWBOBOBJZ-UHFFFAOYSA-N 0.000 description 1
- BVAOHNJUORKMHK-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=C3SC=CC3=NC(NC3=CC=C(CN4CCC(N5CCOCC5)CC4)C=C3)=N2)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=C3SC=CC3=NC(NC3=CC=C(CN4CCC(N5CCOCC5)CC4)C=C3)=N2)=CC=C1 BVAOHNJUORKMHK-UHFFFAOYSA-N 0.000 description 1
- CCBQTDYITDRHKG-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=C3SC=CC3=NC(NC3=CC=C(CN4CCC4)C=C3)=N2)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=C3SC=CC3=NC(NC3=CC=C(CN4CCC4)C=C3)=N2)=CC=C1 CCBQTDYITDRHKG-UHFFFAOYSA-N 0.000 description 1
- JKNPYLIOJYJSKS-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=C3SC=CC3=NC(NC3=CC=C(CN4CCCC4)C=C3)=N2)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=C3SC=CC3=NC(NC3=CC=C(CN4CCCC4)C=C3)=N2)=CC=C1 JKNPYLIOJYJSKS-UHFFFAOYSA-N 0.000 description 1
- PIHHEWBQYVPQMZ-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=C3SC=CC3=NC(NC3=CC=C(CN4CCCCC4)C=C3)=N2)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=C3SC=CC3=NC(NC3=CC=C(CN4CCCCC4)C=C3)=N2)=CC=C1 PIHHEWBQYVPQMZ-UHFFFAOYSA-N 0.000 description 1
- COOVKSWTUVHVNZ-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=C3SC=CC3=NC(NC3=CC=C(CN4CCN(C)CC4)N=C3)=N2)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=C3SC=CC3=NC(NC3=CC=C(CN4CCN(C)CC4)N=C3)=N2)=CC=C1 COOVKSWTUVHVNZ-UHFFFAOYSA-N 0.000 description 1
- QBHALGIZEXFTBS-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=C3SC=CC3=NC(NC3=CC=C(CN4CCN(C5CCN(C)CC5)CC4)C=C3)=N2)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=C3SC=CC3=NC(NC3=CC=C(CN4CCN(C5CCN(C)CC5)CC4)C=C3)=N2)=CC=C1 QBHALGIZEXFTBS-UHFFFAOYSA-N 0.000 description 1
- RWGWSFWBNHFPIT-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=C3SC=CC3=NC(NC3=CC=C(CN4CCN(CC)CC4)C=C3)=N2)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=C3SC=CC3=NC(NC3=CC=C(CN4CCN(CC)CC4)C=C3)=N2)=CC=C1 RWGWSFWBNHFPIT-UHFFFAOYSA-N 0.000 description 1
- GHGUSSUBRUYXOQ-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=C3SC=CC3=NC(NC3=CC=C(CN4CCN(CC5CC5)CC4)C=C3)=N2)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=C3SC=CC3=NC(NC3=CC=C(CN4CCN(CC5CC5)CC4)C=C3)=N2)=CC=C1 GHGUSSUBRUYXOQ-UHFFFAOYSA-N 0.000 description 1
- LHLFSXQPGLSVKW-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=C3SC=CC3=NC(NC3=CC=C(F)C(Cl)=C3)=N2)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=C3SC=CC3=NC(NC3=CC=C(F)C(Cl)=C3)=N2)=CC=C1 LHLFSXQPGLSVKW-UHFFFAOYSA-N 0.000 description 1
- VORFEMDIUABHDK-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=C3SC=CC3=NC(NC3=CC=C(N(C)C)C=C3)=N2)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=C3SC=CC3=NC(NC3=CC=C(N(C)C)C=C3)=N2)=CC=C1 VORFEMDIUABHDK-UHFFFAOYSA-N 0.000 description 1
- ZGFWVGWJRAOFCL-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=C3SC=CC3=NC(NC3=CC=C(N4CCC(C(=O)N(C)C)CC4)C=C3)=N2)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=C3SC=CC3=NC(NC3=CC=C(N4CCC(C(=O)N(C)C)CC4)C=C3)=N2)=CC=C1 ZGFWVGWJRAOFCL-UHFFFAOYSA-N 0.000 description 1
- COOSSIHKRGQMLZ-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=C3SC=CC3=NC(NC3=CC=C(N4CCC(CN(C)C)CC4)C=C3)=N2)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=C3SC=CC3=NC(NC3=CC=C(N4CCC(CN(C)C)CC4)C=C3)=N2)=CC=C1 COOSSIHKRGQMLZ-UHFFFAOYSA-N 0.000 description 1
- UOGJCLDBCGVJTI-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=C3SC=CC3=NC(NC3=CC=C(N4CCC(CN5CCCCC5)CC4)C=C3)=N2)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=C3SC=CC3=NC(NC3=CC=C(N4CCC(CN5CCCCC5)CC4)C=C3)=N2)=CC=C1 UOGJCLDBCGVJTI-UHFFFAOYSA-N 0.000 description 1
- VNSUCGBWVHAPDD-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=C3SC=CC3=NC(NC3=CC=C(N4CCC(N5C=CN=C5)CC4)C=C3)=N2)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=C3SC=CC3=NC(NC3=CC=C(N4CCC(N5C=CN=C5)CC4)C=C3)=N2)=CC=C1 VNSUCGBWVHAPDD-UHFFFAOYSA-N 0.000 description 1
- UYQKOVCBLLFQCE-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=C3SC=CC3=NC(NC3=CC=C(N4CCC(N5CCCC5)CC4)C(Cl)=C3)=N2)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=C3SC=CC3=NC(NC3=CC=C(N4CCC(N5CCCC5)CC4)C(Cl)=C3)=N2)=CC=C1 UYQKOVCBLLFQCE-UHFFFAOYSA-N 0.000 description 1
- JAJPNBFUFDOVGU-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=C3SC=CC3=NC(NC3=CC=C(N4CCC(N5CCCC5)CC4)C(F)=C3)=N2)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=C3SC=CC3=NC(NC3=CC=C(N4CCC(N5CCCC5)CC4)C(F)=C3)=N2)=CC=C1 JAJPNBFUFDOVGU-UHFFFAOYSA-N 0.000 description 1
- HNUGFTKBEBTUIQ-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=C3SC=CC3=NC(NC3=CC=C(N4CCC(N5CCCC5)CC4)C=C3)=N2)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=C3SC=CC3=NC(NC3=CC=C(N4CCC(N5CCCC5)CC4)C=C3)=N2)=CC=C1 HNUGFTKBEBTUIQ-UHFFFAOYSA-N 0.000 description 1
- OHGDUDXLXPRWKQ-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=C3SC=CC3=NC(NC3=CC=C(N4CCC(N5CCCC5)CC4)N=C3)=N2)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=C3SC=CC3=NC(NC3=CC=C(N4CCC(N5CCCC5)CC4)N=C3)=N2)=CC=C1 OHGDUDXLXPRWKQ-UHFFFAOYSA-N 0.000 description 1
- PHCRMGUARHGRRY-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=C3SC=CC3=NC(NC3=CC=C(N4CCC(N5CCOCC5)CC4)C=C3)=N2)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=C3SC=CC3=NC(NC3=CC=C(N4CCC(N5CCOCC5)CC4)C=C3)=N2)=CC=C1 PHCRMGUARHGRRY-UHFFFAOYSA-N 0.000 description 1
- PNADSKKWVCXQEN-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=C3SC=CC3=NC(NC3=CC=C(N4CCN(C(C)C)CC4)N=C3)=N2)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=C3SC=CC3=NC(NC3=CC=C(N4CCN(C(C)C)CC4)N=C3)=N2)=CC=C1 PNADSKKWVCXQEN-UHFFFAOYSA-N 0.000 description 1
- NGDFPGCUNSZJLP-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=C3SC=CC3=NC(NC3=CC=C(N4CCN(C5CCN(C)CC5)CC4)C=C3)=N2)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=C3SC=CC3=NC(NC3=CC=C(N4CCN(C5CCN(C)CC5)CC4)C=C3)=N2)=CC=C1 NGDFPGCUNSZJLP-UHFFFAOYSA-N 0.000 description 1
- PLGOXYSOTOBVDJ-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=C3SC=CC3=NC(NC3=CC=C(N4CCN(C5CCN(C)CC5)CC4)N=C3)=N2)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=C3SC=CC3=NC(NC3=CC=C(N4CCN(C5CCN(C)CC5)CC4)N=C3)=N2)=CC=C1 PLGOXYSOTOBVDJ-UHFFFAOYSA-N 0.000 description 1
- ZWVKEJGYVZTDOP-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=C3SC=CC3=NC(NC3=CC=C(N4CCN(CCN(C)C)CC4)N=C3)=N2)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=C3SC=CC3=NC(NC3=CC=C(N4CCN(CCN(C)C)CC4)N=C3)=N2)=CC=C1 ZWVKEJGYVZTDOP-UHFFFAOYSA-N 0.000 description 1
- VEWBHTPEKABZKT-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=C3SC=CC3=NC(NC3=CC=C(N4CCOCC4)N=C3)=N2)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=C3SC=CC3=NC(NC3=CC=C(N4CCOCC4)N=C3)=N2)=CC=C1 VEWBHTPEKABZKT-UHFFFAOYSA-N 0.000 description 1
- YZTILQAATQEGAE-BOXHHOBZSA-N C=CC(=O)NC1=CC(OC2=C3SC=CC3=NC(NC3=CC=C(N4CC[C@H](N(C)C)C4)C=C3)=N2)=CC=C1.S Chemical compound C=CC(=O)NC1=CC(OC2=C3SC=CC3=NC(NC3=CC=C(N4CC[C@H](N(C)C)C4)C=C3)=N2)=CC=C1.S YZTILQAATQEGAE-BOXHHOBZSA-N 0.000 description 1
- PWUQCRABBPAVAU-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=C3SC=CC3=NC(NC3=CC=C(OCCN4CCOCC4)C(F)=C3)=N2)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=C3SC=CC3=NC(NC3=CC=C(OCCN4CCOCC4)C(F)=C3)=N2)=CC=C1 PWUQCRABBPAVAU-UHFFFAOYSA-N 0.000 description 1
- HOUATSZNAZZYNG-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=C3SC=CC3=NC(NC3=CC=C(OCCN4CCOCC4)C(OC)=C3)=N2)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=C3SC=CC3=NC(NC3=CC=C(OCCN4CCOCC4)C(OC)=C3)=N2)=CC=C1 HOUATSZNAZZYNG-UHFFFAOYSA-N 0.000 description 1
- LFDFWUWZMDGLIF-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=C3SC=CC3=NC(NC3=CC=C(OCCN4CCOCC4)C=C3)=N2)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=C3SC=CC3=NC(NC3=CC=C(OCCN4CCOCC4)C=C3)=N2)=CC=C1 LFDFWUWZMDGLIF-UHFFFAOYSA-N 0.000 description 1
- CJAISBZDOSBBLD-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=C3SC=CC3=NC(NC3=CC=C(S(C)=O)N=C3)=N2)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=C3SC=CC3=NC(NC3=CC=C(S(C)=O)N=C3)=N2)=CC=C1 CJAISBZDOSBBLD-UHFFFAOYSA-N 0.000 description 1
- JNBDCSNOXVWJGS-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=C3SC=CC3=NC(NC3=CC=C4COCCNC4=C3)=N2)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=C3SC=CC3=NC(NC3=CC=C4COCCNC4=C3)=N2)=CC=C1 JNBDCSNOXVWJGS-UHFFFAOYSA-N 0.000 description 1
- NJPUNDYURPEELC-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=NC(NC3=C(C)C=C(CN(C)C)C=C3)=NC3=C2SC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=NC(NC3=C(C)C=C(CN(C)C)C=C3)=NC3=C2SC=C3)=CC=C1 NJPUNDYURPEELC-UHFFFAOYSA-N 0.000 description 1
- OPQVCYGPIAMSLA-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=NC(NC3=C(F)C=C(N4CCN(C)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=NC(NC3=C(F)C=C(N4CCN(C)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 OPQVCYGPIAMSLA-UHFFFAOYSA-N 0.000 description 1
- QCCMTKUAYQVOND-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=NC(NC3=C(OC)C(F)=C(N4CCN(C)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=NC(NC3=C(OC)C(F)=C(N4CCN(C)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 QCCMTKUAYQVOND-UHFFFAOYSA-N 0.000 description 1
- GRGFCLNXIJALEX-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=NC(NC3=C(OC)C=C(C(=O)NCCN4CCCC4)C=C3)=NC3=C2SC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=NC(NC3=C(OC)C=C(C(=O)NCCN4CCCC4)C=C3)=NC3=C2SC=C3)=CC=C1 GRGFCLNXIJALEX-UHFFFAOYSA-N 0.000 description 1
- IYTDJXRCGXGMTD-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=NC(NC3=C(OC)C=C(CN(CC)CC)C=C3)=NC3=C2SC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=NC(NC3=C(OC)C=C(CN(CC)CC)C=C3)=NC3=C2SC=C3)=CC=C1 IYTDJXRCGXGMTD-UHFFFAOYSA-N 0.000 description 1
- ZYRIQILFIFHGJA-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=NC(NC3=C(OC)C=C(N4CCN(C)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=NC(NC3=C(OC)C=C(N4CCN(C)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 ZYRIQILFIFHGJA-UHFFFAOYSA-N 0.000 description 1
- RDDIHOSMRYOTPZ-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=NC(NC3=C(OC)C=C(N4CCOCC4)C=C3)=NC3=C2SC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=NC(NC3=C(OC)C=C(N4CCOCC4)C=C3)=NC3=C2SC=C3)=CC=C1 RDDIHOSMRYOTPZ-UHFFFAOYSA-N 0.000 description 1
- PKLPIVYQQIENSP-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=NC(NC3=CC(C)=C(C(=O)NC4CCN(C)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=NC(NC3=CC(C)=C(C(=O)NC4CCN(C)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 PKLPIVYQQIENSP-UHFFFAOYSA-N 0.000 description 1
- CBBLWQNEHXIURV-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=NC(NC3=CC(Cl)=C(C(=O)N(C)C)C=C3)=NC3=C2SC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=NC(NC3=CC(Cl)=C(C(=O)N(C)C)C=C3)=NC3=C2SC=C3)=CC=C1 CBBLWQNEHXIURV-UHFFFAOYSA-N 0.000 description 1
- PMQDAOIENMVTCP-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=NC(NC3=CC(Cl)=C(C(=O)NC4CCN(C)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=NC(NC3=CC(Cl)=C(C(=O)NC4CCN(C)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 PMQDAOIENMVTCP-UHFFFAOYSA-N 0.000 description 1
- OSMFESYKOOMPDI-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=NC(NC3=CC(Cl)=C(C4CCN(C)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=NC(NC3=CC(Cl)=C(C4CCN(C)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 OSMFESYKOOMPDI-UHFFFAOYSA-N 0.000 description 1
- BWTFKNKIYABPJZ-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=NC(NC3=CC(Cl)=C(CC4CCN(C)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=NC(NC3=CC(Cl)=C(CC4CCN(C)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 BWTFKNKIYABPJZ-UHFFFAOYSA-N 0.000 description 1
- ZHJMIDBUIUHBDP-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=NC(NC3=CC(Cl)=C(N4CCN(C)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=NC(NC3=CC(Cl)=C(N4CCN(C)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 ZHJMIDBUIUHBDP-UHFFFAOYSA-N 0.000 description 1
- OHIQIWVVVZTWME-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=NC(NC3=CC(Cl)=C(N4CCNCC4)C=C3)=NC3=C2SC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=NC(NC3=CC(Cl)=C(N4CCNCC4)C=C3)=NC3=C2SC=C3)=CC=C1 OHIQIWVVVZTWME-UHFFFAOYSA-N 0.000 description 1
- YMGGQALURVRNNM-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=NC(NC3=CC(F)=C(C4CCCN(C)C4)C=C3)=NC3=C2SC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=NC(NC3=CC(F)=C(C4CCCN(C)C4)C=C3)=NC3=C2SC=C3)=CC=C1 YMGGQALURVRNNM-UHFFFAOYSA-N 0.000 description 1
- NMQNTFXWODVNPS-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=NC(NC3=CC(F)=C(C4CCN(C)CC4)C=C3)=NC3=C2OC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=NC(NC3=CC(F)=C(C4CCN(C)CC4)C=C3)=NC3=C2OC=C3)=CC=C1 NMQNTFXWODVNPS-UHFFFAOYSA-N 0.000 description 1
- MIDOKPLINBYQGA-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=NC(NC3=CC(F)=C(C4CCN(C)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=NC(NC3=CC(F)=C(C4CCN(C)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 MIDOKPLINBYQGA-UHFFFAOYSA-N 0.000 description 1
- SNUGZZQSOJVPGE-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=NC(NC3=CC(F)=C(CC(=O)N4CCN(C)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=NC(NC3=CC(F)=C(CC(=O)N4CCN(C)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 SNUGZZQSOJVPGE-UHFFFAOYSA-N 0.000 description 1
- FKALZTONOTYVJK-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=NC(NC3=CC(F)=C(CC4CCN(C(C)C)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=NC(NC3=CC(F)=C(CC4CCN(C(C)C)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 FKALZTONOTYVJK-UHFFFAOYSA-N 0.000 description 1
- PZUSLBFWFSIHDD-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=NC(NC3=CC(F)=C(CC4CCN(C)CC4)C=C3)=NC3=C2OC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=NC(NC3=CC(F)=C(CC4CCN(C)CC4)C=C3)=NC3=C2OC=C3)=CC=C1 PZUSLBFWFSIHDD-UHFFFAOYSA-N 0.000 description 1
- FGDQKIHBTKQQCM-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=NC(NC3=CC(F)=C(CCCN(C)C)C=C3)=NC3=C2OC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=NC(NC3=CC(F)=C(CCCN(C)C)C=C3)=NC3=C2OC=C3)=CC=C1 FGDQKIHBTKQQCM-UHFFFAOYSA-N 0.000 description 1
- BNHRCKBPHHCGRB-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=NC(NC3=CC(F)=C(CN(C)C)C=C3)=NC3=C2SC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=NC(NC3=CC(F)=C(CN(C)C)C=C3)=NC3=C2SC=C3)=CC=C1 BNHRCKBPHHCGRB-UHFFFAOYSA-N 0.000 description 1
- HMNHICZIPDCXOI-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=NC(NC3=CC(F)=C(CN4CCC(N(C)C)C4)C=C3)=NC3=C2SC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=NC(NC3=CC(F)=C(CN4CCC(N(C)C)C4)C=C3)=NC3=C2SC=C3)=CC=C1 HMNHICZIPDCXOI-UHFFFAOYSA-N 0.000 description 1
- ZOIAUCPWBVPLQX-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=NC(NC3=CC(F)=C(CN4CCC(N(C)C)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=NC(NC3=CC(F)=C(CN4CCC(N(C)C)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 ZOIAUCPWBVPLQX-UHFFFAOYSA-N 0.000 description 1
- HOLPNXRYDFLNNB-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=NC(NC3=CC(F)=C(CN4CCN(C)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=NC(NC3=CC(F)=C(CN4CCN(C)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 HOLPNXRYDFLNNB-UHFFFAOYSA-N 0.000 description 1
- CPIZNRFMCCHSKA-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=NC(NC3=CC(F)=C(CNC4CCN(C)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=NC(NC3=CC(F)=C(CNC4CCN(C)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 CPIZNRFMCCHSKA-UHFFFAOYSA-N 0.000 description 1
- RUKRDPXODWVRSI-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=NC(NC3=CC(F)=C(N4CC(C)OC(C)C4)C=C3)=NC3=C2SC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=NC(NC3=CC(F)=C(N4CC(C)OC(C)C4)C=C3)=NC3=C2SC=C3)=CC=C1 RUKRDPXODWVRSI-UHFFFAOYSA-N 0.000 description 1
- WOFBBWFYUIGWRK-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=NC(NC3=CC(F)=C(N4CCN(C(=O)CN(C)C)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=NC(NC3=CC(F)=C(N4CCN(C(=O)CN(C)C)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 WOFBBWFYUIGWRK-UHFFFAOYSA-N 0.000 description 1
- FLVPQYPPHDEPEJ-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=NC(NC3=CC(F)=C(N4CCN(C)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=NC(NC3=CC(F)=C(N4CCN(C)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 FLVPQYPPHDEPEJ-UHFFFAOYSA-N 0.000 description 1
- JFXHJSWGJBXDAJ-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=NC(NC3=CC(F)=C(N4CCOCC4)C=C3)=NC3=C2SC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=NC(NC3=CC(F)=C(N4CCOCC4)C=C3)=NC3=C2SC=C3)=CC=C1 JFXHJSWGJBXDAJ-UHFFFAOYSA-N 0.000 description 1
- MSDQWYDMOMGUMM-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=NC(NC3=CC(F)=C(OCCOC)C=C3)=NC3=C2SC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=NC(NC3=CC(F)=C(OCCOC)C=C3)=NC3=C2SC=C3)=CC=C1 MSDQWYDMOMGUMM-UHFFFAOYSA-N 0.000 description 1
- NSIJBEVLSTVGHI-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=NC(NC3=CC(OC)=C(C(=O)NC4CCN(C)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=NC(NC3=CC(OC)=C(C(=O)NC4CCN(C)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 NSIJBEVLSTVGHI-UHFFFAOYSA-N 0.000 description 1
- AKLFIBVZWHENGA-VOTSOKGWSA-N C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(/C=C/CN(C)C)C=C3)=NC3=C2SC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(/C=C/CN(C)C)C=C3)=NC3=C2SC=C3)=CC=C1 AKLFIBVZWHENGA-VOTSOKGWSA-N 0.000 description 1
- GEZLPGGQCUWCPD-BQYQJAHWSA-N C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(/C=C/CN4CCCCC4)C=C3)=NC3=C2SC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(/C=C/CN4CCCCC4)C=C3)=NC3=C2SC=C3)=CC=C1 GEZLPGGQCUWCPD-BQYQJAHWSA-N 0.000 description 1
- MBANDQUKRWLYJE-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(C(=O)N(C)C)C=C3)=NC3=C2SC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(C(=O)N(C)C)C=C3)=NC3=C2SC=C3)=CC=C1 MBANDQUKRWLYJE-UHFFFAOYSA-N 0.000 description 1
- DKWJQHNVRLZDKF-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(C(=O)N4CCC(N(C)C)C4)C=C3)=NC3=C2SC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(C(=O)N4CCC(N(C)C)C4)C=C3)=NC3=C2SC=C3)=CC=C1 DKWJQHNVRLZDKF-UHFFFAOYSA-N 0.000 description 1
- NBFHBAAQCBELRC-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(C(=O)N4CCC(NC)C4)C=C3)=NC3=C2SC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(C(=O)N4CCC(NC)C4)C=C3)=NC3=C2SC=C3)=CC=C1 NBFHBAAQCBELRC-UHFFFAOYSA-N 0.000 description 1
- IVNBVRMIPSPLOT-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(C(=O)N4CCC(O)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(C(=O)N4CCC(O)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 IVNBVRMIPSPLOT-UHFFFAOYSA-N 0.000 description 1
- JFNQKGPYGZNKAR-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(C(=O)N4CCN(C)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(C(=O)N4CCN(C)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 JFNQKGPYGZNKAR-UHFFFAOYSA-N 0.000 description 1
- LHNVHIKKOQNOEQ-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(C(=O)N4CCN(C5CCN(C)CC5)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(C(=O)N4CCN(C5CCN(C)CC5)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 LHNVHIKKOQNOEQ-UHFFFAOYSA-N 0.000 description 1
- ROMKXEZIKSINRH-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(C(=O)N4CCOCC4)C=C3)=NC3=C2SC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(C(=O)N4CCOCC4)C=C3)=NC3=C2SC=C3)=CC=C1 ROMKXEZIKSINRH-UHFFFAOYSA-N 0.000 description 1
- XOAWGOIGVWIXFT-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(C(=O)NC)C=C3)=NC3=C2SC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(C(=O)NC)C=C3)=NC3=C2SC=C3)=CC=C1 XOAWGOIGVWIXFT-UHFFFAOYSA-N 0.000 description 1
- NECPZYKACAQJGN-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(C(=O)NC4CCN(C(C)C)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(C(=O)NC4CCN(C(C)C)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 NECPZYKACAQJGN-UHFFFAOYSA-N 0.000 description 1
- LSYACBMQMAFWGP-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(C(=O)NC4CCN(C)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(C(=O)NC4CCN(C)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 LSYACBMQMAFWGP-UHFFFAOYSA-N 0.000 description 1
- SPWQTHXEUFREPP-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(C(=O)NC4CCOCC4)C=C3)=NC3=C2SC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(C(=O)NC4CCOCC4)C=C3)=NC3=C2SC=C3)=CC=C1 SPWQTHXEUFREPP-UHFFFAOYSA-N 0.000 description 1
- LXCBWHJYCFEPDZ-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(C(=O)NCCN(C)C)C=C3)=NC3=C2SC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(C(=O)NCCN(C)C)C=C3)=NC3=C2SC=C3)=CC=C1 LXCBWHJYCFEPDZ-UHFFFAOYSA-N 0.000 description 1
- PTTBDFVTUMLVLY-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(C(=O)NCCN4CCCC4)C=C3)=NC3=C2SC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(C(=O)NCCN4CCCC4)C=C3)=NC3=C2SC=C3)=CC=C1 PTTBDFVTUMLVLY-UHFFFAOYSA-N 0.000 description 1
- UTQVGLOAONMCEP-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(C(=O)OCCCN(C)C)C=C3)=NC3=C2SC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(C(=O)OCCCN(C)C)C=C3)=NC3=C2SC=C3)=CC=C1 UTQVGLOAONMCEP-UHFFFAOYSA-N 0.000 description 1
- IHKIKQTYWMIDMA-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(C(C)=O)C=C3)=NC3=C2SC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(C(C)=O)C=C3)=NC3=C2SC=C3)=CC=C1 IHKIKQTYWMIDMA-UHFFFAOYSA-N 0.000 description 1
- LJQITSXHGWVZFK-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(C4(N)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(C4(N)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 LJQITSXHGWVZFK-UHFFFAOYSA-N 0.000 description 1
- VWPQNXJHQKCCBS-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(C4=CCN(C)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(C4=CCN(C)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 VWPQNXJHQKCCBS-UHFFFAOYSA-N 0.000 description 1
- KRNYIISKHBZNQP-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(C4=NCCCN4)C=C3)=NC3=C2SC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(C4=NCCCN4)C=C3)=NC3=C2SC=C3)=CC=C1 KRNYIISKHBZNQP-UHFFFAOYSA-N 0.000 description 1
- QALWAICOFRTCKE-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(C4C(=O)N(C)CCN4C)C=C3)=NC3=C2SC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(C4C(=O)N(C)CCN4C)C=C3)=NC3=C2SC=C3)=CC=C1 QALWAICOFRTCKE-UHFFFAOYSA-N 0.000 description 1
- NAZWWSNCCXEAOS-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(C4CCCN(C)C4)C=C3)=NC3=C2SC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(C4CCCN(C)C4)C=C3)=NC3=C2SC=C3)=CC=C1 NAZWWSNCCXEAOS-UHFFFAOYSA-N 0.000 description 1
- ZDRXLBFZEXNFNH-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(C4CCN(C(C)C)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(C4CCN(C(C)C)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 ZDRXLBFZEXNFNH-UHFFFAOYSA-N 0.000 description 1
- OQHHZDWBRPNNEL-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(C4CCN(CC)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(C4CCN(CC)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 OQHHZDWBRPNNEL-UHFFFAOYSA-N 0.000 description 1
- ZJIOVUJBIWSGFH-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(CC(=O)CC4CCN(C)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(CC(=O)CC4CCN(C)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 ZJIOVUJBIWSGFH-UHFFFAOYSA-N 0.000 description 1
- IWGGECOSZQRMJQ-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(CC(=O)CCN4CCCC4)C=C3)=NC3=C2SC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(CC(=O)CCN4CCCC4)C=C3)=NC3=C2SC=C3)=CC=C1 IWGGECOSZQRMJQ-UHFFFAOYSA-N 0.000 description 1
- NINZBWUBLNPYBR-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(CC(=O)N4CCN(C)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(CC(=O)N4CCN(C)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 NINZBWUBLNPYBR-UHFFFAOYSA-N 0.000 description 1
- ILPJILDMYBAGKV-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(CC(=O)O)C=C3)=NC3=C2SC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(CC(=O)O)C=C3)=NC3=C2SC=C3)=CC=C1 ILPJILDMYBAGKV-UHFFFAOYSA-N 0.000 description 1
- OZCVSONZHHKNQR-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(CC4CCN(C)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(CC4CCN(C)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 OZCVSONZHHKNQR-UHFFFAOYSA-N 0.000 description 1
- TWTDGFCNAHCIDT-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(CCN4CCCCC4)C=C3)=NC3=C2SC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(CCN4CCCCC4)C=C3)=NC3=C2SC=C3)=CC=C1 TWTDGFCNAHCIDT-UHFFFAOYSA-N 0.000 description 1
- USZVADZVLQPDAI-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(CCO)C=C3)=NC3=C2SC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(CCO)C=C3)=NC3=C2SC=C3)=CC=C1 USZVADZVLQPDAI-UHFFFAOYSA-N 0.000 description 1
- GZQMAEZSOHBECI-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(CCS(C)(=O)=O)C=C3)=NC3=C2SC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(CCS(C)(=O)=O)C=C3)=NC3=C2SC=C3)=CC=C1 GZQMAEZSOHBECI-UHFFFAOYSA-N 0.000 description 1
- DPGPDMKAPJFOJC-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(CCS(C)=O)C=C3)=NC3=C2SC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(CCS(C)=O)C=C3)=NC3=C2SC=C3)=CC=C1 DPGPDMKAPJFOJC-UHFFFAOYSA-N 0.000 description 1
- GOYQOAICURKXLC-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(CN(CC)CC)C=C3)=NC3=C2SC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(CN(CC)CC)C=C3)=NC3=C2SC=C3)=CC=C1 GOYQOAICURKXLC-UHFFFAOYSA-N 0.000 description 1
- XUHZHQCRUUGYQF-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(CN4CCC(N(C)C)C4)C=C3)=NC3=C2SC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(CN4CCC(N(C)C)C4)C=C3)=NC3=C2SC=C3)=CC=C1 XUHZHQCRUUGYQF-UHFFFAOYSA-N 0.000 description 1
- KBMBMWYZVYBKIA-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(CN4CCC(N(C)C)CC4)C=C3)=NC3=C2OC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(CN4CCC(N(C)C)CC4)C=C3)=NC3=C2OC=C3)=CC=C1 KBMBMWYZVYBKIA-UHFFFAOYSA-N 0.000 description 1
- SWOPJQKTHDPAEL-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(CN4CCC(N(C)C)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(CN4CCC(N(C)C)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 SWOPJQKTHDPAEL-UHFFFAOYSA-N 0.000 description 1
- WNRARNWBCIPKBI-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(CN4CCC(O)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(CN4CCC(O)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 WNRARNWBCIPKBI-UHFFFAOYSA-N 0.000 description 1
- TUBJUJIZDHZLMR-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(CN4CCOCC4)C=C3)=NC3=C2SC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(CN4CCOCC4)C=C3)=NC3=C2SC=C3)=CC=C1 TUBJUJIZDHZLMR-UHFFFAOYSA-N 0.000 description 1
- SGOKIWXZYLSQMH-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(CP(C)(C)=O)C=C3)=NC3=C2SC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(CP(C)(C)=O)C=C3)=NC3=C2SC=C3)=CC=C1 SGOKIWXZYLSQMH-UHFFFAOYSA-N 0.000 description 1
- MNOAVOVYZWZOBJ-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(CS(C)(=O)=O)C=C3)=NC3=C2SC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(CS(C)(=O)=O)C=C3)=NC3=C2SC=C3)=CC=C1 MNOAVOVYZWZOBJ-UHFFFAOYSA-N 0.000 description 1
- LCIIKOVYESNSLK-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(CS(C)=O)C=C3)=NC3=C2SC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(CS(C)=O)C=C3)=NC3=C2SC=C3)=CC=C1 LCIIKOVYESNSLK-UHFFFAOYSA-N 0.000 description 1
- NZPKGKDDFMDXOO-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(N4C=CN=C4)C=C3)=NC3=C2SC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(N4C=CN=C4)C=C3)=NC3=C2SC=C3)=CC=C1 NZPKGKDDFMDXOO-UHFFFAOYSA-N 0.000 description 1
- ZYRHKIILJWFSNA-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(N4CCC(C(=O)O)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(N4CCC(C(=O)O)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 ZYRHKIILJWFSNA-UHFFFAOYSA-N 0.000 description 1
- ACEHACURALCMLJ-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(N4CCC(CCO)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(N4CCC(CCO)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 ACEHACURALCMLJ-UHFFFAOYSA-N 0.000 description 1
- ANHUCFWHUCHOIZ-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(N4CCC(CO)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(N4CCC(CO)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 ANHUCFWHUCHOIZ-UHFFFAOYSA-N 0.000 description 1
- HYFCVPUUKBHRLR-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(N4CCC(N(C)C)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(N4CCC(N(C)C)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 HYFCVPUUKBHRLR-UHFFFAOYSA-N 0.000 description 1
- ZNYQZWGAZMLJOY-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(N4CCC(N5CCCCC5)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(N4CCC(N5CCCCC5)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 ZNYQZWGAZMLJOY-UHFFFAOYSA-N 0.000 description 1
- PROAQXPTZIBYKC-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(N4CCC(N5CCN(CC)CC5)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(N4CCC(N5CCN(CC)CC5)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 PROAQXPTZIBYKC-UHFFFAOYSA-N 0.000 description 1
- WMSKYJLZQMVBFB-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(N4CCC(O)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(N4CCC(O)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 WMSKYJLZQMVBFB-UHFFFAOYSA-N 0.000 description 1
- JZQGOGWQWIOSOR-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(N4CCCC4)C=C3)=NC3=C2SC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(N4CCCC4)C=C3)=NC3=C2SC=C3)=CC=C1 JZQGOGWQWIOSOR-UHFFFAOYSA-N 0.000 description 1
- YYEBRDULXDATSO-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(N4CCCCC4)C=C3)=NC3=C2SC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(N4CCCCC4)C=C3)=NC3=C2SC=C3)=CC=C1 YYEBRDULXDATSO-UHFFFAOYSA-N 0.000 description 1
- GZHDEPFUGDNQBR-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(N4CCN(C(=O)CN(C)C)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(N4CCN(C(=O)CN(C)C)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 GZHDEPFUGDNQBR-UHFFFAOYSA-N 0.000 description 1
- DYBXDSIUDRTQCB-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(N4CCN(C(=O)CO)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(N4CCN(C(=O)CO)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 DYBXDSIUDRTQCB-UHFFFAOYSA-N 0.000 description 1
- MZWONPIPVJKSMI-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(N4CCN(C(=O)N5CCOCC5)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(N4CCN(C(=O)N5CCOCC5)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 MZWONPIPVJKSMI-UHFFFAOYSA-N 0.000 description 1
- WXCVJXDTLYGORM-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(N4CCN(C(=O)OC(C)(C)C)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(N4CCN(C(=O)OC(C)(C)C)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 WXCVJXDTLYGORM-UHFFFAOYSA-N 0.000 description 1
- FHQJBLUAKWFDOG-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(N4CCN(C(C)(C)C)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(N4CCN(C(C)(C)C)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 FHQJBLUAKWFDOG-UHFFFAOYSA-N 0.000 description 1
- ZQERDWVSWRXVDT-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(N4CCN(C(C)=O)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(N4CCN(C(C)=O)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 ZQERDWVSWRXVDT-UHFFFAOYSA-N 0.000 description 1
- USFHTAJFJGLYEV-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(N4CCN(C(C)C)CC4)C=C3)=NC3=C2OC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(N4CCN(C(C)C)CC4)C=C3)=NC3=C2OC=C3)=CC=C1 USFHTAJFJGLYEV-UHFFFAOYSA-N 0.000 description 1
- HDBDASRZBKUFQH-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(N4CCN(C(C)C)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(N4CCN(C(C)C)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 HDBDASRZBKUFQH-UHFFFAOYSA-N 0.000 description 1
- LZMJNVRJMFMYQS-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(N4CCN(C)CC4)C=C3)=NC3=C2OC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(N4CCN(C)CC4)C=C3)=NC3=C2OC=C3)=CC=C1 LZMJNVRJMFMYQS-UHFFFAOYSA-N 0.000 description 1
- LRQGGNMSAKGHEN-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(N4CCN(C)CC4)C=C3)=NC3=C2SC=C3)=C(C)C=C1 Chemical compound C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(N4CCN(C)CC4)C=C3)=NC3=C2SC=C3)=C(C)C=C1 LRQGGNMSAKGHEN-UHFFFAOYSA-N 0.000 description 1
- DZPFGPRUVJQRDP-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(N4CCN(C)CC4)C=C3)=NC3=C2SC=C3)=C(OC)C=C1 Chemical compound C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(N4CCN(C)CC4)C=C3)=NC3=C2SC=C3)=C(OC)C=C1 DZPFGPRUVJQRDP-UHFFFAOYSA-N 0.000 description 1
- KYPHPVKNJJONBF-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(N4CCN(C)CC4)C=N3)=NC3=C2SC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(N4CCN(C)CC4)C=N3)=NC3=C2SC=C3)=CC=C1 KYPHPVKNJJONBF-UHFFFAOYSA-N 0.000 description 1
- DIFRWOOHSXTTPR-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(N4CCN(C)CC4)N=C3)=NC3=C2SC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(N4CCN(C)CC4)N=C3)=NC3=C2SC=C3)=CC=C1 DIFRWOOHSXTTPR-UHFFFAOYSA-N 0.000 description 1
- DRRKWGQACUGSNH-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(N4CCN(C5CCCCC5)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(N4CCN(C5CCCCC5)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 DRRKWGQACUGSNH-UHFFFAOYSA-N 0.000 description 1
- MOJXPKHLRNMLSL-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(N4CCN(CC(F)(F)F)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(N4CCN(CC(F)(F)F)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 MOJXPKHLRNMLSL-UHFFFAOYSA-N 0.000 description 1
- BWCZXAJVWXOBOQ-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(N4CCN(CC(F)F)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(N4CCN(CC(F)F)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 BWCZXAJVWXOBOQ-UHFFFAOYSA-N 0.000 description 1
- BTMOYFIQWCCAEO-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(N4CCN(CC)CC4)C=N3)=NC3=C2SC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(N4CCN(CC)CC4)C=N3)=NC3=C2SC=C3)=CC=C1 BTMOYFIQWCCAEO-UHFFFAOYSA-N 0.000 description 1
- ITKPZRDXQACKHU-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(N4CCN(CCF)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(N4CCN(CCF)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 ITKPZRDXQACKHU-UHFFFAOYSA-N 0.000 description 1
- CKPUFSSNDGJRRO-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(N4CCN(CCO)CC4)C=N3)=NC3=C2SC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(N4CCN(CCO)CC4)C=N3)=NC3=C2SC=C3)=CC=C1 CKPUFSSNDGJRRO-UHFFFAOYSA-N 0.000 description 1
- NPUIDGDAXIVCNU-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(N4CCNCC4)C=C3)=NC3=C2SC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(N4CCNCC4)C=C3)=NC3=C2SC=C3)=CC=C1 NPUIDGDAXIVCNU-UHFFFAOYSA-N 0.000 description 1
- PKBYFAJEHHXRCJ-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(N4CCOCC4)C=C3)=NC3=C2OC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(N4CCOCC4)C=C3)=NC3=C2OC=C3)=CC=C1 PKBYFAJEHHXRCJ-UHFFFAOYSA-N 0.000 description 1
- VZHFTDGTXQBXEK-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(N4CCOCC4)C=C3)=NC3=C2SC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(N4CCOCC4)C=C3)=NC3=C2SC=C3)=CC=C1 VZHFTDGTXQBXEK-UHFFFAOYSA-N 0.000 description 1
- FTBRSDJLPYSVEI-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(N4CCS(=O)(=O)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(N4CCS(=O)(=O)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 FTBRSDJLPYSVEI-UHFFFAOYSA-N 0.000 description 1
- LFGBSQOCMZPMDP-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(N4CCS(=O)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(N4CCS(=O)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 LFGBSQOCMZPMDP-UHFFFAOYSA-N 0.000 description 1
- ZQBJXWJCTRAWSN-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(N4CCSCC4)C=C3)=NC3=C2SC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(N4CCSCC4)C=C3)=NC3=C2SC=C3)=CC=C1 ZQBJXWJCTRAWSN-UHFFFAOYSA-N 0.000 description 1
- WKXQIEDFEFSOIL-UHFFFAOYSA-O C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(N4CC[N+](C)(O)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(N4CC[N+](C)(O)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 WKXQIEDFEFSOIL-UHFFFAOYSA-O 0.000 description 1
- WYIXLWWPNCLEOS-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(O)C=C3)=NC3=C2SC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(O)C=C3)=NC3=C2SC=C3)=CC=C1 WYIXLWWPNCLEOS-UHFFFAOYSA-N 0.000 description 1
- VGUALUXEUUXVOU-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(OCCN(C)C)C=C3)=NC3=C2SC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(OCCN(C)C)C=C3)=NC3=C2SC=C3)=CC=C1 VGUALUXEUUXVOU-UHFFFAOYSA-N 0.000 description 1
- MSTGVMBRJCYTHE-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(OCCN(CC)CC)C=C3)=NC3=C2SC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(OCCN(CC)CC)C=C3)=NC3=C2SC=C3)=CC=C1 MSTGVMBRJCYTHE-UHFFFAOYSA-N 0.000 description 1
- UOFSFMMBWORVPO-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(OCCN4CCCC4)C=C3)=NC3=C2SC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(OCCN4CCCC4)C=C3)=NC3=C2SC=C3)=CC=C1 UOFSFMMBWORVPO-UHFFFAOYSA-N 0.000 description 1
- RAGHEXWSUJJTGH-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(OCCOC)C=C3)=NC3=C2SC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(OCCOC)C=C3)=NC3=C2SC=C3)=CC=C1 RAGHEXWSUJJTGH-UHFFFAOYSA-N 0.000 description 1
- VRTRDOAVMRAOPY-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(P(C)(C)=O)C=C3)=NC3=C2SC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(P(C)(C)=O)C=C3)=NC3=C2SC=C3)=CC=C1 VRTRDOAVMRAOPY-UHFFFAOYSA-N 0.000 description 1
- VIYYOJATIGJJFN-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(S(=O)(=O)CC4CC4)C=C3)=NC3=C2SC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(S(=O)(=O)CC4CC4)C=C3)=NC3=C2SC=C3)=CC=C1 VIYYOJATIGJJFN-UHFFFAOYSA-N 0.000 description 1
- QDLMSSNRFROTGQ-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(S(=O)(=O)N4CCOCC4)C=C3)=NC3=C2SC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(S(=O)(=O)N4CCOCC4)C=C3)=NC3=C2SC=C3)=CC=C1 QDLMSSNRFROTGQ-UHFFFAOYSA-N 0.000 description 1
- KPXFKOSXFMFWSF-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(S(=O)(=O)NC4CCN(C(C)C)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(S(=O)(=O)NC4CCN(C(C)C)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 KPXFKOSXFMFWSF-UHFFFAOYSA-N 0.000 description 1
- FHNRAMZUCHQETC-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(S(=O)(=O)NC4CCN(C)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(S(=O)(=O)NC4CCN(C)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 FHNRAMZUCHQETC-UHFFFAOYSA-N 0.000 description 1
- GCSFWYGODSJAIO-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(S(=O)(=O)NCCN(C)C)C=C3)=NC3=C2SC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(S(=O)(=O)NCCN(C)C)C=C3)=NC3=C2SC=C3)=CC=C1 GCSFWYGODSJAIO-UHFFFAOYSA-N 0.000 description 1
- DSRWCCSWIUKESP-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(S(C)(=O)=O)C=C3)=NC3=C2SC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(S(C)(=O)=O)C=C3)=NC3=C2SC=C3)=CC=C1 DSRWCCSWIUKESP-UHFFFAOYSA-N 0.000 description 1
- AETBMZDZUNWJEL-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(S(C)=O)C=C3)=NC3=C2SC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(S(C)=O)C=C3)=NC3=C2SC=C3)=CC=C1 AETBMZDZUNWJEL-UHFFFAOYSA-N 0.000 description 1
- OFNGBYJBEIPNRO-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(S(N)(=O)=O)C=C3)=NC3=C2SC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(S(N)(=O)=O)C=C3)=NC3=C2SC=C3)=CC=C1 OFNGBYJBEIPNRO-UHFFFAOYSA-N 0.000 description 1
- AHQUZOVIUOFCAE-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(S)C=C3)=NC3=C2OC=C3)=CC=C1.N.O.O Chemical compound C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C(S)C=C3)=NC3=C2OC=C3)=CC=C1.N.O.O AHQUZOVIUOFCAE-UHFFFAOYSA-N 0.000 description 1
- XBZKAICZTBMLEA-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C4C(=C3)CCN4C(=O)CN(C)C)=NC3=C2SC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=NC(NC3=CC=C4C(=C3)CCN4C(=O)CN(C)C)=NC3=C2SC=C3)=CC=C1 XBZKAICZTBMLEA-UHFFFAOYSA-N 0.000 description 1
- GWNLZXMQHOUQLR-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=NC(NC3=CN=C(N4CCC(N(C)C)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=NC(NC3=CN=C(N4CCC(N(C)C)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 GWNLZXMQHOUQLR-UHFFFAOYSA-N 0.000 description 1
- OPSIOPMXERWSOG-UHFFFAOYSA-N C=CC(=O)NC1=CC(OC2=NC(NC3=CN=C(N4CCC(N5CCCCC5)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(OC2=NC(NC3=CN=C(N4CCC(N5CCCCC5)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 OPSIOPMXERWSOG-UHFFFAOYSA-N 0.000 description 1
- XXQLPJRHXPVITA-UHFFFAOYSA-N C=CC(=O)NC1=CC(S(=O)C2=NC(NC3=CC=C(N4CCN(C)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(S(=O)C2=NC(NC3=CC=C(N4CCN(C)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 XXQLPJRHXPVITA-UHFFFAOYSA-N 0.000 description 1
- SDRMNLCRSANCIY-UHFFFAOYSA-N C=CC(=O)NC1=CC(SC2=NC(NC3=CC=C(N4CCN(C)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 Chemical compound C=CC(=O)NC1=CC(SC2=NC(NC3=CC=C(N4CCN(C)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 SDRMNLCRSANCIY-UHFFFAOYSA-N 0.000 description 1
- JVLUJWWOIGXGOS-UHFFFAOYSA-N C=CC(=O)NC1=CC=C(F)C(N)=C1 Chemical compound C=CC(=O)NC1=CC=C(F)C(N)=C1 JVLUJWWOIGXGOS-UHFFFAOYSA-N 0.000 description 1
- DTWKLSRHQLSXKB-UHFFFAOYSA-N C=CC(=O)NC1=CC=C(F)C([N+](=O)[O-])=C1 Chemical compound C=CC(=O)NC1=CC=C(F)C([N+](=O)[O-])=C1 DTWKLSRHQLSXKB-UHFFFAOYSA-N 0.000 description 1
- URYCUYYZEXPIKD-UHFFFAOYSA-N C=CC(=O)NC1=CC=CC(NC2=C3SC=CC3=NC(NC3=CC=C(CN4CCCCC4)C=C3OC)=N2)=C1 Chemical compound C=CC(=O)NC1=CC=CC(NC2=C3SC=CC3=NC(NC3=CC=C(CN4CCCCC4)C=C3OC)=N2)=C1 URYCUYYZEXPIKD-UHFFFAOYSA-N 0.000 description 1
- BEFPYAYUCSNYES-UHFFFAOYSA-N C=CC(=O)NC1=CC=CC(NC2=NC(NC3=CC=C(C4CCCN(C)C4)C=C3)=NC3=C2SC=C3)=C1 Chemical compound C=CC(=O)NC1=CC=CC(NC2=NC(NC3=CC=C(C4CCCN(C)C4)C=C3)=NC3=C2SC=C3)=C1 BEFPYAYUCSNYES-UHFFFAOYSA-N 0.000 description 1
- LFNSARVTQDFEMX-UHFFFAOYSA-N C=CC(=O)NC1=CC=CC(NC2=NC(NC3=CC=C(C4CCN(C)CC4)C(F)=C3)=NC3=C2SC=C3)=C1 Chemical compound C=CC(=O)NC1=CC=CC(NC2=NC(NC3=CC=C(C4CCN(C)CC4)C(F)=C3)=NC3=C2SC=C3)=C1 LFNSARVTQDFEMX-UHFFFAOYSA-N 0.000 description 1
- UIAHCCPZIYODSZ-UHFFFAOYSA-N C=CC(=O)NC1=CC=CC(NC2=NC(NC3=CC=C(CCN(C)C)C=C3)=NC3=C2SC=C3)=C1 Chemical compound C=CC(=O)NC1=CC=CC(NC2=NC(NC3=CC=C(CCN(C)C)C=C3)=NC3=C2SC=C3)=C1 UIAHCCPZIYODSZ-UHFFFAOYSA-N 0.000 description 1
- ICWBOKDWEYPDBE-UHFFFAOYSA-N C=CC(=O)NC1=CC=CC(NC2=NC(NC3=CC=C(CCN4CCN(C)CC4)C=C3)=NC3=C2SC=C3)=C1 Chemical compound C=CC(=O)NC1=CC=CC(NC2=NC(NC3=CC=C(CCN4CCN(C)CC4)C=C3)=NC3=C2SC=C3)=C1 ICWBOKDWEYPDBE-UHFFFAOYSA-N 0.000 description 1
- WVYLPZBGXKALQH-UHFFFAOYSA-N C=CC(=O)NC1=CC=CC(NC2=NC(NC3=CC=C(CN4CCCCC4)C=C3)=NC3=C2SC=C3)=C1 Chemical compound C=CC(=O)NC1=CC=CC(NC2=NC(NC3=CC=C(CN4CCCCC4)C=C3)=NC3=C2SC=C3)=C1 WVYLPZBGXKALQH-UHFFFAOYSA-N 0.000 description 1
- INYLGZXWICJCNB-UHFFFAOYSA-N C=CC(=O)NC1=CC=CC(NC2=NC(NC3=CC=C(N4CCN(C(C)C)CC4)C=C3)=NC3=C2SC=C3)=C1 Chemical compound C=CC(=O)NC1=CC=CC(NC2=NC(NC3=CC=C(N4CCN(C(C)C)CC4)C=C3)=NC3=C2SC=C3)=C1 INYLGZXWICJCNB-UHFFFAOYSA-N 0.000 description 1
- RMZLOKARFUKDCN-UHFFFAOYSA-N C=CC(=O)NC1=CC=CC(NC2=NC(NC3=CC=C(N4CCN(C)CC4)C(F)=C3)=NC3=C2SC=C3)=C1 Chemical compound C=CC(=O)NC1=CC=CC(NC2=NC(NC3=CC=C(N4CCN(C)CC4)C(F)=C3)=NC3=C2SC=C3)=C1 RMZLOKARFUKDCN-UHFFFAOYSA-N 0.000 description 1
- KKCAITVAVNAFOL-UHFFFAOYSA-N C=CC(=O)NC1=CC=CC(OC2=C3SC=CC3=NC(NC3=CC=C(C(=O)N4CCN(S(=O)(=O)CC)CC4)C(Cl)=C3)=N2)=C1 Chemical compound C=CC(=O)NC1=CC=CC(OC2=C3SC=CC3=NC(NC3=CC=C(C(=O)N4CCN(S(=O)(=O)CC)CC4)C(Cl)=C3)=N2)=C1 KKCAITVAVNAFOL-UHFFFAOYSA-N 0.000 description 1
- OAUYGRWYKKWDGQ-UHFFFAOYSA-N C=CC(=O)NC1=CC=CC(OC2=C3SC=CC3=NC(NC3=CC=C(N4CC(C)N(C)C(C)C4)C=C3)=N2)=C1 Chemical compound C=CC(=O)NC1=CC=CC(OC2=C3SC=CC3=NC(NC3=CC=C(N4CC(C)N(C)C(C)C4)C=C3)=N2)=C1 OAUYGRWYKKWDGQ-UHFFFAOYSA-N 0.000 description 1
- PLYLXYBCUZTVLR-UHFFFAOYSA-N C=CC(=O)NC1=CC=CC(OC2=C3SC=CC3=NC(NC3=CC=C(N4CC5CC4CN5C)C=C3)=N2)=C1 Chemical compound C=CC(=O)NC1=CC=CC(OC2=C3SC=CC3=NC(NC3=CC=C(N4CC5CC4CN5C)C=C3)=N2)=C1 PLYLXYBCUZTVLR-UHFFFAOYSA-N 0.000 description 1
- MTDDJUIATSIVAY-UHFFFAOYSA-N C=CC(=O)NC1=CC=CC(OC2=C3SC=CC3=NC(NC3=CC=C(N4CCN(CCO)CC4)C=C3)=N2)=C1 Chemical compound C=CC(=O)NC1=CC=CC(OC2=C3SC=CC3=NC(NC3=CC=C(N4CCN(CCO)CC4)C=C3)=N2)=C1 MTDDJUIATSIVAY-UHFFFAOYSA-N 0.000 description 1
- UWEVULWNUVFDGD-UHFFFAOYSA-N C=CC(=O)NC1=CC=CC(OC2=C3SC=CC3=NC(NC3=CC=C(N4CCN(CCOC)CC4)C=C3)=N2)=C1 Chemical compound C=CC(=O)NC1=CC=CC(OC2=C3SC=CC3=NC(NC3=CC=C(N4CCN(CCOC)CC4)C=C3)=N2)=C1 UWEVULWNUVFDGD-UHFFFAOYSA-N 0.000 description 1
- XRZMIOUYGJLCEW-UHFFFAOYSA-N C=CC(=O)NC1=CC=CC(OC2=NC(NC3=CC(F)=C(N4CCN(S(=O)(=O)CC)CC4)C=C3)=NC3=C2SC=C3)=C1 Chemical compound C=CC(=O)NC1=CC=CC(OC2=NC(NC3=CC(F)=C(N4CCN(S(=O)(=O)CC)CC4)C=C3)=NC3=C2SC=C3)=C1 XRZMIOUYGJLCEW-UHFFFAOYSA-N 0.000 description 1
- TXXNBQZYCJRMTB-UHFFFAOYSA-N C=CC(=O)NC1=CC=CC(OC2=NC(NC3=CC(F)=C(N4CCN(S(C)(=O)=O)CC4)C=C3)=NC3=C2SC=C3)=C1 Chemical compound C=CC(=O)NC1=CC=CC(OC2=NC(NC3=CC(F)=C(N4CCN(S(C)(=O)=O)CC4)C=C3)=NC3=C2SC=C3)=C1 TXXNBQZYCJRMTB-UHFFFAOYSA-N 0.000 description 1
- FBPWWTQOIPRTRX-UHFFFAOYSA-N C=CC(=O)NC1=CC=CC(OC2=NC(NC3=CC=C(CCN4CCN(S(=O)(=O)C=C)CC4)C=C3)=NC3=C2SC=C3)=C1 Chemical compound C=CC(=O)NC1=CC=CC(OC2=NC(NC3=CC=C(CCN4CCN(S(=O)(=O)C=C)CC4)C=C3)=NC3=C2SC=C3)=C1 FBPWWTQOIPRTRX-UHFFFAOYSA-N 0.000 description 1
- YKSRQHPQMDNONR-UHFFFAOYSA-N C=CC(=O)NC1=CC=CC(OC2=NC(NC3=CC=C(N4CCN(S(=O)(=O)CC)CC4)C=C3)=NC3=C2SC=C3)=C1 Chemical compound C=CC(=O)NC1=CC=CC(OC2=NC(NC3=CC=C(N4CCN(S(=O)(=O)CC)CC4)C=C3)=NC3=C2SC=C3)=C1 YKSRQHPQMDNONR-UHFFFAOYSA-N 0.000 description 1
- ANSCOPFJFYTCMS-UHFFFAOYSA-N C=CC(=O)NC1=CC=CC(OC2=NC(NC3=CC=C(N4CCN(S(=O)(=O)N(C)C)CC4)C=C3)=NC3=C2SC=C3)=C1 Chemical compound C=CC(=O)NC1=CC=CC(OC2=NC(NC3=CC=C(N4CCN(S(=O)(=O)N(C)C)CC4)C=C3)=NC3=C2SC=C3)=C1 ANSCOPFJFYTCMS-UHFFFAOYSA-N 0.000 description 1
- UWYCPGNPOVYYQE-UHFFFAOYSA-N C=CC(=O)NC1=CC=CC(OC2=NC(NC3=CC=C(N4CCN(S(C)(=O)=O)CC4)C=C3)=NC3=C2SC=C3)=C1 Chemical compound C=CC(=O)NC1=CC=CC(OC2=NC(NC3=CC=C(N4CCN(S(C)(=O)=O)CC4)C=C3)=NC3=C2SC=C3)=C1 UWYCPGNPOVYYQE-UHFFFAOYSA-N 0.000 description 1
- WKQOGCVNLPSRTD-UHFFFAOYSA-N C=CC(=O)NC1=CC=CC(OC2=NC(NC3=CC=C(S(=O)(=O)N4CCN(CC)CC4)C=C3)=NC3=C2SC=C3)=C1 Chemical compound C=CC(=O)NC1=CC=CC(OC2=NC(NC3=CC=C(S(=O)(=O)N4CCN(CC)CC4)C=C3)=NC3=C2SC=C3)=C1 WKQOGCVNLPSRTD-UHFFFAOYSA-N 0.000 description 1
- ZZRWXFHUTRJSSS-UHFFFAOYSA-N C=CC(=O)NC1=CC=CC(OC2=NC(NC3=CC=C4C(=C3)CCCC(=O)N4C)=NC3=C2SC=C3)=C1 Chemical compound C=CC(=O)NC1=CC=CC(OC2=NC(NC3=CC=C4C(=C3)CCCC(=O)N4C)=NC3=C2SC=C3)=C1 ZZRWXFHUTRJSSS-UHFFFAOYSA-N 0.000 description 1
- RSRAFZMBJHKIRL-UHFFFAOYSA-N C=CC(=O)NC1=CC=CC(SC2=NC(NC3=CC=C(C4CCN(C)CC4)C(F)=C3)=NC3=C2SC=C3)=C1 Chemical compound C=CC(=O)NC1=CC=CC(SC2=NC(NC3=CC=C(C4CCN(C)CC4)C(F)=C3)=NC3=C2SC=C3)=C1 RSRAFZMBJHKIRL-UHFFFAOYSA-N 0.000 description 1
- CQGFELJMXYGSOH-UHFFFAOYSA-N C=CC(=O)NC1=CC=CC(SC2=NC(NC3=CC=C(N4CCOCC4)C(F)=C3)=NC3=C2SC=C3)=C1 Chemical compound C=CC(=O)NC1=CC=CC(SC2=NC(NC3=CC=C(N4CCOCC4)C(F)=C3)=NC3=C2SC=C3)=C1 CQGFELJMXYGSOH-UHFFFAOYSA-N 0.000 description 1
- FUIUIKRJPKFFLC-UHFFFAOYSA-N C=CC(Nc1cccc(Oc2nc(Nc(cc3)ccc3NC(CCN3CCCC3)=O)nc3c2[s]cc3)c1)=O Chemical compound C=CC(Nc1cccc(Oc2nc(Nc(cc3)ccc3NC(CCN3CCCC3)=O)nc3c2[s]cc3)c1)=O FUIUIKRJPKFFLC-UHFFFAOYSA-N 0.000 description 1
- IWDPKUQLKKHZTM-UHFFFAOYSA-N CC(C)(C)OC(=O)NC1=CC(SC2=NC(Cl)=NC3=C2SC=C3)=CC=C1 Chemical compound CC(C)(C)OC(=O)NC1=CC(SC2=NC(Cl)=NC3=C2SC=C3)=CC=C1 IWDPKUQLKKHZTM-UHFFFAOYSA-N 0.000 description 1
- KNOGNUBKEKVRHT-UHFFFAOYSA-N CC(C)C1=CC=C(N2CC(C)N(C)C(C)C2)C=C1.CC(C)C1=CC=C(N2CC3CC2CN3C)C=C1.CC(C)C1=CC=C(N2CCCC2)C=C1.CC(C)C1=CC=C(N2CCN(C(=O)CN(C)C)CC2)C=C1.CC(C)C1=CC=C(N2CCN(C(=O)N3CCOCC3)CC2)C=C1 Chemical compound CC(C)C1=CC=C(N2CC(C)N(C)C(C)C2)C=C1.CC(C)C1=CC=C(N2CC3CC2CN3C)C=C1.CC(C)C1=CC=C(N2CCCC2)C=C1.CC(C)C1=CC=C(N2CCN(C(=O)CN(C)C)CC2)C=C1.CC(C)C1=CC=C(N2CCN(C(=O)N3CCOCC3)CC2)C=C1 KNOGNUBKEKVRHT-UHFFFAOYSA-N 0.000 description 1
- BLKFTQXHKOXHJA-UHFFFAOYSA-N CC(C)C1=CC=C(N2CC3CC2CN3C)C=C1.CC(C)C1=CC=C(N2CCCC2)C=C1.CC(C)C1=CC=C(N2CCN(C(=O)CN(C)C)CC2)C=C1.CC(C)C1=CC=C(N2CCN(C(=O)N3CCOCC3)CC2)C=C1.CC1CN(C2=CC=C(C(C)C)C=C2)CC(C)N1 Chemical compound CC(C)C1=CC=C(N2CC3CC2CN3C)C=C1.CC(C)C1=CC=C(N2CCCC2)C=C1.CC(C)C1=CC=C(N2CCN(C(=O)CN(C)C)CC2)C=C1.CC(C)C1=CC=C(N2CCN(C(=O)N3CCOCC3)CC2)C=C1.CC1CN(C2=CC=C(C(C)C)C=C2)CC(C)N1 BLKFTQXHKOXHJA-UHFFFAOYSA-N 0.000 description 1
- UIWKBLIZIOZOFE-UHFFFAOYSA-N CC(C)C1=CC=C(N2CCC(C(=O)N(C)C)CC2)C=C1.CC(C)C1=CC=C(N2CCC(N(C)C)CC2)C=C1.CC(C)C1=CC=C(N2CCC(N3C=CN=C3)CC2)C=C1.CC(C)C1=CC=C(N2CCC(N3CCCC3)CC2)C=C1 Chemical compound CC(C)C1=CC=C(N2CCC(C(=O)N(C)C)CC2)C=C1.CC(C)C1=CC=C(N2CCC(N(C)C)CC2)C=C1.CC(C)C1=CC=C(N2CCC(N3C=CN=C3)CC2)C=C1.CC(C)C1=CC=C(N2CCC(N3CCCC3)CC2)C=C1 UIWKBLIZIOZOFE-UHFFFAOYSA-N 0.000 description 1
- MXPZPLJATYKSLN-UHFFFAOYSA-N CC(C)C1=CC=C(N2CCC(C(=O)N(C)C)CC2)C=C1.CC(C)C1=CC=C(N2CCC(N3C=CN=C3)CC2)C=C1.CC(C)C1=CC=C(N2CCC(N3CCCC3)CC2)C=C1.CC(C)C1=CC=C(N2CCC(N3CCCCC3)CC2)C=C1 Chemical compound CC(C)C1=CC=C(N2CCC(C(=O)N(C)C)CC2)C=C1.CC(C)C1=CC=C(N2CCC(N3C=CN=C3)CC2)C=C1.CC(C)C1=CC=C(N2CCC(N3CCCC3)CC2)C=C1.CC(C)C1=CC=C(N2CCC(N3CCCCC3)CC2)C=C1 MXPZPLJATYKSLN-UHFFFAOYSA-N 0.000 description 1
- OHNAORQGCHZUFX-UHFFFAOYSA-N CC(C)C1=CC=C(N2CCC(N3CCCCC3)CC2)C=C1 Chemical compound CC(C)C1=CC=C(N2CCC(N3CCCCC3)CC2)C=C1 OHNAORQGCHZUFX-UHFFFAOYSA-N 0.000 description 1
- WCICMTIDOVVABV-UHFFFAOYSA-N CC(C)C1=CC=C(NC2CCN(C)CC2)C=C1.CC(C)C1=CC=C(NCCN2CCN(C)CC2)C=C1.CC(C)C1=CC=C(O)C=C1.CC(C)C1=CC=C(OCCN(C)C)C=C1.CCN(C)CCOC1=CC=C(C(C)C)C=C1.COCCOC1=CC=C(C(C)C)C=C1 Chemical compound CC(C)C1=CC=C(NC2CCN(C)CC2)C=C1.CC(C)C1=CC=C(NCCN2CCN(C)CC2)C=C1.CC(C)C1=CC=C(O)C=C1.CC(C)C1=CC=C(OCCN(C)C)C=C1.CCN(C)CCOC1=CC=C(C(C)C)C=C1.COCCOC1=CC=C(C(C)C)C=C1 WCICMTIDOVVABV-UHFFFAOYSA-N 0.000 description 1
- SUVVXNCLAFHGDE-UHFFFAOYSA-N CC(C)C1=CC=C(NC2CCN(C)CC2)C=C1.CC(C)C1=CC=C(NCCN2CCN(C)CC2)C=C1.CC(C)C1=CC=C(O)C=C1.CC(C)C1=CC=C(OCCN(C)C)C=C1.CCN(CC)CCOC1=CC=C(C(C)C)C=C1.COCCOC1=CC=C(C(C)C)C=C1 Chemical compound CC(C)C1=CC=C(NC2CCN(C)CC2)C=C1.CC(C)C1=CC=C(NCCN2CCN(C)CC2)C=C1.CC(C)C1=CC=C(O)C=C1.CC(C)C1=CC=C(OCCN(C)C)C=C1.CCN(CC)CCOC1=CC=C(C(C)C)C=C1.COCCOC1=CC=C(C(C)C)C=C1 SUVVXNCLAFHGDE-UHFFFAOYSA-N 0.000 description 1
- WKXLBIZISVUKQW-UHFFFAOYSA-N CC(C)C1=CC=C(OCCCN(C)C)C=C1.CC(C)C1=CC=C(OCCN2CCCC2)C=C1.CC(C)C1=CC=C(OCCN2CCOCC2)C=C1.CCN1CCC(OC2=CC=C(C(C)C)C=C2)CC1.CCOP(=O)(OCC)C1=CC=C(C(C)C)C=C1 Chemical compound CC(C)C1=CC=C(OCCCN(C)C)C=C1.CC(C)C1=CC=C(OCCN2CCCC2)C=C1.CC(C)C1=CC=C(OCCN2CCOCC2)C=C1.CCN1CCC(OC2=CC=C(C(C)C)C=C2)CC1.CCOP(=O)(OCC)C1=CC=C(C(C)C)C=C1 WKXLBIZISVUKQW-UHFFFAOYSA-N 0.000 description 1
- HOKXOSIGFUJVHF-UHFFFAOYSA-N CC(Nc1cc(Oc2c3[s]ccc3nc(Nc(cc3)cc(Cl)c3C(NC3CCN(C)CC3)=O)n2)ccc1)=O Chemical compound CC(Nc1cc(Oc2c3[s]ccc3nc(Nc(cc3)cc(Cl)c3C(NC3CCN(C)CC3)=O)n2)ccc1)=O HOKXOSIGFUJVHF-UHFFFAOYSA-N 0.000 description 1
- HPIWKZPHHJTVJG-UHFFFAOYSA-N CC(Nc1cc(Oc2c3[s]ccc3nc(Nc(cc3)cc(F)c3N(CC3)CCN3S(C)(=O)=O)n2)ccc1)=O Chemical compound CC(Nc1cc(Oc2c3[s]ccc3nc(Nc(cc3)cc(F)c3N(CC3)CCN3S(C)(=O)=O)n2)ccc1)=O HPIWKZPHHJTVJG-UHFFFAOYSA-N 0.000 description 1
- QBTFRCNWBRVFIL-UHFFFAOYSA-N CC(Nc1cc(Oc2c3[s]ccc3nc(Nc(cc3)cc(F)c3N3CCOCC3)n2)ccc1)=O Chemical compound CC(Nc1cc(Oc2c3[s]ccc3nc(Nc(cc3)cc(F)c3N3CCOCC3)n2)ccc1)=O QBTFRCNWBRVFIL-UHFFFAOYSA-N 0.000 description 1
- FAGVPSQMYTZTNB-UHFFFAOYSA-N CC(Nc1cc(Oc2nc(Nc(cc3)cc(Cl)c3N(CC3)CCC3N3CCCC3)nc3c2[s]cc3)ccc1)=O Chemical compound CC(Nc1cc(Oc2nc(Nc(cc3)cc(Cl)c3N(CC3)CCC3N3CCCC3)nc3c2[s]cc3)ccc1)=O FAGVPSQMYTZTNB-UHFFFAOYSA-N 0.000 description 1
- NRCGEOHALMQUNE-UHFFFAOYSA-N CC(Nc1cc(Oc2nc(Nc(cc3)ccc3N3C(C4)CN(C)C4C3)nc3c2[s]cc3)ccc1)=O Chemical compound CC(Nc1cc(Oc2nc(Nc(cc3)ccc3N3C(C4)CN(C)C4C3)nc3c2[s]cc3)ccc1)=O NRCGEOHALMQUNE-UHFFFAOYSA-N 0.000 description 1
- MCVCTWKLZRMGBZ-UHFFFAOYSA-N CC1=CC(OC2=NC(NC3=CC=C(N4CCN(C)CC4)C=C3)=NC3=C2OC=C3)=CC=C1 Chemical compound CC1=CC(OC2=NC(NC3=CC=C(N4CCN(C)CC4)C=C3)=NC3=C2OC=C3)=CC=C1 MCVCTWKLZRMGBZ-UHFFFAOYSA-N 0.000 description 1
- ODAVNQAYGKVUFR-VMPITWQZSA-N CN(C)C/C=C/C(=O)NC1=CC(OC2=NC(NC3=CC=C(N4CCN(C)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 Chemical compound CN(C)C/C=C/C(=O)NC1=CC(OC2=NC(NC3=CC=C(N4CCN(C)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 ODAVNQAYGKVUFR-VMPITWQZSA-N 0.000 description 1
- KZIVRCDABPQWEG-VMPITWQZSA-N CN(C)C/C=C/C(=O)NC1=CC(SC2=NC(NC3=CC=C(N4CCN(C)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 Chemical compound CN(C)C/C=C/C(=O)NC1=CC(SC2=NC(NC3=CC=C(N4CCN(C)CC4)C=C3)=NC3=C2SC=C3)=CC=C1 KZIVRCDABPQWEG-VMPITWQZSA-N 0.000 description 1
- LSAILEYADMCUMS-UHFFFAOYSA-N CN(C)CCNc(ccc(Nc(nc1Oc2cccc(NC(C=C)=O)c2)nc2c1[s]cc2)c1)c1F Chemical compound CN(C)CCNc(ccc(Nc(nc1Oc2cccc(NC(C=C)=O)c2)nc2c1[s]cc2)c1)c1F LSAILEYADMCUMS-UHFFFAOYSA-N 0.000 description 1
- BKLQMQDSBFDYNM-UHFFFAOYSA-N CN(CC1)CCC1Nc(ccc(Nc(nc1Oc2cccc(NC(C=C)=O)c2)nc2c1[s]cc2)c1)c1F Chemical compound CN(CC1)CCC1Nc(ccc(Nc(nc1Oc2cccc(NC(C=C)=O)c2)nc2c1[s]cc2)c1)c1F BKLQMQDSBFDYNM-UHFFFAOYSA-N 0.000 description 1
- CMQLYPFJPRJLRL-UHFFFAOYSA-N CN1CCN(C2=CC=C(NC3=NC4=C(OC=C4)C(OC4=CC=CC([N+](=O)[O-])=C4)=N3)C=C2)CC1 Chemical compound CN1CCN(C2=CC=C(NC3=NC4=C(OC=C4)C(OC4=CC=CC([N+](=O)[O-])=C4)=N3)C=C2)CC1 CMQLYPFJPRJLRL-UHFFFAOYSA-N 0.000 description 1
- WJNHDWYVKAPANE-UHFFFAOYSA-N CN1CCN(C2=CC=C(NC3=NC4=C(SC=C4)C(OC4=CC=CC(N)=C4)=N3)C=C2)CC1 Chemical compound CN1CCN(C2=CC=C(NC3=NC4=C(SC=C4)C(OC4=CC=CC(N)=C4)=N3)C=C2)CC1 WJNHDWYVKAPANE-UHFFFAOYSA-N 0.000 description 1
- BHESXBHRLDIHEX-PKNBQFBNSA-N CN1CCN(C2=CC=C(NC3=NC4=C(SC=C4)C(OC4=CC=CC(NC(=O)/C=C/Cl)=C4)=N3)C=C2)CC1 Chemical compound CN1CCN(C2=CC=C(NC3=NC4=C(SC=C4)C(OC4=CC=CC(NC(=O)/C=C/Cl)=C4)=N3)C=C2)CC1 BHESXBHRLDIHEX-PKNBQFBNSA-N 0.000 description 1
- BHESXBHRLDIHEX-LUAWRHEFSA-N CN1CCN(C2=CC=C(NC3=NC4=C(SC=C4)C(OC4=CC=CC(NC(=O)/C=C\Cl)=C4)=N3)C=C2)CC1 Chemical compound CN1CCN(C2=CC=C(NC3=NC4=C(SC=C4)C(OC4=CC=CC(NC(=O)/C=C\Cl)=C4)=N3)C=C2)CC1 BHESXBHRLDIHEX-LUAWRHEFSA-N 0.000 description 1
- ZRFMQVNLVUOVKB-UHFFFAOYSA-N CN1CCN(C2=CC=C(NC3=NC4=C(SC=C4)C(OC4=CC=CC([N+](=O)[O-])=C4)=N3)C=C2)CC1 Chemical compound CN1CCN(C2=CC=C(NC3=NC4=C(SC=C4)C(OC4=CC=CC([N+](=O)[O-])=C4)=N3)C=C2)CC1 ZRFMQVNLVUOVKB-UHFFFAOYSA-N 0.000 description 1
- LQHUBCHGXBDNEO-UHFFFAOYSA-N CN1CCN(C2=CC=C(NC3=NC4=C(SC=C4)C(OC4=CC=CC([N+](=O)[O-])=C4)=N3)N=C2)CC1 Chemical compound CN1CCN(C2=CC=C(NC3=NC4=C(SC=C4)C(OC4=CC=CC([N+](=O)[O-])=C4)=N3)N=C2)CC1 LQHUBCHGXBDNEO-UHFFFAOYSA-N 0.000 description 1
- DYOOOTWBNRWAHC-UHFFFAOYSA-N CN1CCN(C2=CC=C(NC3=NC4=C(SC=C4)C(SC4=CC=CC(N)=C4)=N3)C=C2)CC1 Chemical compound CN1CCN(C2=CC=C(NC3=NC4=C(SC=C4)C(SC4=CC=CC(N)=C4)=N3)C=C2)CC1 DYOOOTWBNRWAHC-UHFFFAOYSA-N 0.000 description 1
- AISCFIDHEMMPFK-UHFFFAOYSA-N CN1CCN(C2=CC=C(NC3=NC4=C(SC=C4)C(SC4=CC=CC(NC(=O)OC(C)(C)C)=C4)=N3)C=C2)CC1 Chemical compound CN1CCN(C2=CC=C(NC3=NC4=C(SC=C4)C(SC4=CC=CC(NC(=O)OC(C)(C)C)=C4)=N3)C=C2)CC1 AISCFIDHEMMPFK-UHFFFAOYSA-N 0.000 description 1
- KLLINDCXWFZPSS-UHFFFAOYSA-N COP(Cc(cc1)ccc1Nc(nc1Oc2cccc(NC(C=C)=O)c2)nc2c1[s]cc2)(OC)=O Chemical compound COP(Cc(cc1)ccc1Nc(nc1Oc2cccc(NC(C=C)=O)c2)nc2c1[s]cc2)(OC)=O KLLINDCXWFZPSS-UHFFFAOYSA-N 0.000 description 1
- AQECFYPZMBRCIA-UHFFFAOYSA-N ClC1=NC2=C(SC=C2)C(Cl)=N1 Chemical compound ClC1=NC2=C(SC=C2)C(Cl)=N1 AQECFYPZMBRCIA-UHFFFAOYSA-N 0.000 description 1
- QAFVXBQPQCSSLI-UHFFFAOYSA-N O=C1NC(=O)C2=C(C=CS2)N1 Chemical compound O=C1NC(=O)C2=C(C=CS2)N1 QAFVXBQPQCSSLI-UHFFFAOYSA-N 0.000 description 1
- ZKXPTHDGIVQQNE-UHFFFAOYSA-N O=[N+]([O-])C1=CC(OC2=NC(Cl)=NC3=C2OC=C3)=CC=C1 Chemical compound O=[N+]([O-])C1=CC(OC2=NC(Cl)=NC3=C2OC=C3)=CC=C1 ZKXPTHDGIVQQNE-UHFFFAOYSA-N 0.000 description 1
- NZXIACCHHSKZIA-UHFFFAOYSA-N O=[N+]([O-])C1=CC(OC2=NC(Cl)=NC3=C2SC=C3)=CC=C1 Chemical compound O=[N+]([O-])C1=CC(OC2=NC(Cl)=NC3=C2SC=C3)=CC=C1 NZXIACCHHSKZIA-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se)
- C07F9/3804—Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se) not used, see subgroups
- C07F9/3834—Aromatic acids (P-C aromatic linkage)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/09—Geometrical isomers
Definitions
- the present invention relates to a novel fused pyrimidine derivative having an inhibitory activity for tyrosine kinases, and a pharmaceutical composition comprising same as an active ingredient.
- Protein tyrosine kinases play important roles in such cellular regulation (Irena Melnikova and James Golden, Nature Reviews Drug Discovery 3, 993, 2004), and their abnormal expression or mutation has been observed in cancer cells or autoimmune diseases.
- the protein tyrosine kinase is an enzyme which catalyzes the transportation of phosphate groups from ATP to tyrosines located on protein substrates.
- Many growth factor receptor proteins function as tyrosine kinases to transport cellular signals.
- the interaction between growth factors and their receptors normally controls the cellular growth, but abnormal signal transduction caused by the mutation or overexpression of any of the receptors often induces various cancers or autoimmune diseases such as rheumatoid arthritis.
- EGFR epidermal growth factors
- EGFR EGF receptor
- EGFR tyrosine kinases are classified based on their structural differences into four subtypes, i.e., EGFR (Erb-B1), Erb-B2, Erb-B3 and Erb-B4, and it is known that EGFR activating mutations, such as L858R point mutation in exon 21 and in-frame deletions in exon 19 of the EGFR tyrosine kinase domain, are the important cause of non-small cell lung cancer.
- Gefitinib (AstraZeneca) was initially developed as a small molecule for the inhibition of EGFR tyrosine kinases, which selectively and reversibly inhibits EGFR (Erb-B1). Erlotinib (Roche) has also similar characteristics. These EGFR-targeted drugs are efficacious for non-small cell lung cancer (NSCLC) and provide therapeutic convenience for patients with EGFR activating mutations.
- NSCLC non-small cell lung cancer
- irreversible inhibitors to target for EGFR are more beneficial in securing excellent efficacy and overcoming the resistance development, as compared to the conventional reversible inhibitors such as Gefitinib and Erlotinib (Danan Li et al., Cancer Cell 12, 81, 2007; and Anja Michalczyk et al., Bioorganic & Medicinal Chemistry 16, 3482, 2008).
- irreversible inhibitors such as BIBW-2992 (Afatinib, Boeringer Ingelheim) (C H Mom et al., British Journal of Cancer 98, 80, 2007), PF00299804 (Dacomitinib, Pfizer) (Engelman J A, et al., Cancer Res. 67, 11924, 2007), and AV-412 (AVEO Pharmaceuticals) (Tsuyoshi Suzuki et al., Cancer Sci. 98(12), 1977, 2007) have been developed and are currently in the clinical stage.
- the compounds have been known to form a covalent bond with Cystein773 (Cys773) positioned at an ATP domain of EGFR, thereby irreversibly blocking the autophosphorylation of EGFR and thus efficiently inhibiting the signal transduction of cancer cells (David W. Fry et al., Proc. Natl. Acad. Sci. U.S.A. 95, 12022, 1998), and exhibit higher inhibitory activities compared to the reversible inhibitors commercially available as dual inhibitors of EGFR/HER-2, or pan-HER inhibitors in in vitro activities and in various in vivo models of carcinomas (Jeff B. Smaill et al., J. Med. Chem. 42, 1803, 1999).
- the compounds may cause serious side effects such as skin rashes, diarrhea and weight loss due to high activities to EGFR WT (wild type) present in normal cells, when they are administered in a dose sufficient to overcome the resistance induced by EGFR T790M mutations, and this has been limited their clinical application, (Martin L. Sos, et al., Cancer Res. 70, 868, 2010).
- B-lymphocytes B-lymphocytes
- T-lymphocytes T-lymphocytes
- aberrant signaling can induce deregulated B-cell proliferation and differentiation to cause all sorts of lymphoma including various acute or chronic lymphoid leukemia and can cause formation of autoantibodies that lead to multiple inflammatory diseases, autoimmune diseases and/or immunity mediated diseases.
- BTK Bruton's tyrosine kinase
- BCR B-cell receptor
- BTK-deficient mice are resistant to collagen-induced arthritis and BTK inhibitors have been demonstrated dose-dependent efficacies in a mouse model of arthritis (Jansson and Holmdahl, Clin. Exp. Immunol. 94, 459, 1993; Pan et al., Chem. Med. Chem. 2, 58, 2007).
- effective BTK inhibitors may be useful in the treatment of rheumatoid arthritis.
- BTK is also expressed by cells other than B-cells that may be involved in disease processes, i.e., bone marrow-derived mast cells. It has been reported that the antigen-induced degranulation is suppressed in BTK-deficient bone marrow-derived mast cells (Iwaki et al., J. Biol. Chem. 280, 40261, 2005). This shows that BTK could be useful to treat pathological mast cell responses such as allergy and asthma.
- monocytes in which BTK activity is absent, showed decreased TNF- ⁇ production following stimulation (Horwood et al. J Exp Med. 197, 1603, 2003). Therefore, TNF- ⁇ mediated inflammation could be modulated by BTK inhibitors.
- BTK has been reported to play a role in apoptosis as some of regulators (Islam and Smith, Immunol. Rev. 178, 49, 2000).
- BTK inhibitors would be useful for the treatment of certain B-cell lymphomas and leukemias (Feldhahn et al., J. Exp. Med. 201, 1837, 2005).
- T-cells play a role in transmitting signals delivered through the T-cell receptor (TCR) on the cell surface from antigen presenting cells into downstream effectors by the activation of intercellular various kinases such as janus kinases. At this time, they secrete various interleukin (IL) or interferon- ⁇ to activate various leukocytes as well as the B-cells.
- IL interleukin
- Protein kinases involved in signal transduction in T-cells are Janus kinases (JAK) such as JAK1, JAK2, JAK3 and TYK2, IL-2 inducible T-cell kinases (ITK), and TEC family of kinases such as resting lymphocyte kinases (RLK).
- JAK3 Janus kinases involving JAK3 have been widely investigated as a target for autoimmune and/or inflammatory diseases.
- JAK3 unlike JAK2 involved in hematosis and erythrocyte homeostasis or JAK1 expressed in various tissues, JAK3 is expressed in lymphocytes and plays a very important role in signal transduction via various cytokines, i.e., IL-2, IL-4, IL-7, IL-9 and IL-15, which is more attractive (Flanagan et al, Journal of medicinal Chemistry, 53, 8468, 2010).
- JAK3 plays a role in the maturation of B-cells and T-cells as well as in maintaining T-cell functions.
- JAK3 inhibitors may be useful in the treatment of rheumatoid arthritis, psoriasis, atopic dermatitis, lupus, multiple sclerosis, Type I diabetes and complications from diabetes, cancer, asthma, autoimmune thyroid disorders, ulcerative colitis, Crohn's disease, Alzheimer's disease, leukemia, and other indications where immunosuppression would be desirable, such as organ transplants or xeno transplantation (Pesu M, Laurence A, Kishore N, et al., Immunol Rev 223, 132, 2008; Kawahara A, Minami Y, Miyazaki T, et al., Proc Natl Acad Sci USA 92, 8724, 1995; Nosaka T, van Deursen J M A, Tripp R A, et al., Science 270, 800, 1995; Papageorgiou Ac, Wikman L E K., et al., Trends Pharm Sci 25, 558, 2004).
- ITK-deficient mice immune symptoms of allergic asthma were attenuated and lung inflammation, eosinophil infiltration, and mucous production in response to challenge with the allergen ovalbumin were drastically reduced (Muller et al., Journal of Immunology 170, 5056, 2003). This shows that ITK inhibitors would be useful in the treatment of asthma.
- ITK has also been implicated in atopic dermatitis. This gene has been reported to be more highly expressed in peripheral blood T-cells from patients with severe atopic dermatitis, compared with controls or patients with mild atopic dermatitis (Matsumoto et al., International archives of Allergy and Immunology 129, 327, 2002).
- RLK functions to activate the secretion of IL-2 which is produced by signal transduction of T-cell receptors of splenocytes.
- the inhibition of RLK may reduce various responses by T-cells (Schaeffer et al., Nature Immunology 2, 1183, 2001; Schaeffer et al., Science 284, 638, 1999).
- BMX bone marrow tyrosine kinase
- a compound for effectively inhibiting the kinases may be useful as a therapeutic agent for various inflammatory diseases, autoimmune diseases, and immunity mediated diseases.
- a compound for inhibiting BTK involved in B-cell activation inducing B-cell lymphoma, and BMX involved in metastasis of cancer cells may be useful as an anticancer or antitumor agent.
- EGFR irreversible inhibitors which form a covalent bond with Cystein773 (Cys773) positioned at an ATP domain of EGFR, may show inhibitory effects on the activities of TEC family of kinases such as BTK, ITK, RLK and BMX in which cysteine is present in a same position of the amino acid sequence, as well as kinases such as JAK3 or BLK (Wooyoung Hur, et al., Bioorg. Med. Chem. Lett. 18, 5916, 2008), there has been no developed for a compound which can inhibit irreversibly, selectively and effectively variant EGFR, BTK, JAK3, ITK, RLK, BMX and/or BLK.
- EGFR epidermal growth factor receptor
- TEC family kinases e.g. BTK, ITK, BMX or RLK
- janus kinases e.g. JAK3
- W is O or S
- X is O, NH, S, SO or SO 2 ;
- Y is hydrogen atom, halogen atom, C 1-6 alkyl or C 1-6 alkoxy
- a and B are each independently hydrogen atom, halogen atom, or di(C 1-6 alkyl)aminomethyl;
- Z is aryl or heteroaryl having one or more substituents selected from the group consisting of: hydrogen atom, halogen atom, hydroxy, nitro, cyano, C 1-6 alkyl, C 1-6 alkoxy, C 1-6 alkylcarbonyl, C 1-6 alkoxycarbonyl, di(C 1-6 alkyl)aminoC 2-6 alkoxycarbonyl, amino, C 1-6 alkylamino, di(C 1-6 alkyl)amino, carbamoyl, C 1-6 alkylcarbamoyl, di(C 1-6 alkyl)carbamoyl, di(C 1-6 alkyl)aminoC 2-6 alkylcarbamoyl, sulfamoyl, C 1-6 alkylsulfamoyl, di(C 1-6 alkyl)sulfamoyl, di(C 1-6 alkyl)amino C 2-6 alkylsulfamoyl, C 1-6 al
- aryl refers to a C 6-12 cyclic or bicyclic aromatic ring
- heteroaryls each independently refer to a 5- to 12-membered cyclic or bicyclic aromatic hetero ring having one or more N, O or S;
- the heterocycles each independently refer to a saturated or partially unsaturated 3- to 12-membered cyclic or bicyclic hetero ring having one or more N, O, S, SO or SO 2 , in which a carbon atom forming the heterocycle optionally has one or more substituents selected from the group consisting of C 1-6 alkyl, hydroxy, hydroxyC 1-6 alkyl, hydroxycarbonyl, C 1-6 alkoxy, amino, C 1-6 alkylamino, di(C 1-6 alkyl)amino, di(C 1-6 alkyl)aminoC 1-6 alkyl, di(C 1-6 alkyl)aminocarbonyl, heterocycle, heterocyclic C 1-6 alkyl, and heteroaryl, and in which, provided that the heterocycle optionally comprises a nitrogen atom, the nitrogen atom optionally has a substituent selected from the group consisting of hydrogen atom, C 1-6 alkyl, monohalogenoC 1-6 alkyl, dihalogenoC 1-6 alkyl,
- the C 1-6 alkyl is partially unsaturated or has a C 3-6 cycloalkyl moiety, and a carbon atom in the heterocycle exists in a carbonyl form.
- a pharmaceutical composition for preventing or treating cancers, tumors, inflammatory diseases, autoimmune diseases, or immunologically mediated diseases which comprises the compound of formula (I) or a pharmaceutically acceptable salt thereof.
- FIG. 1 size change of tumors by oral administration of the compound obtained in Example 2 in nude mice xenografted with NCI-H1975 cancer cells;
- FIG. 2 body-weight change by oral administration of the compound obtained in Example 2 in nude mice xenografted with NCI-H1975 cancer cells;
- FIG. 3 change in an arthritis clinical score by oral administration of the compound obtained in Example 1 in a collagen-induced arthritis (CIA) model.
- Z include substituents selected from the group consisting of formulae Z1 to Z203, but are not limited thereto:
- A, B, W, X, Y and Z have the same meanings as defined above;
- R is hydrogen, methyl, or ethyl
- N′ is nitro, or amine protected with tert-butyloxycarbonyl (Boc).
- a compound of formula (VIII) is subjected to a condensation reaction with urea in an organic solvent (e.g., N,N-dimethylformamide, N,N-dimethylacetamide or N-methylpyrrolidone) at a temperature ranging from reflux temperature to 200° C.; or with potassium cyanate under an acidic condition such as 6% to 50% of aqueous acetic acid at a temperature ranging from room temperature to 100° C., to obtain a condensed compound of formula (VII).
- an organic solvent e.g., N,N-dimethylformamide, N,N-dimethylacetamide or N-methylpyrrolidone
- potassium cyanate under an acidic condition such as 6% to 50% of aqueous acetic acid at a temperature ranging from room temperature to 100° C.
- the compound of formula (VII) thus obtained is refluxed with stirring in the presence of a chlorinating agent (e.g., phosphorus oxychloride or thionyl chloride) to obtain a chlorinated compound of formula (VI), followed by a reaction in an organic solvent (e.g., dimethylsulfoxide, N,N-dimethylformamide, N,N-dimethylacetamide, N-methylpyrrolidone, acetonitrile, tetrahydrofuran, 1,4-dioxane, toluene or benzene) in the presence of an inorganic base (e.g., cesium carbonate, sodium carbonate or potassium carbonate) at a temperature ranging from room temperature to 100° C., inducing the substitution at the C-4 position of the compound of formula (VI) with aniline, phenol or thiophenol derivative of formula (V), to obtain a compound of formula (IV).
- a chlorinating agent e.g.,
- the compound of formula (IV) is reacted with Z—NH 2 in an alcohol solution (e.g., 2-propanol or 2-butanol) in the presence of an inorganic acid (e.g., hydrochloric acid) or organic acid (e.g., trifluoroacetic acid) at a temperature ranging from 70° C.
- an alcohol solution e.g., 2-propanol or 2-butanol
- an inorganic acid e.g., hydrochloric acid
- organic acid e.g., trifluoroacetic acid
- a palladium catalyst e.g., palladium (II) acetate or tris(dibenzylidenacetone)dipalladium(O)
- a ligand e.g., bis(diphenylphosphino)(Xanthene)(Xantphos) or 2,2′-bis(disphenylphosphino)-1,1′-binaphthyl (BINAP)
- an inorganic base e.g., cesium carbonate or sodium t-butoxide
- the compound of formula (III) in which N′ is nitro group is subjected to a hydrogenation using a palladium/carbon catalyst, or a reduction reaction mediated with Fe, to obtain an aniline compound of formula (II) whose a nitro group is substituted with an amino group.
- the compound of formula (III) in which N′ is amine group protected with tert-butyloxycarbonyl (Boc) is subjected to a reaction with an acid (e.g., trifluoroacetic acid or hydrochloric acid) in an organic solvent (e.g., methylene chloride), to obtain a deprotected aniline compound of formula (II).
- the aniline compound of formula (II) is subjected to a reaction with an acryloyl chloride substituted with A and B, in an organic solvent (e.g., methylene chloride or tetrohydrofuran) or a mixed solvent such as 50% aqueous tetrohydrofuran in the presence of an inorganic base (e.g., sodium bicarbonate) or organic base (e.g., triethylamine or diisopropylethylamine) at a low temperature ranging from ⁇ 10° C.
- an organic solvent e.g., methylene chloride or tetrohydrofuran
- a mixed solvent such as 50% aqueous tetrohydrofuran
- an inorganic base e.g., sodium bicarbonate
- organic base e.g., triethylamine or diisopropylethylamine
- a coupling agent e.g., 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDCI) or 2-(1H-7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyl uronium hexafluoro phosphate methaneaminium (HATU)
- EDCI 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide
- HATU 2-(1H-7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyl uronium hexafluoro phosphate methaneaminium
- the compound of formula (I) of the present invention may also be prepared in the form of a pharmaceutically acceptable salt formed with an inorganic or organic acid such as hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid, acetic acid, glycolic acid, lactic acid, pyruvic acid, malonic acid, succinic acid, glutaric acid, fumaric acid, malic acid, mandelic acid, tartaric acid, citric acid, ascorbic acid, palmitic acid, maleic acid, hydroxymaleic acid, benzoic acid, hydroxybenzoic acid, phenylacetic acid, cinnamic acid, salicylic acid, methanesulfonic acid, benzenesulfonic acid and toluenesulfonic acid.
- an inorganic or organic acid such as hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid, acetic acid, glycolic acid, lactic acid, pyruvic
- the pharmaceutically acceptable salt of the present invention may be prepared by conventional methods, for example, by dissolving the compound of formula (I) in a water-miscible organic solvent such as acetone, methanol, ethanol and acetonitrile, adding thereto an excess amount of an organic acid or an aqueous solution of inorganic acid, to induce precipitation of salts from the resulting mixture, removing the solvent and remaining free acid therefrom, and isolating the precipitated salts.
- a water-miscible organic solvent such as acetone, methanol, ethanol and acetonitrile
- inventive compound of formula (I) or the pharmaceutically acceptable salt thereof may include a hydrate and a solvate thereof.
- the present invention provides a use of the inventive compound for the manufacture of a medicament for preventing or treating cancers, tumors, inflammatory diseases, autoimmune diseases, or immunologically mediated diseases.
- the present invention provides a pharmaceutical composition for preventing or treating cancers, tumors, inflammatory diseases, autoimmune diseases, or immunologically mediated diseases which comprises the inventive compound as an active ingredient.
- the present invention provides a method for preventing or treating cancers, tumors, inflammatory diseases, autoimmune diseases, or immunologically mediated diseases, which comprises administering the inventive compound to a mammal in need thereof.
- the inventive compound of formula (I) or a pharmaceutically acceptable salt thereof selectively and effectively inhibits the growth of cancer cells induced by an epidermal growth factor receptor (EGFR) tyrosine kinase or a mutant thereof as well as the resistance against drugs. Accordingly, the present invention provides a pharmaceutical composition for preventing or treating cancers or tumors induced by an EGFR tyrosine kinase or a mutant thereof which comprises the compound of formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient.
- EGFR epidermal growth factor receptor
- cancers or tumors may include, but are not limited to, liver cancer, hepatocellular carcinoma, thyroid cancer, colorectal cancer, testicular cancer, bone cancer, oral cancer, basal cell carcinoma, ovarian cancer, brain tumor, gallbladder carcinoma, biliary tract cancer, head and neck cancer, colorectal cancer, vesical carcinoma, tongue cancer, esophageal cancer, glioma, glioblastoma, renal cancer, malignant melanoma, gastric cancer, breast cancer, sarcoma, pharynx carcinoma, uterine cancer, cervical cancer, prostate cancer, rectal cancer, pancreatic cancer, lung cancer, skin cancer, and other solid cancer.
- inventive compound of formula (I) or a pharmaceutically acceptable salt thereof can provide enhanced anticancer effects when it is administered in combination with another anticancer agent for treating cancers or tumors.
- anticancer agent for treating cancers or tumors may include, but are not limited to, cell signal transduction inhibitors (e.g., imatinib, gefitinib, bortezomib, erlotinib, sorafenib, sunitinib, dasatinib, vorinostat, lapatinib, temsirolimus, nilotinib, everolimus, pazopanib, trastuzumab, bevacizumab, cetuximab, ranibizumab, pegaptanib, panitumumab and the like), mitosis inhibitors (e.g., paclitaxel, vincristine, vinblastine and the like), alkylating agents (e.g., cisplatin, cyclophosphamide, chromabucil, carmustine and the like), anti-metabolites (e.g., methotrexate, 5-FU and the
- inventive compound of formula (I) or a pharmaceutically acceptable salt thereof selectively and effectively inhibits Bruton's tyrosine kinase (BTK), janus kinase 3 (JAK3), interleukin-2 inducing T-cell kinase (ITK), resting lymphocyte kinase (RLK), and bone marrow tyrosine kinase (BMX), which are mainly expressed in abnormally activated B-lymphocytes and/or T-lymphocytes.
- BTK Bruton's tyrosine kinase
- JAK3 janus kinase 3
- ITK interleukin-2 inducing T-cell kinase
- RTK resting lymphocyte kinase
- BMX bone marrow tyrosine kinase
- the inventive compound of formula (I) or a pharmaceutically acceptable salt thereof can treat or prevent cancers, tumors, inflammatory diseases, autoimmune diseases or immunologically mediated diseases caused by the abnormally activated B-lymphocytes, T-lymphocytes or both. Therefore, the present invention also provides a pharmaceutical composition for treating or preventing cancers, tumors, inflammatory diseases, autoimmune diseases, or immunologically mediated diseases which comprises the compound of formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient.
- inflammatory diseases may include, but are not limited to, arthritis, rheumatoid arthritis, spondyloarthropathy, gouty arthritis, osteoarthritis, juvenile arthritis, other arthritic condition, lupus, systemic lupus erythematosus (SLE), skin-related disease, psoriasis, eczema, dermatitis, atopic dermatitis, pain, pulmonary disorder, lung inflammation, adult respiratoty distress syndrome (ARDS), pulmonary sarcoidosis, chronic pulmonary inflammatory disease, chronic obstructive pulmonary disease (COPD), cardiovascular disease, artherosclerosis, myocardial infarction, congestive heart failure, cardiac reperfusion injury, inflammatory bowl disease, Crohn's disease, ulcerative colitis, irritable bowl syndrome, asthma, sjogren syndrome, autoimmunity thyroid disease, urticaria (cnidosis), multiple sclerosis
- inventive compound of formula (I) or a pharmaceutically acceptable salt thereof can provide enhanced therapeutic effects when it is administered in combination with another therapeutic agent for treating inflammatory diseases, autoimmune diseases, or immunologically mediated diseases.
- the therapeutic agent for treating the inflammatory diseases, autoimmune diseases, or immunologically mediated diseases may include, but are not limited to, steroid drugs (e.g., prednisone, prednisolone, methyl prednisolone, cortisone, hydroxycortisone, betametasone, dexametasone and the like), methotrexates, leflunomides, anti-TNF ⁇ agents (e.g., etanercept, infliximab, adalimunab and the like), calcineurin inhibitors (e.g., tacrolimus, pimecrolimus and the like) and antihistaminic drugs (e.g., diphenhydramine, hydroxyzine, loratadine, ebastine, ketotifen, cetirizine, levocetirizine, fexofenadine and the like), and at least one therapeutic agent selected therefrom may be included in the inventive pharmaceutical composition.
- the inventive compound of formula (I) or a pharmaceutically acceptable salt thereof may be administered orally or parenterally as an active ingredient in an effective amount ranging from about 0.1 to 2,000 mg/kg, preferably 1 to 1,000 mg/kg body weight per a day in case of mammals including human (of approximately 70 kg body weight) in a single to 4 divided doses per a day, or on/off schedules.
- the dosage of the active ingredient may be adjusted in light of various relevant factors such as the condition of the subject to be treated, type and seriousness of illness, administration rate, and opinion of doctor. In certain cases, an amount less than the above dosage may be suitable. An amount greater than the above dosage may be used unless it causes deleterious side effects and such amount can be administered in divided doses per day.
- inventive pharmaceutical composition may be formulated in accordance with any of the conventional methods in the form of tablet, granule, powder, capsule, syrup, emulsion or microemulsion for oral administration, or for parenteral administration including intramuscular, intravenous and subcutaneous routes.
- the inventive pharmaceutical composition for oral administration may be prepared by mixing the active ingredient with a carrier such as cellulose, calcium silicate, corn starch, lactose, sucrose, dextrose, calcium phosphate, stearic acid, magnesium stearate, calcium stearate, gelatin, talc, surfactant, suspension agent, emulsifier and diluent.
- a carrier such as cellulose, calcium silicate, corn starch, lactose, sucrose, dextrose, calcium phosphate, stearic acid, magnesium stearate, calcium stearate, gelatin, talc, surfactant, suspension agent, emulsifier and diluent.
- a carrier such as cellulose, calcium silicate, corn starch, lactose, sucrose, dextrose, calcium phosphate, stearic acid, magnesium stearate, calcium stearate, gelatin, talc, surfactant, suspension agent, emulsifier and diluent.
- Step 1 The compound (3.2 g, 19.4 mmol) obtained in Step 1 was dissolved in phosphorous oxychloride (12 mL) and refluxed with stirring for 3 hours at 200° C. After the reaction was complete, the reaction mixture was cooled to room temperature and added dropwise to 4° C. distilled water with stirring vigorously. The resulting solid was filtered under a reduced pressure with washing using distilled water, and the resulting solid was dried under a reduced pressure to obtain the title compound (yield: 2.9 g, 73.3%).
- Example 1 The procedure of Example 1 was repeated except for using various amine derivatives represented by Z—NH 2 (Z is the same as defined above) instead of 4-(4-methylpiperazin-1-yl)benzeneamine in Step 4 to prepare the compounds of Examples 2 to 156 which are shown in Tables 1a to 1v below.
- Step 4 of Example 1 The procedure of Step 4 of Example 1 was repeated except for using tert-butyl 4-(4-aminophenyl)piperazin-1-carboxylate instead of 4-(4-methylpiperazin-1-yl)benzeneamine to obtain the title compound (yield: 610 mg, 91%).
- Example 158 The procedure of Example 158 was repeated except for using tert-butyl
- Example 161 The procedure of Example 161 was repeated except for using trans-3-chloroacrylic acid and (E)-4-(dimethylamino)-2-butenoic acid to prepare the compounds of Examples 162 and 163 which are shown in Table 3 below.
- Example 164 A similar procedure as the procedure of Example 164 was carried out except for using 2-fluoro-5-nitrophenol and 2-methoxy-5-nitrophenol, to obtain compounds of Example 165 and Example 166, respectively.
- step 5) and 6) of Example 1 were repeated sequentially except for using the compound obtained in the step 1) (1.35 mmol), instead of N-(4-(4-methylpiperazin-1-yl)phenyl)-4-(3-nitrophenoxy)thieno[3,2-d]pyrimidin-2-amine, to obtain 50 mg of the title compound (final yield: 34%).
- Example 167 The procedure of Example 167 or a similar procedure was repeated except for using various amine derivatives of Z—NH 2 (Z has the same meaning as defined in the present invention), instead of 5-(4-methylpiperazin-1-yl)piridin-2-amine in step 1) of Example 167, to obtain the title compounds of Examples 168 to 205 as shown in Tables 5a to 5f.
- Example 1 The procedure of Example 1 was repeated except for using 3-nitrobenzeneamine (0.05 mmol), instead of 3-nitrophenol in step 3) of Example 1, to obtain 5 mg of the title compound (final yield: 55%).
- Example 206 The procedure of Example 206 or a similar procedure was repeated except for using various amine derivatives of Z—NH 2 (Z has the same meaning as defined in the present invention), instead of 5-(4-methylpiperazin-1-yl)piridin-2-amine in Example 1, to obtain the title compounds of Examples 207 to 217 as shown in Tables 6a and 6b.
- Example 218 A similar procedure as the procedure of Step 4) of Example 218 was carried out except for using 3-fluoro-4-(4-methylpiperazin-1-yl)anilline (0.03 mmol), instead of 4-(4-methylpiperazin-1-yl)benzeneamine in the Step 4) of Example 218, to obtain 8 mg of the title compound (final yield: 50%).
- Example 218 A procedure similar to the procedure of the Step 4) of Example 218 was carried out except for using 0.67 g (1.94 mmol) of N-(3-(2-chloro-thieno[3,2-d]pyrimidin-4-ylamino)phenyl)acrylamide obtained in Step 1) to 3) of Example 218 and 0.29 g (1.94 mmol) of 4-((dimethylamino)methyl)anilline to obtain 0.69 g of the title compounds (yield: 80%).
- Example 220 A procedure similar to the procedure of Example 220 was carried out except for using 4-(piperidin-1-yl)methylphenylamine and 2-methoxy-4-(piperidin-1-yl)methylphenylamine to obtain the title compounds of Examples 221 and 222 as shown in Table 7.
- Example 223 The procedure of Example 223 or a similar procedure was repeated except for using 3-fluoro-4-morpholin-4-ylphenylamine and 3-fluoro-4-(1-methyl-piperidin-4-yl)phenylamine, instead of 54-(4-methylpiperazin-1-yl)phenylamine in step 2) of Example 223, to obtain the title compounds of Examples 224 and 225 as shown in Table 8.
- Example 228 or a similar procedure was repeated except for using various amine derivatives of Z—NH 2 (Z has the same meaning as defined in the present invention), instead of 4-(4-methylpiperazin-1-yl)benzeneamine in step 2) of Example 228, to obtain the title compounds of Examples 229 to 237 as shown in Tables 9a and 9b.
- Tablets for oral administration comprising each of the compounds of formula (I) obtained in Examples 1 to 237 as an active ingredient were prepared by the conventional method based on the recipe of Table 10.
- Hard gelatin capsules for oral administration comprising each of the compounds of formula (I) obtained in Examples 1 to 237 as an active ingredient were prepared by the conventional method based on the recipe of Table 11.
- Injection formulations comprising each of the compounds of formula (I) obtained in Examples 1 to 237 as an active ingredient were prepared by the conventional method based on the recipe of Table 12, wherein when a salt of the compound of formula (I) was used, the pH value was not manipulated.
- Injection formulations comprising each of the compounds of formula (I) obtained in Examples 1 to 237 as an active ingredient were prepared by the conventional method based on the recipe of Table 13.
- the inhibiting test of the inventive compounds on the cancer cell growth was conducted as follow.
- a lung cancer cell line, HCC827 whose in-frame is deleted at position 19 exon in EGFR tyrosine kinase, and NCI-H1975 expressing EGFR L858R/T790M mutant which have resistance to the approved EGFR inhibitors such as Gefitinib or Erlotinib were employed.
- the inhibiting test of the inventive compounds on the cancer cell growth was conducted in A431 (ATCC CRL-1555), HCC827 (ATCC CRL-2868) and NCI-H1975 (ATCC CRL-5908) cell lines.
- A431 cell line was incubated in a high-glucose DMEM (Dulbecco's Modified Eagle's Medium) supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin (Gibco BRL), and HCC827 and NCI-H1975 cell lines were incubated in an RPMI medium supplemented with 10% FBS, 1% penicillin/streptomycin and 1% sodium pyruvate.
- DMEM Dynamic Eagle's Medium
- FBS fetal bovine serum
- Gabco BRL penicillin/streptomycin
- the cancer cell lines stored in a liquid nitrogen tank were each quickly thawed at 37° C., and centrifuged to remove the medium.
- the resulting cell pellet was mixed with a culture medium, incubated in a culture flask at 37° C. under 5% CO 2 for 2 to 3 days, and the medium was removed.
- the remaining cells were washed with DPBS (Dulbecco's Phosphate Buffered Saline) and separated from the flask by using Tripsin-EDTA.
- the separated cells were diluted with a culture medium to a concentration of 1 ⁇ 10 5 A431 cells/ml, except that in case of HCC827 and NCI-H1975 cells, the dilution was carried out to 5 ⁇ 10 4 cells/ml.
- NCI-H1975 cells were starved in a RPMI-1640 medium containing 0.1% FBS and 1% penicillin/streptomycin to maximize the reacting activities of the cell on the test compounds on the following day.
- the compounds obtained in Examples 1 to 237 were each dissolved in 99.5% dimethylsulfoxide (DMSO) to a concentration of 25 mM.
- DMSO dimethylsulfoxide
- 1% HCl was added thereto and treated in a 40° C. water bath for 30 mins until a complete dissolution was attained.
- the DMSO solution containing test compound was diluted with a culture medium to a final concentration of 100 ⁇ M, and then diluted 10 times serially to 10 ⁇ 6 ⁇ M (a final concentration of DMSO was less than 1%).
- the medium was removed from each well of the 96-well plate. And then, 100 ⁇ l of a test compound solution was added to each well holding the cultured cells, and the plate was incubated at 37° C. under 5% CO 2 for 72 hours (except that NCI-H1975 cells were incubated for 48 hours). After removing the medium from the plate, 50 ⁇ A of 10% trichloroacetic acid was added to each well, and the plate was kept at 4° C. for 1 hour to fix the cells to the bottom of the plate.
- GI 50 the concentration at which 50% inhibition occurs, was evaluated based on the difference between the final density of the test cells and the initial density of the cells incubated in a well not-treated with the test compound which was regarded as 100%.
- the calculation of GI 50 and the result analysis were carried out by using Microsoft Excel, and the results are shown in Tables 14a to 14f.
- A means that GI 50 ⁇ 50 nM
- B means that GI 50 is 50-100 nM
- C means that GI 50 is 100-1,000 nM
- D means that GI 50 ⁇ 1,000 nM.
- such irreversible inhibitor having the quinazoline structure may cause serious adverse side effects (e.g., diarrhea, skin rash and weight loss) when treated in an amount for inhibiting EGFR T790M, and therefore, there still has been a need to develop a safe drug for overcoming the problems of the resistance development of EGFR T790M.
- the inventive compounds showed a highly improved inhibition activity against EGFR mutants including EGFR T790M, with no inhibition activity against EGFR WT expressed in normal cell, which suggests that the inventive compounds can be used as more effective and safe anticancer drugs to NSCLC patients.
- the inhibiting activities of the inventive compounds obtained in Examples 1 to 237 against EGFR WT and EGFR L858R/T790M kinase were determined using z-lyte kinase assay kit (Invitrogen, PV3191). The kinases used in the test were purchased from Invitrogen.
- the compounds obtained in Examples 1 to 237 were each prepared to 10 mM DMSO solution, and a solution containing 4% DMSO were prepared therefrom and diluted to a concentration of 1 ⁇ M to 0.0001 ⁇ M. Then, an approximate Kd value of each kinase was calculated, and diluted using a kinase buffer (50 mM HEPES (PH 7.4), 10 mM MgCl 2 , 1 mM EGTA and 0.01% BRIJ-35) to 1 to 100 ng/assay concentration. The test was conducted in a 384 well polystyrene flat-bottomed plates.
- a kinase buffer 50 mM HEPES (PH 7.4), 10 mM MgCl 2 , 1 mM EGTA and 0.01% BRIJ-35
- the inhibiting activity of the test compounds against the kinases was determined as a phosphorylation percentage (%) compared with control group, according to the kit protocol, and measured for IC 50 , the concentration of x-axis at which 50% inhibition was observed.
- the calculation of IC 50 and the result analysis were carried out by using Microsoft Excel. The results are shown in Table 15. Wherein, A means that IC 50 ⁇ 50 nM, B means that IC 50 is 50-100 nM, C means that IC 50 is 100-1,000 nM, and D means that IC 50 ⁇ 1,000 nM.
- Example 1 The compound obtained in Example 1 was measured for its inhibitory activity on TEC family kinases, i.e., BMX, ITK, TEX and RLK. The measurement was carried out in the same process as in Example 2, except for using BMX, ITK, TEC and RLK enzymes (Invitrogen) instead of EGFR enzyme.
- BMX, ITK, TEC and RLK enzymes Invitrogen
- Table 17 The results are shown in Table 17.
- TEC family kinases such as BTK, BMX, ITK, and RLK kinases
- Example 2 The compound according to the present invention (Example 2) was tested for its anticancer effect and toxicity in nude mice xenografted with NCI-H1975 cancer cells which shows resistance to Erlotinib previously approved for the treatment of non-small cell lung cancer, due to the acquisition of EGFR T790M point mutation.
- BIBW2992 Boehringer Ingelheim
- NCI-H1975 cell lung cancer cell
- ATC American Type Culture Collection
- V volume of tumor
- L long diameter
- S short diameter
- IR tumor growth inhibition rate
- mBWL maximum body weight loss calculated based on the body weight just before administration
- RTG is a relative tumor growth, which is the mean tumor volume on a particular day based on daily mean tumor volume.
- mBWL(%) (1 ⁇ (mean body weight on day x/mean body weight just before administration)) ⁇ 100 ⁇ Equation 3>
- day x is a day on which the body weight loss is largest during the test.
- the compound of the present invention did not inhibit EGFR WT and exhibited an excellent activity on EGFR mutant specific to non-small cell lung cancer (active mutant: EGFR DelR746_A750, EGFR L858R; acquired mutation: EGFR T790M).
- active mutant EGFR DelR746_A750, EGFR L858R; acquired mutation: EGFR T790M.
- the CIA model is a widely used, representative autoimmune arthritis model, arthritis of which is induced by injecting a mixture of type II collagen and an immunologic adjuvant to a specific mouse strain having major histocompatability complex (MHC) class II with H-2q or H-2 r and thus CD4+ T cells and B-cells specifically responsive to the type II collagen are abnormally activated.
- MHC major histocompatability complex
- mice Male DBA/1J mice (8 weeks old) were first immunized by intradermal injection of 0.7 mL of a suspension liquid in which an equal volume of 2 mg/mL of type II collagen is emulsified in 4 mg/mL of complete Freund's adjuvant supplemented with bacteria tuberculosis. After 21 days, the mice were second immunized by the injection as above, except for using a suspension liquid in which an equal volume of 2 mg/mL of type II collagen is emulsified in incomplete Freund's adjuvant containing no bacteria tuberculosis. After 1 week of second immunization, mice were evaluated for clinical scores based on Table 19 and seven animals were grouped such that the average of experimental group is between 1 and 2.
- Test samples and vehicle of given concentrations were orally administered in an amount of 10 mL per body weight for 14 days everyday by using a Sonde.
- the clinical scores of arthritis (David D Brand et al., Nature Protocol. 2(5), 1269, 2007) were evaluated three times a day.
- the compound according to the present invention inhibited the activities of BTK and JAK3 kinases, and the inhibitions reduced edema, inflammation and flare as well as anti-collagen antibody values in a CIA model of autoimmune arthritis, compared to a control group, and also reduced the formation of pannus in histopathologic testing.
- the above results in a rodent model of arthritis suggest that the compound according to the present invention may provide clinical effects for patients with rheumatoid arthritis.
- the compound according to the present invention significantly reduced the secretion of interleukin-6 (IL-6) and TNF- ⁇ in human peripheral blood mononuclear cells (PBMCs) and mouse splenocytes abundant in T-lymphocytes, B-lymphocytes, Cytes and macrophages after treatment of phorbol-12-myristate-13-acetate (PMA), phytohemagglutinin (PHA), lonomycin, and others which stimulate lymphocytes, compared to a control group.
- PMA phorbol-12-myristate-13-acetate
- PHA phytohemagglutinin
- lonomycin lonomycin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Transplantation (AREA)
- Otolaryngology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychology (AREA)
- Vascular Medicine (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/099,171 USRE46511E1 (en) | 2010-06-23 | 2011-06-20 | Fused pyrimidine derivatives for inhibition of tyrosine kinase activity |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20100059686 | 2010-06-23 | ||
KR10-2010-0059686 | 2010-06-23 | ||
PCT/KR2011/004482 WO2011162515A2 (en) | 2010-06-23 | 2011-06-20 | Novel fused pyrimidine derivatives for inhd3ition of tyrosine kinase activity |
US15/099,171 USRE46511E1 (en) | 2010-06-23 | 2011-06-20 | Fused pyrimidine derivatives for inhibition of tyrosine kinase activity |
US13/805,183 US8957065B2 (en) | 2010-06-23 | 2011-06-20 | Fused pyrimidine derivatives for inhibition of tyrosine kinase activity |
Publications (1)
Publication Number | Publication Date |
---|---|
USRE46511E1 true USRE46511E1 (en) | 2017-08-15 |
Family
ID=45371929
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/805,183 Ceased US8957065B2 (en) | 2010-06-23 | 2011-06-20 | Fused pyrimidine derivatives for inhibition of tyrosine kinase activity |
US15/099,171 Active 2032-02-04 USRE46511E1 (en) | 2010-06-23 | 2011-06-20 | Fused pyrimidine derivatives for inhibition of tyrosine kinase activity |
US14/521,766 Active US9345719B2 (en) | 2010-06-23 | 2014-10-23 | Fused pyrimidine derivatives for inhibition of tyrosine kinase activity |
US15/099,815 Abandoned US20160229868A1 (en) | 2010-06-23 | 2016-04-15 | Novel fused pyrimidine derivatives for inhibition of tyrosine kinase activity |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/805,183 Ceased US8957065B2 (en) | 2010-06-23 | 2011-06-20 | Fused pyrimidine derivatives for inhibition of tyrosine kinase activity |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/521,766 Active US9345719B2 (en) | 2010-06-23 | 2014-10-23 | Fused pyrimidine derivatives for inhibition of tyrosine kinase activity |
US15/099,815 Abandoned US20160229868A1 (en) | 2010-06-23 | 2016-04-15 | Novel fused pyrimidine derivatives for inhibition of tyrosine kinase activity |
Country Status (31)
Country | Link |
---|---|
US (4) | US8957065B2 (pt) |
EP (2) | EP2975042B1 (pt) |
JP (2) | JP5834347B2 (pt) |
KR (2) | KR101587506B1 (pt) |
CN (2) | CN102947316B (pt) |
AR (2) | AR081978A1 (pt) |
AU (1) | AU2011269989B2 (pt) |
BR (2) | BR122014012788B1 (pt) |
CA (1) | CA2803056C (pt) |
CY (1) | CY1118750T1 (pt) |
DK (2) | DK2585470T3 (pt) |
ES (2) | ES2622138T3 (pt) |
HK (1) | HK1211575A1 (pt) |
HR (2) | HRP20170456T1 (pt) |
HU (2) | HUE042165T2 (pt) |
IL (2) | IL223689A (pt) |
LT (2) | LT2975042T (pt) |
MX (2) | MX342164B (pt) |
MY (2) | MY162132A (pt) |
NZ (2) | NZ605988A (pt) |
PL (2) | PL2585470T3 (pt) |
PT (2) | PT2585470T (pt) |
RS (2) | RS58265B1 (pt) |
RU (2) | RU2598852C2 (pt) |
SG (1) | SG186378A1 (pt) |
SI (2) | SI2585470T1 (pt) |
TR (1) | TR201821217T4 (pt) |
TW (2) | TWI528962B (pt) |
UA (2) | UA108889C2 (pt) |
WO (1) | WO2011162515A2 (pt) |
ZA (1) | ZA201209742B (pt) |
Families Citing this family (120)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0622054B8 (pt) | 2006-09-22 | 2021-05-25 | Oxford Amherst Llc | composto e composição farmacêutica |
US20120101113A1 (en) | 2007-03-28 | 2012-04-26 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase |
US9273077B2 (en) | 2008-05-21 | 2016-03-01 | Ariad Pharmaceuticals, Inc. | Phosphorus derivatives as kinase inhibitors |
DK2300013T3 (en) | 2008-05-21 | 2017-12-04 | Ariad Pharma Inc | PHOSPHORUS DERIVATIVES AS KINASE INHIBITORS |
MX2011000661A (es) | 2008-07-16 | 2011-05-25 | Pharmacyclics Inc | Inhibidores de tirosina cinasa de bruton para el tratamiento de tumores solidos. |
IL300955A (en) | 2010-06-03 | 2023-04-01 | Pharmacyclics Llc | (R)-1-(3-(4-amino-3-(4-phenoxyphenyl)-H1-pyrazolo[4,3-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1- Indicated for use as a drug to treat chronic lymphocytic leukemia or small lymphocytic lymphoma |
LT2975042T (lt) * | 2010-06-23 | 2019-01-25 | Hanmi Science Co., Ltd. | Naujieji kondensuoti pirimidino dariniai, skirti tirozino kinazės aktyvumo slopinimui |
MX2013003913A (es) * | 2010-10-08 | 2013-09-26 | Abbvie Inc | Compuestos de furo [3, 2-d] pirimidina. |
EA201390550A1 (ru) * | 2010-10-14 | 2013-08-30 | Ариад Фармасьютикалз, Инк. | Способы ингибирования пролиферации клеток в egfr-стимулируемых злокачественных опухолях |
AU2012250517B2 (en) * | 2011-05-04 | 2016-05-19 | Takeda Pharmaceutical Company Limited | Compounds for inhibiting cell proliferation in EGFR-driven cancers |
KR20140048968A (ko) | 2011-07-13 | 2014-04-24 | 파마시클릭스, 인코포레이티드 | 브루톤형 티로신 키나제의 억제제 |
PL3686194T3 (pl) | 2011-07-27 | 2022-01-17 | Astrazeneca Ab | Związki 2-(2,4,5-podstawione-anilino)pirymidynowe |
KR20130076046A (ko) * | 2011-12-28 | 2013-07-08 | 한미약품 주식회사 | 타이로신 카이네이즈 억제 활성을 갖는 신규 이미다조피리딘 유도체 |
US8377946B1 (en) | 2011-12-30 | 2013-02-19 | Pharmacyclics, Inc. | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors |
US9464089B2 (en) | 2012-01-13 | 2016-10-11 | Acea Biosciences Inc. | Heterocyclic compounds and uses thereof |
US9034885B2 (en) | 2012-01-13 | 2015-05-19 | Acea Biosciences Inc. | EGFR modulators and uses thereof |
EP2802568A1 (en) | 2012-01-13 | 2014-11-19 | Acea Biosciences, Inc. | Heterocyclic compounds and uses as anticancer agents. |
US9586965B2 (en) | 2012-01-13 | 2017-03-07 | Acea Biosciences Inc. | Pyrrolo[2,3-d]pyrimidine compounds as inhibitors of protein kinases |
KR20130091464A (ko) * | 2012-02-08 | 2013-08-19 | 한미약품 주식회사 | 타이로신 카이네이즈 억제 활성을 갖는 트리아졸로피리딘 유도체 |
ES2580530T3 (es) * | 2012-02-23 | 2016-08-24 | Taiho Pharmaceutical Co., Ltd. | Compuesto con anillo fusionado de quinolilpirrolopirimidilo o sal del mismo |
AU2013204563B2 (en) | 2012-05-05 | 2016-05-19 | Takeda Pharmaceutical Company Limited | Compounds for inhibiting cell proliferation in EGFR-driven cancers |
UA114421C2 (uk) | 2012-06-04 | 2017-06-12 | Фармасайклікс Ллс | Кристалічна форма інгібітору тирозинкінази брутона |
WO2013184766A1 (en) * | 2012-06-06 | 2013-12-12 | Irm Llc | Compounds and compositions for modulating egfr activity |
CN104704129A (zh) | 2012-07-24 | 2015-06-10 | 药品循环公司 | 与对布鲁顿酪氨酸激酶(btk)抑制剂的抗性相关的突变 |
MX2015006168A (es) | 2012-11-15 | 2015-08-10 | Pharmacyclics Inc | Compuestos de pirrolopirimidina como inhibidores de quinasas. |
KR20150119401A (ko) | 2013-02-22 | 2015-10-23 | 다이호야쿠힌고교 가부시키가이샤 | 3환성 화합물의 제조 방법 및 상기 제조 방법에 의해 얻을 수 있는 3환성 화합물 |
US9611283B1 (en) | 2013-04-10 | 2017-04-04 | Ariad Pharmaceuticals, Inc. | Methods for inhibiting cell proliferation in ALK-driven cancers |
CN103242341B (zh) * | 2013-04-19 | 2015-12-09 | 中国科学院广州生物医药与健康研究院 | 噻吩并2,4取代嘧啶类化合物及其药物组合物与应用 |
CA2902686C (en) | 2013-04-25 | 2017-01-24 | Beigene, Ltd. | Fused heterocyclic compounds as protein kinase inhibitors |
WO2014175370A1 (ja) * | 2013-04-25 | 2014-10-30 | 塩野義製薬株式会社 | ピロリジン誘導体およびそれらを含有する医薬組成物 |
JP6564771B2 (ja) * | 2013-07-11 | 2019-08-21 | エイシア バイオサイエンシーズ インコーポレイテッド | キナーゼ阻害剤としてのピリミジン誘導体 |
EP2832358A1 (en) | 2013-08-02 | 2015-02-04 | Bionsil S.r.l. | Pharmaceutical kit for use in the treatment of colon and colorectal cancer |
TWI649081B (zh) | 2013-08-02 | 2019-02-01 | 製藥公司 | 治療固態腫瘤之方法 |
US9415050B2 (en) | 2013-08-12 | 2016-08-16 | Pharmacyclics Llc | Methods for the treatment of HER2 amplified cancer |
AU2013400609B9 (en) | 2013-09-13 | 2020-03-05 | Beigene Switzerland Gmbh | Anti-PD1 antibodies and their use as therapeutics and diagnostics |
RU2650512C2 (ru) | 2013-09-18 | 2018-04-16 | Бейджин Ханми Фармасьютикал Ко., Лтд. | Соединение, ингибирующее активности киназ ВТК и/или JAK3 |
MA38961A1 (fr) | 2013-09-30 | 2018-05-31 | Pharmacyclics Llc | Composés 3-phenyl-1h-pyrazolo[3,4-d]pyrimidin-4-ylamine substitués inhibiteurs de la tyrosine kinase de bruton utilisés pour traiter par exemple les maladies auto-immunes, respiratoires et inflammatoires, cancer, mastocytose et osteoporose |
FR3015483B1 (fr) * | 2013-12-23 | 2016-01-01 | Servier Lab | Nouveaux derives de thienopyrimidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
WO2015143400A1 (en) | 2014-03-20 | 2015-09-24 | Pharmacyclics, Inc. | Phospholipase c gamma 2 and resistance associated mutations |
WO2015148904A1 (en) * | 2014-03-28 | 2015-10-01 | Driver Group | Methods for predicting egfr tyrosine kinase inhibitor efficacy |
CN106659765B (zh) | 2014-04-04 | 2021-08-13 | 德玛医药 | 二脱水半乳糖醇及其类似物或衍生物用于治疗非小细胞肺癌和卵巢癌的用途 |
KR20160144399A (ko) | 2014-05-01 | 2016-12-16 | 노파르티스 아게 | 톨-유사 수용체 7 효능제로서의 화합물 및 조성물 |
KR102139847B1 (ko) | 2014-05-01 | 2020-07-31 | 노파르티스 아게 | 톨-유사 수용체 7 효능제로서의 화합물 및 조성물 |
MA39908A (fr) * | 2014-05-28 | 2015-12-03 | Astellas Pharma Inc | Composition médicinale comprenant un composé pyrazine carboxamide utilisé comme principe actif |
WO2016000619A1 (en) | 2014-07-03 | 2016-01-07 | Beigene, Ltd. | Anti-pd-l1 antibodies and their use as therapeutics and diagnostics |
EP2974729A1 (en) * | 2014-07-17 | 2016-01-20 | Abivax | Quinoline derivatives for use in the treatment of inflammatory diseases |
CA2959602A1 (en) | 2014-08-01 | 2016-02-04 | Pharmacyclics Llc | Inhibitors of bruton's tyrosine kinase |
BR112017002231A2 (pt) | 2014-08-07 | 2018-07-17 | Pharmacyclics Llc | novas formulações de um inibidor de tirosina cinase de bruton |
AR101476A1 (es) | 2014-08-07 | 2016-12-21 | Acerta Pharma Bv | Métodos para tratar cánceres, enfermedades inmunes y autoinmunes, y enfermedades inflamatorias en base a la tasa de ocupación de la tirosin quinasa de bruton (btk) y a la tasa de resíntesis de la tirosin quinasa de bruton (btk) |
US10040801B2 (en) | 2014-12-30 | 2018-08-07 | Hanmi Pharm. Co., Ltd. | Method for preparing thienopyrimidine compound and intermediates used therein |
KR20160082062A (ko) | 2014-12-30 | 2016-07-08 | 한미약품 주식회사 | 싸이옥소 퓨로피리미디논 유도체의 제조방법 및 이에 사용되는 중간체 |
CN105837572B (zh) * | 2015-02-02 | 2019-04-19 | 四川大学 | N-取代苯基酰胺衍生物及其制备方法和用途 |
RU2572709C1 (ru) * | 2015-03-03 | 2016-01-20 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Курский государственный медицинский университет" Министерства здравоохранения Российской Федерации | Способ коррекции структурно-функциональных нарушений артериального русла у больных ревматоидным артритом |
SG11201707122QA (en) | 2015-03-03 | 2017-09-28 | Pharmacyclics Llc | Pharmaceutical formulations of bruton's tyrosine kinase inhibtor |
EP3312179B1 (en) | 2015-04-29 | 2019-07-10 | Nanjing Sanhome Pharmaceutical Co., Ltd. | Fused-ring or tricyclic aryl pyrimidine compound used as kinase inhibitor |
CA2992161A1 (en) | 2015-07-17 | 2017-01-26 | Institut Pasteur | 5-hydroxytryptamine 1b receptor-stimulating agent for use as a promoter of satellite cells self-renewal and/or differentiation |
MA44909A (fr) | 2015-09-15 | 2018-07-25 | Acerta Pharma Bv | Association thérapeutique d'un inhibiteur du cd19 et d'un inhibiteur de la btk |
CN107949388B (zh) | 2015-10-09 | 2021-10-26 | 艾森医药公司 | 吡咯并嘧啶激酶抑制剂的药用盐、物理形态和组合物及其制备方法 |
MA44334A (fr) | 2015-10-29 | 2018-09-05 | Novartis Ag | Conjugués d'anticorps comprenant un agoniste du récepteur de type toll |
KR20170050453A (ko) * | 2015-10-30 | 2017-05-11 | 한미약품 주식회사 | 싸이에노피리미딘 화합물의 신규 제조방법 및 이에 사용되는 중간체 |
CN108137614B (zh) * | 2015-12-02 | 2021-01-05 | 深圳市塔吉瑞生物医药有限公司 | 一种稠合嘧啶化合物及包含该化合物的组合物及其用途 |
EP3383401B1 (en) * | 2015-12-03 | 2020-05-20 | Zheijiang Jianfreng-Yien Biotechnology Co., Ltd. | Thieno-pyrimidine derivatives and uses thereof |
US10844074B2 (en) | 2015-12-03 | 2020-11-24 | Zhejiang Jianfeng-Yien Biotechnology Co., Ltd. | Heterocycle compounds and uses thereof |
AU2016382385A1 (en) | 2015-12-31 | 2018-07-12 | Hanmi Pharm. Co., Ltd. | Crystalline forms of thienopyrimidine compound |
RU2018122050A (ru) * | 2015-12-31 | 2020-01-31 | Ханми Фарм. Ко., Лтд. | Кристаллические формы гидрохлоридных солей тиенопиримидинового соединения |
PL3402503T3 (pl) | 2016-01-13 | 2021-04-19 | Acerta Pharma B.V. | Kombinacje terapeutyczne antyfolianu oraz inhibitora btk |
WO2017198602A1 (en) * | 2016-05-18 | 2017-11-23 | Boehringer Ingelheim International Gmbh | Anticancer combination therapy |
WO2017204582A1 (en) * | 2016-05-27 | 2017-11-30 | Hanmi Pharm. Co., Ltd. | Pharmaceutical composition comprising an amide derivative or a pharmaceutically acceptable salt thereof inhibiting growth of cancer cells and a stabilizer having low melting point |
JP2019519579A (ja) | 2016-06-30 | 2019-07-11 | デウン ファーマシューティカル カンパニー リミテッド | キナーゼ阻害剤としてのピラゾロピリミジン誘導体 |
CN109475536B (zh) | 2016-07-05 | 2022-05-27 | 百济神州有限公司 | 用于治疗癌症的PD-l拮抗剂和RAF抑制剂的组合 |
BR112019000706A8 (pt) | 2016-07-15 | 2022-12-06 | Pasteur Institut | Agente de estímulo do receptor 1b de 5-hidroxitriptamina para reparo de pele e/ou cabelo |
CN107698603B (zh) | 2016-08-09 | 2022-04-08 | 南京红云生物科技有限公司 | 噻吩并嘧啶类化合物、其制备方法、药用组合物及其应用 |
AU2017314178B2 (en) | 2016-08-16 | 2021-11-18 | Beigene Switzerland Gmbh | Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof |
EP4353747A2 (en) | 2016-08-19 | 2024-04-17 | BeiGene Switzerland GmbH | Combination of zanubrutinib with an anti-cd20 or an anti-pd-1 antibody for use in treating cancer |
US20190201409A1 (en) | 2016-09-19 | 2019-07-04 | Mei Pharma, Inc. | Combination therapy |
CN106565612B (zh) * | 2016-10-25 | 2018-10-16 | 大连医科大学 | 二苯乙烯基嘧啶类化合物,组合物及其用途 |
CN110545826A (zh) | 2016-12-03 | 2019-12-06 | 朱诺治疗学股份有限公司 | 用于与激酶抑制剂组合使用治疗性t细胞的方法和组合物 |
KR20180075228A (ko) * | 2016-12-26 | 2018-07-04 | 한미약품 주식회사 | 싸이에노피리미딘 화합물의 신규 제조방법 및 중간체 |
WO2018134786A1 (en) | 2017-01-19 | 2018-07-26 | Acerta Pharma B.V. | Compositions and methods for the assessment of drug target occupancy for bruton's tyrosine kinase |
WO2018137681A1 (en) | 2017-01-25 | 2018-08-02 | Beigene, Ltd. | Crystalline forms of (s) -7- (1- (but-2-ynoyl) piperidin-4-yl) -2- (4-phenoxyphenyl) -4, 5, 6, 7-tetrahy dropyrazolo [1, 5-a] pyrimidine-3-carboxamide, preparation, and uses thereof |
WO2018139883A1 (ko) * | 2017-01-26 | 2018-08-02 | 부광약품 주식회사 | 다중 표적 키나아제 저해제로서 융합피리미딘 유도체 |
CN106831814B (zh) * | 2017-02-15 | 2018-11-23 | 山东大学 | 一种噻吩并[3,2-d]嘧啶类HIV-1逆转录酶抑制剂及其制备方法和应用 |
CN106916112B (zh) * | 2017-03-02 | 2019-12-20 | 四川海思科制药有限公司 | 嘧啶衍生物及其制备方法和在医药上的应用 |
CN106866699B (zh) * | 2017-03-29 | 2019-03-08 | 山东大学 | 一种二芳基噻吩并嘧啶类hiv-1逆转录酶抑制剂及其制备方法和应用 |
CN111212837A (zh) | 2017-04-07 | 2020-05-29 | 艾森医药公司 | 吡咯并嘧啶激酶抑制剂的药用盐、物理形态和组合物及其制备方法 |
CN108727382B (zh) * | 2017-04-19 | 2022-07-19 | 华东理工大学 | 作为btk抑制剂的杂环化合物及其应用 |
US11597768B2 (en) | 2017-06-26 | 2023-03-07 | Beigene, Ltd. | Immunotherapy for hepatocellular carcinoma |
CN109206435B (zh) * | 2017-06-29 | 2020-09-08 | 中国医药研究开发中心有限公司 | 噻吩并[3,2-d]嘧啶类化合物及其制备方法和医药用途 |
CN110997677A (zh) | 2017-08-12 | 2020-04-10 | 百济神州有限公司 | 具有改进的双重选择性的Btk抑制剂 |
US20200172529A1 (en) * | 2017-08-18 | 2020-06-04 | Beijing Hanmi Pharm. Co., Ltd. | Chemical Compound, Pharmaceutical Composition Thereof, and Use and Application Thereof |
CN109575045B (zh) * | 2017-09-28 | 2021-02-12 | 南京红云生物科技有限公司 | 噻吩并嘧啶类化合物、其制备方法、药用组合物及其应用 |
KR102613433B1 (ko) * | 2017-10-11 | 2023-12-13 | 주식회사 대웅제약 | 신규한 페닐피리딘 유도체 및 이를 포함하는 약학 조성물 |
SG11202004019SA (en) | 2017-11-17 | 2020-05-28 | Cellix Bio Private Ltd | Compositions and methods for the treatment of eye disorders |
CN111801334B (zh) | 2017-11-29 | 2023-06-09 | 百济神州瑞士有限责任公司 | 使用包含btk抑制剂的组合治疗惰性或侵袭性b-细胞淋巴瘤 |
JP7043098B2 (ja) * | 2017-12-21 | 2022-03-29 | 深▲チェン▼市塔吉瑞生物医薬有限公司 | キナーゼ活性を阻害するためのジアニリノピリミジン系化合物 |
KR102577241B1 (ko) * | 2017-12-28 | 2023-09-11 | 주식회사 대웅제약 | 카이네이즈 저해제로서의 아미노-플루오로피페리딘 유도체 |
RS63515B1 (sr) | 2017-12-28 | 2022-09-30 | Daewoong Pharmaceutical Co Ltd | Derivat oksi-fluoropiperidina kao inhibitor kinaze |
KR102577242B1 (ko) * | 2017-12-28 | 2023-09-11 | 주식회사 대웅제약 | 카이네이즈 저해제로서의 아미노-메틸피페리딘 유도체 |
LT3784663T (lt) * | 2018-04-23 | 2023-10-25 | Celgene Corporation | Pakeistieji 4-aminoizoindolin-1,3-diono junginiai ir jų naudojimas limfomos gydymui |
WO2019208805A1 (ja) | 2018-04-27 | 2019-10-31 | 小野薬品工業株式会社 | Btk阻害活性を有する化合物を有効成分として含む自己免疫疾患の予防および/または治療剤 |
US20210308140A1 (en) | 2018-07-25 | 2021-10-07 | Novartis Ag | Nlrp3 inflammasome inhibitors |
KR101954370B1 (ko) * | 2018-07-25 | 2019-03-05 | 한미약품 주식회사 | 피리미딘 화합물 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물 |
US20220362357A1 (en) | 2018-08-31 | 2022-11-17 | Stichting Radboud Universitair Medisch Centrum | Synergistic Combinations of Amino Acid Depletion Agent Sensitizers (AADAS) and Amino Acid Depletion Agents (AADA), and Therapeutic Methods of Use Thereof |
CN109265469A (zh) * | 2018-11-12 | 2019-01-25 | 大连医科大学附属第医院 | 嘧啶并噻唑类杂环化合物,组合物及其治疗淋巴细胞白血病的用途 |
KR20200114776A (ko) * | 2019-03-29 | 2020-10-07 | 한미약품 주식회사 | 퓨로피리미딘 화합물의 산 부가염의 결정형 |
CN111747931A (zh) * | 2019-03-29 | 2020-10-09 | 深圳福沃药业有限公司 | 用于治疗癌症的氮杂芳环酰胺衍生物 |
CN111909101B (zh) * | 2019-05-10 | 2022-07-19 | 浙江大学 | 一种egfr激酶抑制剂及其在制备抗癌药物方面的应用 |
AR119731A1 (es) | 2019-05-17 | 2022-01-05 | Novartis Ag | Inhibidores del inflamasoma nlrp3 |
JP2022534650A (ja) * | 2019-05-31 | 2022-08-03 | 海思科医▲薬▼有限公司 | Btk阻害薬環誘導体、その調製方法及びその医薬品適用 |
WO2020257385A1 (en) * | 2019-06-20 | 2020-12-24 | Dana-Farber Cancer Institute, Inc. | Small molecule inhibitors of src tyrosine kinase |
CN110372529B (zh) * | 2019-08-08 | 2022-05-24 | 黄河水利职业技术学院 | N-[(3,4,5-三氟)苯基]丙烯酰胺及其制备方法 |
CN110511994B (zh) * | 2019-09-09 | 2023-05-26 | 中南大学湘雅二医院 | miRNA-4769-3p及其同源物的应用 |
EP4077316A1 (en) * | 2019-12-20 | 2022-10-26 | Pfizer Inc. | Benzimidazole derivatives |
BR112022024729A2 (pt) | 2020-06-05 | 2023-02-28 | Kinnate Biopharma Inc | Inibidores de quinases do receptor do fator de crescimento de fibroblastos |
CN116239603A (zh) * | 2020-06-20 | 2023-06-09 | 江西科技师范大学 | 一种2-氨基嘧啶杂环类化合物及其应用 |
UY39377A (es) | 2020-08-14 | 2022-03-31 | Novartis Ag | Derivados de espiropiperidinilo sustituidos con heteroarilo y usos farmacéuticos de los mismos |
JP2023547220A (ja) * | 2020-10-29 | 2023-11-09 | 蘇州亜宝薬物研発有限公司 | 置換ジアリールアミン化合物及びその医薬組成物、製造方法と用途 |
WO2022212893A1 (en) | 2021-04-02 | 2022-10-06 | Biogen Ma Inc. | Combination treatment methods of multiple sclerosis |
US11786531B1 (en) | 2022-06-08 | 2023-10-17 | Beigene Switzerland Gmbh | Methods of treating B-cell proliferative disorder |
TW202406550A (zh) | 2022-08-03 | 2024-02-16 | 瑞士商諾華公司 | Nlrp3炎性小體抑制劑 |
Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998002438A1 (en) | 1996-07-13 | 1998-01-22 | Glaxo Group Limited | Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors |
WO2007089768A2 (en) | 2006-01-30 | 2007-08-09 | Exelixis, Inc. | 4-aryl-2-amino-pyrimidines or 4-aryl-2-aminoalkyl-pyrimidines as jak-2 modulators and pharmaceutical compositions containing them |
JP2008013527A (ja) | 2006-07-10 | 2008-01-24 | Sankyo Co Ltd | チエノ[3,2−d]ピリミジン−2,4−ジアミン誘導体 |
WO2009017838A2 (en) | 2007-08-01 | 2009-02-05 | Exelixis, Inc. | Combinations of jak-2 inhibitors and other agents |
WO2009062258A1 (en) | 2007-11-15 | 2009-05-22 | Cytopia Research Pty Ltd | N-containing heterocyclic compounds |
WO2009126515A1 (en) | 2008-04-07 | 2009-10-15 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
WO2009158571A1 (en) | 2008-06-27 | 2009-12-30 | Avila Therapeutics And Uses Thereof | Heteroaryl compounds and uses thereof |
WO2010054285A2 (en) | 2008-11-10 | 2010-05-14 | National Health Research Institutes | Fused bicyclic and tricyclic pyrimidine compounds as tyrosine kinase inhibitors |
WO2010129053A2 (en) | 2009-05-05 | 2010-11-11 | Dana Farber Cancer Institute | Egfr inhibitors and methods of treating disorders |
WO2011079231A1 (en) | 2009-12-23 | 2011-06-30 | Gatekeeper Pharmaceutical, Inc. | Compounds that modulate egfr activity and methods for treating or preventing conditions therewith |
WO2013042006A1 (en) * | 2011-09-22 | 2013-03-28 | Pfizer Inc. | Pyrrolopyrimidine and purine derivatives |
US9345719B2 (en) * | 2010-06-23 | 2016-05-24 | Hanmi Science Co., Ltd. | Fused pyrimidine derivatives for inhibition of tyrosine kinase activity |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MXPA06001590A (es) * | 2003-08-19 | 2006-05-19 | Wyeth Corp | Proceso para la preparacion de 4-amino-3-quinolincarbonitrilos. |
KR101507182B1 (ko) * | 2006-12-07 | 2015-03-30 | 제넨테크, 인크. | 포스포이노시타이드 3-키나제 억제제 화합물 및 그의 사용 방법 |
WO2008152394A1 (en) * | 2007-06-12 | 2008-12-18 | F.Hoffmann-La Roche Ag | Pharmaceutical compounds |
-
2011
- 2011-06-20 LT LTEP15181011.6T patent/LT2975042T/lt unknown
- 2011-06-20 US US13/805,183 patent/US8957065B2/en not_active Ceased
- 2011-06-20 EP EP15181011.6A patent/EP2975042B1/en active Active
- 2011-06-20 CA CA2803056A patent/CA2803056C/en active Active
- 2011-06-20 LT LTEP11798350.2T patent/LT2585470T/lt unknown
- 2011-06-20 DK DK11798350.2T patent/DK2585470T3/en active
- 2011-06-20 WO PCT/KR2011/004482 patent/WO2011162515A2/en active Application Filing
- 2011-06-20 PT PT117983502T patent/PT2585470T/pt unknown
- 2011-06-20 JP JP2013516501A patent/JP5834347B2/ja active Active
- 2011-06-20 SG SG2012092862A patent/SG186378A1/en unknown
- 2011-06-20 PL PL11798350T patent/PL2585470T3/pl unknown
- 2011-06-20 ES ES11798350.2T patent/ES2622138T3/es active Active
- 2011-06-20 MY MYPI2012005536A patent/MY162132A/en unknown
- 2011-06-20 MX MX2014005025A patent/MX342164B/es unknown
- 2011-06-20 ES ES15181011T patent/ES2703552T3/es active Active
- 2011-06-20 RU RU2014147193/04A patent/RU2598852C2/ru active
- 2011-06-20 EP EP11798350.2A patent/EP2585470B1/en active Active
- 2011-06-20 PL PL15181011T patent/PL2975042T3/pl unknown
- 2011-06-20 BR BR122014012788-0A patent/BR122014012788B1/pt active IP Right Grant
- 2011-06-20 HU HUE15181011A patent/HUE042165T2/hu unknown
- 2011-06-20 DK DK15181011.6T patent/DK2975042T3/en active
- 2011-06-20 NZ NZ605988A patent/NZ605988A/en not_active IP Right Cessation
- 2011-06-20 US US15/099,171 patent/USRE46511E1/en active Active
- 2011-06-20 MX MX2012014601A patent/MX2012014601A/es active IP Right Grant
- 2011-06-20 CN CN201180030338.6A patent/CN102947316B/zh active Active
- 2011-06-20 NZ NZ627709A patent/NZ627709A/en unknown
- 2011-06-20 TR TR2018/21217T patent/TR201821217T4/tr unknown
- 2011-06-20 UA UAA201300777A patent/UA108889C2/uk unknown
- 2011-06-20 BR BR112012033253A patent/BR112012033253A2/pt not_active IP Right Cessation
- 2011-06-20 AU AU2011269989A patent/AU2011269989B2/en not_active Ceased
- 2011-06-20 HU HUE11798350A patent/HUE032515T2/en unknown
- 2011-06-20 RS RS20190004A patent/RS58265B1/sr unknown
- 2011-06-20 RS RS20170267A patent/RS55783B1/sr unknown
- 2011-06-20 RU RU2013102881/04A patent/RU2585177C2/ru not_active IP Right Cessation
- 2011-06-20 SI SI201131094A patent/SI2585470T1/sl unknown
- 2011-06-20 CN CN201510477438.3A patent/CN105061438B/zh active Active
- 2011-06-20 PT PT15181011T patent/PT2975042T/pt unknown
- 2011-06-20 SI SI201131644T patent/SI2975042T1/sl unknown
- 2011-06-20 UA UAA201410791A patent/UA111272C2/uk unknown
- 2011-06-20 KR KR1020110059612A patent/KR101587506B1/ko active IP Right Review Request
- 2011-06-22 TW TW100121796A patent/TWI528962B/zh not_active IP Right Cessation
- 2011-06-22 TW TW103121058A patent/TWI513701B/zh active
- 2011-06-23 AR ARP110102172A patent/AR081978A1/es unknown
-
2012
- 2012-12-17 IL IL223689A patent/IL223689A/en active IP Right Grant
- 2012-12-20 MY MYPI2016002018A patent/MY174196A/en unknown
- 2012-12-21 ZA ZA2012/09742A patent/ZA201209742B/en unknown
-
2014
- 2014-04-09 KR KR1020140042459A patent/KR101589114B1/ko active IP Right Review Request
- 2014-04-23 AR ARP140101695A patent/AR096075A2/es active IP Right Grant
- 2014-04-30 IL IL232382A patent/IL232382A/en active IP Right Grant
- 2014-05-13 JP JP2014099471A patent/JP5852173B2/ja active Active
- 2014-10-23 US US14/521,766 patent/US9345719B2/en active Active
-
2015
- 2015-12-14 HK HK15112265.6A patent/HK1211575A1/xx unknown
-
2016
- 2016-04-15 US US15/099,815 patent/US20160229868A1/en not_active Abandoned
-
2017
- 2017-03-20 HR HRP20170456TT patent/HRP20170456T1/hr unknown
- 2017-03-20 CY CY20171100349T patent/CY1118750T1/el unknown
-
2019
- 2019-01-03 HR HRP20190012TT patent/HRP20190012T1/hr unknown
Patent Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998002438A1 (en) | 1996-07-13 | 1998-01-22 | Glaxo Group Limited | Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors |
WO2007089768A2 (en) | 2006-01-30 | 2007-08-09 | Exelixis, Inc. | 4-aryl-2-amino-pyrimidines or 4-aryl-2-aminoalkyl-pyrimidines as jak-2 modulators and pharmaceutical compositions containing them |
JP2008013527A (ja) | 2006-07-10 | 2008-01-24 | Sankyo Co Ltd | チエノ[3,2−d]ピリミジン−2,4−ジアミン誘導体 |
WO2009017838A2 (en) | 2007-08-01 | 2009-02-05 | Exelixis, Inc. | Combinations of jak-2 inhibitors and other agents |
WO2009062258A1 (en) | 2007-11-15 | 2009-05-22 | Cytopia Research Pty Ltd | N-containing heterocyclic compounds |
WO2009126515A1 (en) | 2008-04-07 | 2009-10-15 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
WO2009158571A1 (en) | 2008-06-27 | 2009-12-30 | Avila Therapeutics And Uses Thereof | Heteroaryl compounds and uses thereof |
WO2010054285A2 (en) | 2008-11-10 | 2010-05-14 | National Health Research Institutes | Fused bicyclic and tricyclic pyrimidine compounds as tyrosine kinase inhibitors |
WO2010129053A2 (en) | 2009-05-05 | 2010-11-11 | Dana Farber Cancer Institute | Egfr inhibitors and methods of treating disorders |
WO2011079231A1 (en) | 2009-12-23 | 2011-06-30 | Gatekeeper Pharmaceutical, Inc. | Compounds that modulate egfr activity and methods for treating or preventing conditions therewith |
US9345719B2 (en) * | 2010-06-23 | 2016-05-24 | Hanmi Science Co., Ltd. | Fused pyrimidine derivatives for inhibition of tyrosine kinase activity |
WO2013042006A1 (en) * | 2011-09-22 | 2013-03-28 | Pfizer Inc. | Pyrrolopyrimidine and purine derivatives |
Non-Patent Citations (12)
Title |
---|
European Patent Office, Applicant Reply to Communication, dated Jun. 26, 2014, filed in counterpart European Patent Application No. 11798350.2. |
European Patent Office, Applicant Reply to Communication, dated Oct. 21, 2015, filed in counterpart European Patent Application No. 11798350.2. |
European Patent Office, Communication dated Oct. 15, 2015, issued in counterpart European Patent Application No. 15181011.6. |
European Patent Office, Communication Pursuant to Article 94(3) EPC, dated Apr. 13, 2015, issued in counterpart European Patent Application No. 11798350.2. |
European Patent Office, Search Report dated Dec. 4, 2013, issued in European Patent Application No. 11798350.2. |
H.D. Hollis Showalter, "Tyrosine Kinase Inhibitors. 16. 6,5,6-Tricyclic Benzothieno [3,2-d] pyrimidines and Pyrimido [5,4-b]- and -[4,5-b] indoles as Potent Inhibitors of the Epidermal Growth Factor Receptor Tyrosine Kinase", J. Med. Chem. 1999, pp. 5464-5474, vol. 42, No. 11. |
International Searching Authority, International Search Report, PCT/KR2011/004482, Feb. 29, 2012. |
Japanese Patent Office, Communication dated Mar. 3, 2015, issued in corresponding Japanese application No. 2013-516501. |
Peter Traxler, et al., "Use of a Pharmacophore Model for the Design of EGF-R Tyrosine Kinase Inhibitors: 4-(Phenylamino) Pyrazolo [3,4-d] pyrimidines", J. Med. Chem., 1997, pp. 3601-3616, vol. 40, No. 22. |
Susanne Trumpp-Kallmeyer, et al., Development of a Binding Model to Protein Tyrosine Kinases for Substituted Pyrido [2,3-d] pyrimidine Inhibitors, J. Med. Chem. 1998, pp. 1752-1763, vol. 41, No. 11. |
United States Patent Office, Examiner Search Strategy and Results, from parent U.S. Appl. No. 13/805,183, dated Oct. 15, 2014. |
Zhou, W. et al., Discovery of selective irreversible inhibitors for EGFR-T790M., 2011, Bioorganic & Medicinal Chemistry Letters 21 (2011) 638-643. |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9345719B2 (en) | Fused pyrimidine derivatives for inhibition of tyrosine kinase activity | |
JP6059260B2 (ja) | 環状ジアミノピリジン誘導体 | |
TW201336850A (zh) | 呋喃并吡啶衍生物 | |
AU2013218539A1 (en) | Triazolopyridine derivatives as a tyrosine kinase inhibitor | |
AU2014202057B2 (en) | Novel Fused Pyrimidine Derivatives for Inhibition of Tyrosine Kinase Activity | |
KR20140118488A (ko) | Fms 키나아제 저해 활성을 갖는 티에노피리미딘 유도체 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1551) Year of fee payment: 4 |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1552); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY Year of fee payment: 8 |